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 Venous thromboembolism (VTE), a collective term for deep vein thrombosis and pulmonary 
embolism, is a severe and multifactorial disease. Heritability has been found to explain up to 60% of 
VTE events, however, the role of genetics on VTE in cancer is scarcely studied. VTE occurs frequently 
in cancer patients and is a common cause of morbidity and mortality in this patient group. The aim of 
the present thesis was to investigate the impact of individual prothrombotic genotypes and the 
combination of genotypes in a genetic risk score (GRS) on the risk of VTE in cancer patients. Further, 
VTE may be the first sign of an underlying malignancy, and therefore we also aimed to investigate the 
effect of prothrombotic genotypes on VTE risk in subjects with an occult (i.e. undetected) cancer. 
 All four papers in the present thesis utilize data from the fourth survey of the Tromsø Study 
(Tromsø 4), conducted in 1994-1995. The study populations in Paper I and III are also recruited from 
the second survey of the Nord-Trøndelag Health Study (HUNT 2), conducted in 1995-1997. Paper IV is 
based on the Scandinavian Thrombosis and Cancer (STAC) Cohort, which consists of merged data from 
the Tromsø 4 Study, the HUNT 2 Study and the Danish Diet, Cancer and Health (DCH) Study. 
Participants were followed from date of enrollment (1993-1997) in the different surveys to the date of 
an incident VTE event, the date of death or migration, or until end of follow-up (2007-2012). All 
potential cases of incident VTE events and cancer diagnoses during this time-period were recorded. 
 We reported the effect of several single nucleotide polymorphisms (SNPs) on VTE risk in 
subjects with and without cancer. A SNP of the GP6 gene (rs1613662), affecting platelet adhesion and 
activation, displayed a decreased risk of VTE in cancer-free subjects, while an increased risk was 
observed in cancer patients homozygous for GP6 SNP. The genotype was also found to be associated 
with prothrombotic and metastatic cancers. These findings support a role of platelet reactivity in the 
pathogenesis of VTE, which may differ according to cancer status.  
The risk of VTE was also found to increase by the presence of ABO (rs8176719), and risk alleles 
in F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914) in both cancer-free subjects and 
in cancer patients. Moreover, a synergistic effect was discovered for the genetic variants of FGG, FVL 
and ABO in combination with cancer on the VTE risk. We found a dose-response relationship between 
number of risk alleles in the 5-SNP score (genetic risk score, GRS) and VTE risk in subjects with and 
without cancer, and the combined effect of cancer and high-number of risk alleles (≥4 risk alleles) 
yielded a supra-additive effect for the risk of VTE. However, the five prothrombotic genotypes, alone 
or combined, did not increase the risk of VTE in occult cancer. 
Our findings suggest that the genetic risk score and prothrombotic genotypes may be useful 




Venøs tromboembolisme (VTE), en fellesbetegnelse for dyp venetrombose og lungeemboli, er 
en alvorlig og multifaktoriell sykdom. Det er vist at opp mot 60% av VTE hendelser kan forklares av 
arvelighet, likevel er genetikkens rolle lite undersøkt hos personer med VTE og kreft. VTE forekommer 
hyppig blant kreftpasienter og er en vanlig årsak til sykelighet og dødelighet i denne pasientgruppen. 
Formålet med denne avhandlingen har vært å undersøke hvordan individuelle protrombotiske 
genotyper og kombinasjonen av genotyper i en genetisk risikoskår (GRS) påvirker risikoen for VTE hos 
kreftpasienter. VTE kan være det første tegnet på en underliggende malignitet, og vi hadde derfor også 
som mål å undersøke effekten av protrombotiske genotyper på risikoen for VTE blant personer med 
okkult (dvs. ikke påvist) kreft. 
 Alle fire artiklene i avhandlingen bruker data fra den fjerde Tromsøundersøkelsen (Tromsø 4), 
gjennomført i 1995-1997. Studiepopulasjonene i artikkel I og III er i tillegg rekruttert fra den andre 
Helseundersøkelsen i Nord-Trøndelag (HUNT 2), gjennomført i 1995-1997. Artikkel IV er basert på «the 
Scandinavian Thrombosis and Cancer (STAC) Cohort», som består av sammenslåtte data fra Tromsø 4 
studien, HUNT 2 og den danske «Diet, Cancer and Health» (DCH) studien. Deltakere ble fulgt fra 
registrering (1993-1997) i de ulike studiene til datoen for en førstegangshendelse av VTE, datoen for 
død eller flytting, eller til studieslutt (2007-2012). Alle potensielle tilfeller av førstegangs VTE og 
kreftdiagnoser i denne tidsperioden ble registrert. 
Vi rapporterte effekten av flere ulike «single nucleotide polymorphisms» (SNPs) på risikoen for 
VTE blant personer med og uten kreft. En SNP i GP6 genet (rs1613662), som påvirker 
blodplateadhesjon og blodplateaktivering, viste seg å redusere risikoen for VTE hos kreftfrie, mens en 
økt risiko for VTE ble observert hos kreftpasienter homozygote for GP6 SNP’en. Genotypen var også 
assosiert med protrombotiske og metastaserende krefttyper. Disse funnene støtter at blodplater 
spiller en rolle for patogenesen av VTE, hvilket kan variere i henhold til kreftstatus. 
 Risikoen for VTE økte for både kreftfrie personer og kreftpasienter med ABO rs8176719 og 
risikoalleler for F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914. Videre oppdaget vi 
en synergistisk effekt mellom kreft og genetiske varianter av FGG, FVL og ABO på risikoen for VTE. Vi 
fant også et dose-respons forhold mellom antall risikoalleler i 5-SNP skåren (GRS) og VTE risikoen blant 
personer med og uten kreft. Kombinasjonen av kreft og et høyt antall risikoalleler (≥4) utøvde en supra-
additiv effekt på risikoen for VTE. Dog var der ingen sammenheng mellom de fem protrombotiske 
genotypene, alene eller i kombinasjon, og risikoen for VTE hos personer med okkult kreft. 
 Våre funn tyder på at den genetiske risikoskåren og protrombotiske genotyper kan være 
nyttige for å identifisere kreftpasienter med økt risiko for VTE. 
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Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common multifactorial disease with a potentially fatal outcome.1 It occurs in 1-2 
per 1000 persons per year in the general population, 2-5 affecting all age groups, ethnicities and both 
genders.4,6 A DVT is the formation of a thrombus in the deep veins, arising most frequently in large 
veins of the lower extremities, but can also occur in deep veins of the upper extremities, abdominal 
veins and cerebral veins and sinuses.7 Prevalent signs and symptoms of DVT are pain, swelling and 
erythema of the affected extremity.8 Since autopsy studies by Virchow in the 19th century, PE has until 
recently mainly been considered as a complication of DVT. A PE often occurs by embolization of the 
original DVT, i.e. parts or all of the blood clot dislodges, travels via the blood stream to the pulmonary 
circulation where it lodges and, subsequently, obstructs blood flow. However, imaging studies have 
reported that concurrent DVT can be found in less than 50% of PE patients, indicating other etiologies 
for some PE cases.9,10 Other possible origins for PE are de novo thrombus formation in pulmonary 
arteries,9,10 or embolization from a right sided cardiac thrombus caused by atrial fibrillation.11 The 
clinical course of a PE ranges from asymptomatic to fatal circulatory collapse.8,12 Nevertheless, 
frequent signs and symptoms seen in PE patients include dyspnea, tachypnea, coughing and pleuritic 
chest pain.8 
The association between cancer and venous thrombosis has been known for more than a 
century and is well established.13-15 As the French physician Armand Trousseau is credited for 
describing the relationship between VTE and cancer in 1865, the spontaneous formation of a venous 
thrombus in relation to an underlying malignancy has been termed the Trousseau’s syndrome. The 
term is particularly known in the field of medicine not only because Trousseau described the 
association, he also diagnosed himself with a VTE secondary to gastric cancer only two years later, and 
then died shortly after.16 Not many people know that Jean Baptiste Bouillaud had already reported the 
association nearly half a century earlier, in 1823.14,17  
Since the time of Bouillaud and Trousseau, several studies have convincingly demonstrated the 
link between cancer and VTE, 18,19 and today cancer is acknowledged as one of the most important risk 
factors for VTE in the population.15 Cancer patients who develop VTE have a shortened life expectancy 
compared to cancer patients without VTE.20,21 Furthermore, the clinical consequences of VTE, such as 
post-thrombotic syndrome (PTS), recurrent VTE and treatment-related bleeding, are more prevalent 
in cancer patients than in cancer-free subjects.20,22 The two-way relationship between venous 
thrombosis and malignancy has also been confirmed in studies describing increased risk of cancer after 
a VTE event,23-28 and approximately 5% of patients with unprovoked VTE are diagnosed with cancer 
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within one year.29-33 This finding has raised the question to what extent we should screen for cancer in 
subjects with VTE, which has been heavily debated.30,31,34 
Despite the quantity of knowledge on cancer-related VTE assembled over the last decades, the 
incidence of VTE in cancer is high and increasing.35 Cancer is a heterogeneous disease, and the risk of 
VTE depends on the interaction between tumor cells, treatment regime, the hemostatic system and 
individual patient characteristics. A strong hereditary component is found in VTE patients, and several 
genotypes are established as patient-related risk factors for VTE.36 However, the role of prothrombotic 
genotypes in the complex interplay with malignancy is not yet well established, as only a few of these 
genotypes have been studied in cancer patients. 
Even though VTE is a potentially preventable disease by the use of antithrombotic treatment, 
current guidelines do not recommend routine anticoagulant prophylaxis to all cancer patients due to 
the high risk of bleeding and uncertain benefit-to-harm ratio in these patients.37-39 The severe 
complications and potentially fatal outcome of VTE in cancer stresses the need and importance of 
identifying high-risk subjects, to determine who would benefit from targeted prevention. Thus, even 
150 years after the death of Trousseau, there are still knowledge gaps to fill. Hence why I chose genetic 
risk factors for cancer-related VTE as the topic of my thesis. 
 
1.1. Epidemiology 
1.1.1. Venous thromboembolism in cancer patients 
Cancer is a strong and independent risk factor for VTE,35,40 and studies have consistently 
demonstrated that 20-30% of all first venous thromboembolic events are cancer-related.2,19,41,42 The 
relative risk (RR) of VTE in subjects with active cancer ranges from 4 to 7, compared to the general 
population or subjects without cancer.35,40,43,44 Studies have reported an absolute risk (cumulative 
incidence) of VTE in cancer, which varies widely from 1% to 12%.45-47 The wide range reported might 
be attributable to methodological variations between studies, such as study population, follow-up 
duration, definition of active cancer and assessment of outcome (i.e. cancer and VTE). Further, cancer 
is a heterogeneous disease and risk estimates of VTE are highly dependent on different risk factors, 
which can be broadly stratified into cancer-related, treatment-related and patient-related risk factors. 
A meta-analysis from 2012 of 38 individual studies demonstrated this heterogeneity as the overall risk 
of VTE in average risk patients with cancer (those representative of all patients with cancer type under 
investigation or overall cancer) and high risk patients with cancer (those with high-grade or metastatic 
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disease or treated with therapeutic strategies that increase VTE risk), were 13 per 1000 person-years 
(95% CI 7-12) and 68 per 1000 person-years (95% CI 48-96), respectively.48 
The VTE incidence varies between ethnic groups, with Asian/Pacific Islanders having the lowest 
risk of both first-time VTE and cancer-related VTE.49 Interestingly, there appears to be little difference 
in the incidence of cancer-related VTE between African-Americans, Hispanics and Caucasians.49 The 
incidence of VTE in cancer is high and several studies have noted an increasing incidence of cancer-
related VTE.35,50,51 A large cohort study of more than 83000 cancer patients derived from four different 
United Kingdom databases presented an increase in overall incidence of VTE among cancer patients 
from 10 per 1000 person-years (95% CI 8-14) in 1997 to 19 per 1000 person-years (95% CI 18-21) in 
2006, while no similar trend was seen in the 577000 cancer-free controls.35 The rise in VTE incidence 
is reported for different cancer types.35 Several factors could be the explanation for the increasing 
incidence, including greater awareness of cancer-related VTE and improvements in diagnostic imaging 
for detection and staging of cancer, which may incidentally identify VTE events. Additionally, more 
aggressive cancer treatments (e.g. chemotherapy and surgery) and increasing survival, leading to 
elderly patients undergoing more cancer treatments, also increase VTE risk. 
Incidental (i.e. asymptomatic) VTE is a relative common finding in cancer patients.52 Extended 
use of computed tomography (CT) scan for evaluation of cancer treatment effect and improved CT 
scan technology may have affected the increase in incidence of VTE over time, especially incidental 
VTE. In a recent retrospective study by Di Nisio et al., 3.2% of cancer patients had asymptomatic VTE, 
while 2% presented with symptomatic VTEs.53 Similar rates of recurrence and mortality have been 
noted in patients with symptomatic and asymptomatic cancer-related VTE, and guidelines suggest that 
incidental PE should be managed like symptomatic events.54-57 
There are a limited number of studies investigating the differences in clinical presentation of 
VTE between cancer patients and cancer-free subjects. Bilateral DVT seems to be more prevalent in 
cancer patients than non-cancer.58-60 In a recent study, the rates of PE and symptomatic proximal DVT 
were similar, however, rates of symptomatic thrombosis in inferior vena cava and iliac veins, upper 
limb DVT and bilateral lower limb DVT were higher in cancer patients compared to cancer-free 
subjects.61 It is to be noted that the relative high prevalence of upper limb DVT in cancer, could partly 
be explained by the frequent use of central venous catheters (CVC) in these patients.62 Lastly, cancer 
is shown to be common in rare forms of VTE such as extrahepatic portal vein obstruction, Budd-Chiari 
syndrome and thrombosis of mesenteric veins.63 
 VTE is a serious disease in cancer patients. In general, clinical consequences such as recurrent 
VTE, PTS and bleeding complications are typically more common and more severe in cancer patients 
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suffering a VTE event than cancer-free VTE patients.64-66 The International Initiative on Thrombosis and 
Cancer (ITAC) developed the first international evidence-based clinical practice guidelines in 2013 to 
provide clinicians with practical and accessible recommendations for treatment and prevention of 
cancer-related VTE.67 The ITAC guidelines were updated in 2019 and recommend patients with cancer-
related VTE initial treatment with low-molecular-weight heparin (LMWH) for a minimum of 6 months, 
or DOACs (direct oral anticoagulants, i.e. Rivaroxaban or Endoxaban) for the same duration of time in 
cancer patients who are not at high risk of gastrointestinal or genitourinary bleeding.67 Thus, cancer 
patients receive an extended duration of anticoagulant therapy. However, despite adequate 
anticoagulation, treatment failure occurs frequently in cancer patients with VTE and subsequently, 
cancer patients have a two to nine-fold higher risk of VTE recurrence compared to cancer-free 
subjects.66,68-70 In the Tromsø Study, the incidence rate of recurrent VTE per 100 person-years, were 
8.5 following a cancer-related VTE versus 3.6 following a non-cancer unprovoked VTE.71 In a cohort 
study of 477 subjects from Olmsted County diagnosed with cancer-related VTE, the cumulative 
incidence of VTE recurrence was 18% at three months and 27% at one year.72 Furthermore, this study 
also reported an increased risk of treatment-related bleeding in cancer, with the cumulative incidence 
of major bleeding being 2.5% and 4.7% at three months and at one year, respectively. 
 Cancer-related VTE is associated with poor survival. A retrospective study by Khorana and 
colleagues found that in-hospital mortality was two to five fold increased in neutropenic cancer 
patients hospitalized with VTE compared to those without VTE.73 Similarly, a study of the California 
Cancer Registry (CCR) from 1993 to 1995, determined that VTE diagnosis was a significant predictor of 
increased mortality the first year at all 12 cancer sites investigated, with hazard ratios (HRs) of 1.6-4.2 
after adjustment for race, age and cancer stage.45 VTE was associated with increased mortality in 
localized, regional and metastatic-stage cancers, with metastatic cancers, not surprisingly being the 
strongest predictor of decreased survival. The strong association between metastatic-stage disease 
and development of VTE suggests that the biological aggressiveness of the cancer itself may be the 
main cause of death in cancer patients with VTE. However, it is possible that the cause of death could 
be related to the VTE event itself (i.e. massive PE), VTE treatment (bleeding due to anticoagulants), 
cancer treatment (i.e. major surgery, chemotherapy or radiation treatment) or presence of comorbid 
conditions. 
 Altogether, cancer-related VTE leads to substantial increase in consumption of healthcare 
resources and healthcare costs. As the incidence is increasing and VTE treatment is resource-intensive 
and costly, the disease burden of VTE in cancer is not expected to decrease. More effective agents and 
less costly management strategies are needed. In a retrospective study of 529 cancer patients, VTE 
and VTE-related complications occupied 6% of the bed-capacity at the oncology department.74 Further, 
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the mean hospitalization cost for VTE in cancer patients was more than double the cost per episode of 
VTE in the general medical population.74,75  
  
1.1.2. Venous thromboembolism as a first sign of cancer 
As described by Armand Trousseau, VTE can be the first manifestation of an occult cancer. 
Several studies have shown that VTE-patients have an increased risk of subsequent cancer compared 
to the general population.23-28 The reported rates of occult cancer detection in patients with 
unprovoked VTE seem to have been decreasing significantly over time.76  A systematic review 
published in 2008 by Carrier and colleagues based on 34 studies, reported that the prevalence of occult 
cancer detection following an unprovoked VTE event was up to 10%,25 and that the risk of occult cancer 
detection was 7-fold increased in VTE patients compared to the general population.25 More recent 
clinical studies have reported that approximately 3.7 to 5.0% of patients with unprovoked VTE are 
diagnosed with cancer within the first year following a VTE event.33,77 Similarly, a large prospective 
study reported a 5% rate of occult cancer detection over a follow-up period of 30 months.78 A 
systematic review and individual patient-level meta-analysis from 2017 reported a prevalence of occult 
cancer detection of 5.2% (95% CI 4.1-6.5%) during 12 months in patients with unprovoked VTE.31 A 
large case-control study suggested that even though the risk of occult cancer was strongest within the 
first year following a VTE event, the risk remained elevated for up to six years for multiple myeloma, 
colon and pancreatic cancer.79 
The incidence of occult cancer detection are thought to vary widely according to the presence 
or absence of provoking factors for VTE (i.e. surgery, immobilization, infection etc.). In a study by 
Prandoni and colleagues, only 1.9% of patients with provoked VTE develop cancer during follow-up 
compared to 7.6% in patients with unprovoked events.80 Similar findings was reported by Carrier and 
coworkers in a systematic review where the one-year incidence of cancer following a VTE event was 
10% (95% CI 8.6-11.3%) and 2.6% (95% CI, 1.6-3.6%), for unprovoked and provoked VTE, respectively. 
However, using the Scandinavian Thrombosis and Cancer (STAC) cohort, the risk of cancer did not vary 
as greatly in provoked and unprovoked VTE events.81 The risk of cancer was 4.5-fold (95% CI 3.4-5.8) 
increased for unprovoked VTE and 3.5-fold (95% CI 2.4-5.2) increased for provoked events the first 12 
months following a VTE event. The difference was even smaller after the initial 12 months, suggesting 
that VTE may be the first sign of malignancy regardless of the presence of other provoking factors. 
The risk of cancer after VTE does not differ according to the origin of the VTE event (i.e. lower 
limb, upper extremities, abdominal veins etc.). A large Danish registry study presented essentially 
similar risks of cancer during the first year of follow-up in subjects with superficial VTE (2.2%), DVT 
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(2.7%) and PE (2.9%).27 The corresponding standardized incidence ratios (SIRs) were 2.5 (95% CI 2.1-
2.9) for superficial VTE, 2.8 (95% CI 2.6-2.9) for DVT and 3.3 (95% CI 3.0-3.5) for PE. Comparable results 
was seen in the STAC cohort, with the risk of cancer after 12 months yielding HRs of 4.1 (95% CI 3.1-
5.4) for DVT and 4.0 (95% CI 2.8-5.6) for PE.81 Further, a large multicenter, prospective observational 
study reported an overall incidence of cancer of 1.4% (95% CI 0.9-2.1) for distal DVT and 1.5% (95% CI 
0.8-2.4) for proximal DVT.82 
The cancer sites found following a VTE event constitutes a large and heterogeneous 
group.18,23,24,26 In a meta-analysis of four large cohorts, the highest relative risk of cancer after VTE was 
found for ovarian, pancreatic, liver, hematological, brain, lung and kidney cancer, while the lowest risks 
was reported for cancers of breast and bladder.28 Jensvoll and colleagues found the highest HRs 
following a VTE event in the STAC cohort, for kidney, ovarian, lymphatic, pancreatic, stomach and lung 
cancer.81 Subjects diagnosed with cancer subsequent to a venous thrombotic event have a higher 
prevalence of malignant disease and advanced stages,20,24,83 and consequently poorer prognosis 
compared to cancer patients without VTE.20,83  
Several studies have investigated predictors of cancer in patients with unprovoked VTE. 
Analysis of a randomized controlled trial of patients with unprovoked VTE, reported that age, previous 
provoked VTE and current smoking were associated with higher HRs of cancer the following year after 
a VTE event.84 Using the RIETE registry (the Registro Informatizado de Pacientes con Enfermedad 
TromboEmbólica), several biomarkers for cancer were found to be independent predictors such as 
patients aged 60 to 75 years, unprovoked (i.e. idiopathic) VTE, bilateral deep vein thrombosis and 
anemia.83 No significant association was detected for measured platelet count, D-dimer levels, surgery 
or anticoagulant treatment. However, other studies have shown a correlation between D-dimer levels 
measured at the time of the VTE event and risk of subsequent cancer,85-87 suggesting that high plasma 
D-dimer levels at incident VTE diagnosis should be taken into consideration when the decision to 
screen for underlying cancer is made. 
Sørensen and co-workers were the first to demonstrate that patients with VTE and a following 
cancer diagnosis have poor prognosis compared to cancer patients without a prior or concurrent VTE 
event at the time of cancer diagnosis.20 In this Danish population-based study, the one-year survival 
rate was found to be 12% in patients with a cancer diagnosed at the same time as the VTE event, 
compared to 36% in cancer patients with no previous or concurrent VTE event. Further, the one-year 
survival rate was only 38% for cancer patients diagnosed with VTE within one year after the cancer 
diagnosis, compared to 47% in the cancer controls who never had a VTE, matched for cancer type, age, 
sex and year of diagnosis.20 They also found that VTE was associated with advanced stages of cancer, 
with higher prevalence of distant metastasis among VTE-patients compared to those without VTE. In 
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the prospective RIETE registry, VTE patients with occult cancer had a mortality rate of 20% in 80 days, 
compared to 5.4% in 80 days for VTE patients without occult cancer.83 
During the last decade, there has been an ongoing debate on to what extent patients with VTE 
should be further examined for an occult cancer (i.e. limited vs extensive screening). Several studies 
have evaluated a more extensive cancer screening strategy, which may include CT or 
fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scanning.33,78,88 As the clinical 
benefit may increase by applying extensive screening only to patients at high risk of occult cancer, the 
RIETE score and the Screening for Occult Malignancy in Patients with Idiopathic Venous 
Thromboembolism (SOME) score have been introduced.84,89 In a recently published individual patient 
data meta-analysis of prospective studies, Mulder and colleagues evaluated the predictive 
performance of the RIETE and SOME score.90 Both scores had a poor predictive discriminatory 
performance between low- and high-risk patients, which does not support the use of these scores in 
daily clinical practice. In a Canadian randomized controlled trial, limited screening versus limited 
screening combined with abdominal and pelvic CT scan, did not differ in average time to cancer 
diagnosis, nor mortality.33 A study comparing FDG PET/CT with limited screening found that extensive 
screening did not result in higher rates of cancer after unprovoked VTE.88 One could speculate that 
extensive screening might result in earlier cancer detection, however, it does not seem to increase the 
rate of occult cancer detection, decrease morbidity, or increase survival or cost-effectiveness.33,76 Thus, 
the mortality rates of cancer remains the same by the use of extensive and limited screening. 
 Currently, the limited screening approach is recommended for patients with unprovoked VTE. 
Limited screening usually consists of medical history, physical examination, laboratory investigations 
(complete blood count, calcium, urinalysis, and liver function tests), and chest X-ray, as well as age- 
and gender specific cancer screening (colon, breast, cervix and prostate) according to national 
guidelines.32 The limited screening should also be used for patients with VTE at unusual sites. Further, 
patients with splanchnic vein thrombosis or cerebral vein thrombosis should be tested for an 
underlying myeloproliferative disorder. Additionally, for those with splanchnic vein thrombosis and 
aplasia or hemolytic anemia, and patients with Budd-Chiari syndrome, they suggest testing for 
paroxysmal nocturnal hemoglobinuria. Routine cancer screening in patients with provoked VTE is not 
recommended. 
Few studies have evaluated the incidence of occult cancer detection in patients with recurrent 
unprovoked VTE. However, the incidence of occult cancer detection seems to vary according to 
whether the VTE is an initial or recurrent event. In the cohort study by Prandoni et al, it was reported 
that patients with recurrent VTE had a particular higher risk of cancer (OR 2.3, 95% CI 1.0-5.2) 
compared to patients with a first lifetime unprovoked VTE.80 In the Tromsø Study, the majority of those 
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with an incident VTE during the occult cancer period (54%) who also experienced a recurrent VTE, had 
a VTE recurrence before the date of cancer diagnosis, and 69% experienced a recurrent event either 
before or within 5 days of the cancer diagnosis.91 These findings indicate that the recurrent VTE often 
occurs prior to cancer detection, while the patients receive anticoagulant treatment. As there is limited 
knowledge on recurrent VTE and occult cancer detection, there has been some uncertainties regarding 
cancer screening in these patients. Today, the limited screening is recommended for this patient group, 
nonetheless, clinicians are recommended to maintain a lower threshold for cancer investigations and 
extensive screening procedures than for those used for patients with an incident unprovoked VTE.32 
 
1.2. Pathophysiology of venous thromboembolism in cancer 
Hemostasis is the physiological process that prevents 
bleeding after a vascular injury while maintaining blood flow 
of the general circulation, holding vital importance and 
delicately balancing pro- and antithrombotic mechanisms. 
Simplified, VTE occurs as a result of changes in blood flow 
(stasis), changes in blood composition (hypercoagulability), 
and/or damage of the vessel wall which may overcome the 
protective anticoagulant pathways and trigger thrombosis.  
The triad of pathophysiological alterations is referred to as Virchow’s triad (Figure 1, Figure 2).92-94 
Figure 2 is an overview of risk factors in the pathogenesis of VTE in the general population. 
 
Figure 1. Virchow's triad. Three main factors 
contributing to thrombus formation. 
 




Primary hemostasis is the process of platelet activation and adhesion, and secondary 
hemostasis refers to the initiation of the coagulation cascade. The coagulation cascade is a sequential 
process of different pathways (i.e. the extrinsic, intrinsic and common pathway), culminating in fibrin 
formation, which is the central stabilizing component of a blood clot (Figure 3).95  
 
Tissue factor (TF) is the main trigger for the extrinsic pathway of the coagulation cascade, and 
has a key role in hemostasis.95 Under pathological conditions, TF is expressed on circulating monocytes, 
microvesicles (MVs) and activated endothelial cells.94 FXII and FXI provide an alternate route of clotting 
initiation through activation of FIX, in the intrinsic pathway. This pathway may also be triggered by 
cellular RNA and polyphosphates (PolyP) released from activated platelets or bacteria, resulting in 
formation of a venous thrombus.94 The common pathway consists of FXa, FVa and thrombin (FIIa), 
which converts fibrinogen to fibrin.94 Tissue factor pathway inhibitor (TFPI) inhibits FXa and the 
TF/FVIIa complex, antithrombin inhibits all coagulation factors, and activated protein C (APC) 
inactivates FVa and FVIIa. The cascade is thoroughly regulated, and disorders of the coagulation 
proteins can lead to excessive bleeding or thrombus formation.  
Figure 3. A simplified figure of the coagulation cascade. Pathological activation of the extrinsic pathway 
(FVIIa and TF) occurs via expression in monocytes, microvesicles, and activated endothelial cells. Cellular 
RNA and polyphosphates released by activated platelets and bacteria activate the intrinsic pathway (FXIIa, 




Although endothelial damage with exposure of TF is a main trigger of the coagulation cascade, 
the majority of VTEs develop in the presence of intact endothelium.94,96 Autopsy and phlebography 
studies have shown that most non-trauma-related VTEs originate in sinuses behind venous valves.97 
This is indirectly supported by the increased risk of DVT in subjects with more valves.98 As blood travels 
against gravity in veins, some is caught in a secondary vortex of the valve sinuses, leading to hypoxia 
(Figure 4). Immobility can result in prolonged blood stasis and further potentiate hypoxia in these 
regions.97 Localized hypoxia activates endothelial cells, and recruits and activates white blood cells and 
platelets.97 Endothelial cells mobilize P-selectin and von Willebrand factor (vWF) on their surface, 
which recruit leukocytes and platelets expressing TF, which then activates the coagulation cascade. In 
addition, activated endothelial cells can downregulate endothelial expression of protein C receptor 
and thrombomodulin, and upregulate TF expression.99 
 
 Changes in blood composition are essential in the pathogenesis of VTE. The term 
thrombophilia describes the tendency of VTE development on the basis of a hypercoagulable state, 
which can be a result of both inherited and acquired disorders of blood coagulation or fibrinolysis. 
Inherited disorders may induce thrombus formation by decreasing levels of anticoagulant factors, such 
as antithrombin, protein C and protein S, or increase procoagulant factors and the thrombus formation 
tendency (i.e. gene mutations such as Factor V Leiden (FVL), prothrombin G20210A and non-O blood 
group).36,100 Several known risk factors for VTE may cause acquired thrombophilia, such as obesity, 
pregnancy, oral contraceptives, and importantly, cancer. 
Cancer itself represents a hypercoagulable state, and the pathophysiological mechanisms of 
endothelial damage, hypercoagulability and stasis of Virchow’s tirad, are important features of cancer 
in development of VTE. Coagulation activation and tumor growth and progression are closely related. 
Cancer cells can activate the coagulation system through several mechanisms, (i) by production of 
procoagulant, fibrinolytic, and proaggregating activities, (ii) release of proinflammatory and 
proangiogenetic cytokines, and lastly, (iii) through direct interaction with vascular and blood cells (e.g. 
Figure 4. The venous valvular sinus as a 
predilection site for DVT initiation. Blood is 
trapped in a vortex of the valve pockets, and 
the resultant hypoxia activates the venous 
endothelium, leading to the recruitment 
and binding of leukocytes, especially 
monocytes (Mc), platelets (Plt) and TF-
positive microparticles (MP). Consequently, 
TF from activated monocytes and 
microparticles may activate the coagulation 




endothelial cells, leukocytes and platelets) by adhesion molecyles.101 Studies have shown that cancer 
patients have increased levels of coagulation factors V, VIII, IX, and XI as well as increased markers of 
coagulation activation such as elevated plasma D-dimer levels.102 Further, cancer-induced deficiency 
of the vWF cleavage protein ADAMTS-13 has been described, resulting in unusually large vWF 
multimeres, which increases thrombosis risk.103 In normal vascular cells, TF is not expressed, except 
when induced. Malignant cells however, have an abnormal expression of TF. In a study by Kakkar and 
colleagues, cancer patients had significantly higher levels of both TF and FVIIa compared to cancer-
free subjects, suggesting a strong activation of the extrinsic pathway.104 Interestingly, the intrinsic 
pathway is found not to be as important in cancer-related VTE pathophysiology, as levels of FXIIa are 
only slightly elevated in cancer patients.105 Cancer cells are also found to induce hypercoagulability 
through inflammatory responses with increased level of circulating proinflammatory cytokines,106-108 
and inhibition of fibrinolytic activity through expression of plasminogen activator inhibitor-1 (PAI-1).109-
111 Moreover cancer tumors release cell-free DNA and growth factors that promote release of 
neutrophil extracellular traps (NETs) from neutrophils, which are suggested to play a key role in 
inflammatory-mediated thrombosis.112 
Activated platelets play an important role in the hypercoagulable state of malignancies, where 
they promote angiogenesis, tumor progression and metastasis.113,114 Previous studies have shown that 
elevated platelet counts in cancer patients are frequently observed and associated with decreased 
survival.113,115 Platelet activation by thrombin leads to release of vascular endothelial growth factor 
(VEGF) and other growth factors, thereby stimulating angiogenesis and inhibiting apoptosis.17,116 
Cancer cells express P-selectin ligands and adhere to various cells including platelets, in addition to 
enhance P-selectin expression in these cells. This results in enhanced adhesion to the endothelium and 
a “cloak” of platelets surrounding the tumor cells, protecting them from circulatory immune cells or 
natural killing cells.17,116 
 Venous stasis may be a result of tall stature, obesity, pregnancy, conditions preventing normal 
function of the skeletal muscles and normal blood flow or atrial fibrillation. It could also occur in 
patients with malignancy as a result of tumor expansion leading to compression of blood vessels 
nearby. Furthermore stasis is also seen as a consequence of immobilization secondary to surgery, 
cancer treatment, complications, and advanced cancer stage.117 
 Vascular trauma and endothelial damage may be a result of tumor invasion by solid tumors. 
Consequently, the endothelium is activated and may increase VTE risk. Chemotherapy, radiotherapy 
and surgery are all cancer treatment modalities that could result in vessel wall injury and through the 
same pathway as solid tumor invasion, induce coagulation.118 The vessel wall may also be damaged by 
insertion of CVCs, or cancer treatment (i.e. surgery, chemotherapy and radiation).119,120 
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1.3. Venous thromboembolism – a multicausal disease 
VTE is a multicausal disease. The thrombosis potential model proposed by Frits Rosendaal 
(Figure 5), illustrates the key concepts of VTE where several factors must be present for a VTE event to 
occur.121 A risk factor can be any attribute, characteristic, or exposure of an individual that increases 
the likelihood of disease development. The model by Rosendaal illustrates the complex interplay 
between genetic and acquired risk factors, and how VTE occurs once a set of sufficient risk factors have 
accumulated in a patient and the thrombosis threshold is exceeded. Further, the model demonstrates 
the dynamics of interactions between risk factors and how risk factors can result in either additive or 
synergistic effects. As the red line in Figure 5 represent, VTE has a strong age-dependency, indicating 
that more risk factors have to be present for VTE to occur in children than in adults or elderly.121 The 
green line represents intrinsic factors that are stable over time such as the genetic variation FVL. The 
orange line demonstrates the combined effect of FVL, age and other provoking factor (e.g. surgery, 
cancer or immobilization), with sufficient pathophysiological changes to exceed the thrombosis 
threshold. The thrombosis potential remains increased following a VTE event, and a provoking factor 
may exceed the threshold again, resulting in a recurrent event. After the recurrent VTE, the risk of 
another recurrent VTE event is even higher than following the incident VTE. 
 
A fundamental challenge in the management of patients suffering a VTE event and prevention 
of VTE occurrence, is that no obvious preceding cause or risk factor is identified in 30-50% of VTE cases 
(i.e. an unprovoked event). This underlines the disease complexity and that further research is 
necessary to unravel the causes of VTE and to improve strategies for VTE prevention, both in the 
general population and in cancer patients. 
Figure 5. The thrombosis potential model. (Adapted from Rosendaal, Lancet, 1999) 
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Risk factors for venous thromboembolism can be categorized into acquired and genetic 
factors. Several acquired risk factors for VTE have been established for the general population. The 
risk of VTE increases exponentially with age,2,3,122,123 and thus, VTE is mainly a disease of the elderly.4,122 
The incidence of VTE is 0.6 per 100 000 per year in children, whereas 1 per 100 in elderly.124,125 
Numerous medical illnesses and autoimmune diseases are known acquired risk factors for VTE, such 
as congestive heart failure,126-129 acute infections,127-130 myocardial infarction,128,129,131 ischemic 
stroke,126-129 inflammatory bowel disease,128,132-135 systemic lupus erythematosus,133,134 and chronic 
kidney disease.136-138 Hospitalization for an acute medical condition is associated with an 8-fold 
increased VTE risk.37 Further, anthropometric measures including obesity (i.e. body mass index (BMI) 
≥30 kg/m2) and tall stature, are found to have a 2- to 3-fold and 2- to 4-fold increased VTE risk, 
respectively.139-144 Other important and well-known risk factors include surgery,40,128,145 previous 
VTE,68,71 immobilization,121,126,146 trauma,40 pregnancy and puerperium,147,148 oral contraceptives,128,145 
hormone replacement therapy,128,149,150 and lastly, use of CVCs.145,151 Cancer is one of the strongest 
acquired risk factors for VTE and will later be described in detail by the stratification of different 
features of the disease. 
 VTE is to a large extent a genetic disease. It is estimated that genetic risk factors account for 
as much as 50 to 60% of VTE risk.152-155 Inherited thrombophilia can be the result of either gain-of-
function mutations of procoagulant factors or loss-of-function mutations of anticoagulants, with the 
loss-of-function mutations being less frequent, however, tend to be associated with higher risk 
estimates for VTE.156 The first discovery of inherited thrombophilia was antithrombin deficiency in a 
family from Skjervøy, Norway, in 1965, where a 12 year old boy and his mother were found to have 
significantly lower activity in antithrombin and heparin co-factor.157 The following decades, genetic 
variations of ABO-blood group were found to affect VTE risk,158 and deficiencies of protein C and its 
co-factor protein S were discovered.159,160 Non-O blood type is present in approximately 65% of the 
population and is associated with a 1.5- to 2.0-fold higher risk of VTE,161,162 partly mediated by higher 
levels of vWF and FVIII.163 Heterozygous protein C and protein S deficiencies occur in less than 1% of 
the general population, but when present, the VTE risk is 10-fold increased.163 Since these discoveries, 
a number of relatively common prothrombotic genetic variations and single nucleotide polymorphisms 
(SNPs) have been elucidated (Table 1). Factor V Leiden (FVL), also known as rs6025, is a missense 
mutation (arginine to glutamine) discovered in 1994 that results in APC-resistance with abnormal 
decomposition of FVIII.156,164 Heterozygous carriers of FVL have a 2- to 5-fold increased VTE risk, and 
the risk is further dramatically increased in homozygous carriers.165 The prothrombin mutation, 
G2021A or rs1799963, was identified only two years after FVL and is a gain-of-function mutation,166 
associated with higher levels of prothrombin (FII) and thus, a 1.5- to 3.0-fold higher VTE risk.161,167 
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About ten years then passed before the discovery of a novel genetic risk factor for VTE.36 In 2005, the 
rs2066865 of the fibrinogen gamma gene (FGG) was discovered and found to be associated with 
reduced levels of one of the three subunits of fibrinogen.168 The T-allele of the FGG SNP has a frequency 
of 0.25, and has been found to increase VTE risk by an OR of 1.61.168,169 
 Genome-wide association studies (GWAS) became available in the 2000s, resulting in major 
advances in understanding the role of genetic variations on VTE risk. GWAS approaches allowed 
identification of genotypes associated with VTE (Table 1). In 2019, GWAS and transcriptome-wide 
association studies (TWAS) of larger study populations revealed several novel susceptibility loci for 
VTE, whit some loci located outside the known coagulation pathways.170 However, the majority of VTE-
associated SNPs encode proteins that are involved in the coagulation cascade, altering the function 
and/or levels of proteins.163,171 Bezemer and coworkers were the first to conduct a large-scale 
association genetic study on VTE.172 Although the novel SNPs identified from GWAS display weaker 
associations with VTE, with OR ranging from 1.11 to 1.35, the SNPs may be of clinical significance if 
they interact with other risk factors (e.g. cancer) for VTE, giving supra-additive risk estimates. Supra-
additive risk estimates are seen when two exposures have a synergistic effect (i.e. biological 
interaction) on an outcome, resulting in a joint effect greater than the expected sum of the individual 
exposures.173 Biological interaction can be approached in several ways, e.g. by calculating the relative 
excess risk due to interaction (RERI) or the proportion attributable to interaction (AP) or assessing the 
synergy index (SI). Biological interaction will be further discussed in later sections of the thesis. 
Table 1. Known prothrombotic genotypes associated with VTE.36,171 
Gene Site Associated phenotype Frequency VTE OR 
Genes associated with VTE identified before GWAS 
 
F2 rs1799963 ↑ F11 0.02 2.50 
F5 rs6025 APC resistancy 0.05 3.00 
FGG rs2066865 ↓ Fibrinogen γγ’ 0.25 1.47 
ABO rs8176719 ↑ VWF, ↑ VIII 0.3 1.50 
PROCR rs867186 ↑ sEPCR, ↑ PC 0.07 1.22 
PROS1 Multiple VTE Rare ~ 10 
SERPINC1 Multiple VTE Rare ~ 10 
Novel SNPs associated with VTE identified by GWAS 
VWF rs1063856 ↑ vWF 0.37 1.15 
STXBP5 rs1039084 ↑ vWF 0.46 1.11 
GP6 rs1613662 ↑ platelet function 0.82 1.15 
F11 rs2289252 ↑ FXI 0.41 1.35 
F11 rs2036914 ↑ FXI 0.52 1.35 
C4BPB/C4BPA rs3813948 ↑ C4BP 0.08 1.18 
KNG1 rs710446 ↓ aPTT 0.45 1.2 
SERPINC1 rs2227589 ↓antithrombin 0.10 1.29 
TSPAN15 rs78707713 Unknown 0.88 1.28 
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Several of the SNPs discovered through the GWAS approach got our attention. Glycoprotein VI 
(GP6) rs1613662, is an A/G single nucleotide variation in amino acid 219, resulting in a serine to proline 
substitution, affecting the GPVI receptor for collagen.174 Carriers of the G-allele of the GP6 SNP have 
been found to express fewer GPVI receptors on platelets,175 causing less platelet adhesion and platelet 
activation.176 Observational studies have over the last two decades demonstrated a 20% decreased 
risk of VTE in carriers of the GP6 G-allele, and inversely, that A-allele carriers have a 15% higher risk of 
VTE than those not carrying the A-allele.177,178 The allele frequency of the A-allele at GP6 rs1613662 is 
found to be 0.82.36 Another SNP identified in recent years, is rs2036914 of F11 encoding for coagulation 
factor XI. The presence of the C-allele at the F11 SNP is found to correlate to higher plasma levels of 
F11 and to increase VTE risk by an OR of around 1.35.36,172,179,180 
Furthermore, the combination of prothrombotic genotypes may improve risk prediction 
models for VTE.171,181 Emerging studies have attempted to create genetic risk scores (GRS) based on 
several VTE-associated SNPs to improve prediction of VTE. Using a large case-control study of cancer-
free subjects, de Haan and colleagues created a GRS based on 31 VTE associated SNPs.181 SNPs with 
the highest odds ratios of VTE were added one by one to construct a more parsimonious GRS with 
fewer SNPs. This resulted in a score of five VTE-associated SNPs (ABO rs8176719, F5 rs6025, F2 
rs1799963, FGG rs2066865, and F11 rs2036914), performing just as good as the score of all 31 SNPs 
for VTE risk assessment (Figure 6). The 5-SNP score has been evaluated in several studies, in both 
incident and recurrent VTE, with a predictive capacity ranging from 0.59 to 0.69.181-183 Nonetheless, 
the authors concluded that in order for the GRS’ to become useful in a clinical setting, high-risk subjects 




Figure 6. Area under the ROC of genetic risk scores based on increasing numbers of SNPs. SNPs were added in 
order of the OR as found in the literature. The figure presents how a GRS of the five SNPs with the highest OR for 
VTE perform similarly to a GRS of VTE associated 31 SNPs. (Adapted from de Haan, Blood, 2012). 
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1.4. Risk factors for venous thromboembolism in cancer 
Risk factors for VTE in cancer can be 
grouped into cancer-, treatment- and patient-
related risk factors (Figure 7). Further, several 
biomarkers for VTE risk are detected in cancer 
patients. A better understanding of clinical risk 
factors and biomarkers in this patient group, 
could improve prediction of VTE risk in 
individual cancer patients, and thus, identify 
high-risk patients that would benefit from thrombosis-prophylaxis. 
 
1.4.1. Cancer-related risk factors for venous thromboembolism in cancer 
Extensive work has been published on cancer type and subsequent risk of VTE.15 Even though 
the VTE incidence vary between studies, and studies might be difficult to compare due to differences 
in study population, design and duration of follow-up, they have consistently reported pancreatic, 
brain, lung and ovarian cancers to induce the highest VTE risks.35,44,48,184 Further, the literature has also 
reported a moderate increase in VTE risk for myeloma, lymphomas, gastrointestinal, and kidney 
cancer, and a rather low VTE risk is induced by breast and prostate cancers.44,45,50 However, it needs to 
be addressed that although breast, prostate and colorectal cancers are associated with lower risks of 
VTE, they still contribute to the overall disease burden of VTE due to the high prevalence of these 
cancer types. In the STAC cohort, the incidence rates of VTE per 1000 person-years were 7.5 (95% CI 
3.7-14.9), 9.0 (95% CI 4.8-16.7) and 33.2 (23.4-47.3) 0-6 months following a cancer diagnosis date for 
breast, prostate and colorectal cancer, respectively.185 
Cancer stage highly correlates with VTE risk, and metastatic disease is one of the strongest risk 
factors for VTE in cancer.43-45,48 In a large Danish follow-up study of more than 55000 cancer patients, 
VTE risk was strongly dependent on cancer stage, with an adjusted RR of 2.9 for subjects with stage I 
and II, and RRs of 7.5 and 17.1 for those with stage III and IV, respectively.44 Similar trends were seen 
for 12 different cancer types in the CCR, with increased RR for VTE in metastatic cancer patients 
compared to those with localized disease.45 Additionally, the Multiple Environmental and Genetic 
Assessment (MEGA) Study found that patients with metastatic cancer had a 20-fold (95% CI 3-149) 
increased VTE risk compared to patients with localized cancer.43 It appears that fast growing cancers, 
i.e. cancer that are biologically aggressive, correlates with high VTE risk. This is evidenced by short 
survival time, and in the CCR study of 13000 women with ovarian cancer, 15% of those with metastatic 
Figure 7. Categorization of risk factors for cancer-related VTE.  
(Adapted from Gran, Thrombosis Research, 2018) 
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disease died within three months after the cancer diagnosis date and an additional 15% died in the 
four to 12 months following the cancer diagnosis.186 Furthermore, slow-growing cancers such as breast 
and prostate cancer, have significantly lower thromboembolic tendencies.45,187 
The histological subtype and tumor grade of cancers are also found to influence VTE 
risk.186,188,189 In the CCR, different subtypes of lung cancer affect the risk of VTE to different degrees, 
with the risk of VTE being 2-fold higher for subjects with adenocarcinomas compared to squamous cell 
lung cancer, with incidence rates of 9.9 and 4.4 per 100 person-years, respectively.188 Not surprisingly, 
high grade tumors induce higher risk of VTE than low grade tumors. In an observational cohort study 
of 747 cancer patients, the Vienna Cancer and Thrombosis Study (CATS), the risk of VTE was 2-fold 
higher for high-grade tumors (grade 3 and 4) compared to low-grade tumors (grade 1 and 2), after 
adjustment for sex, age, cancer type, cancer stage and histological type.190 
The incidence of VTE is clearly highest the first few months following a cancer diagnosis, and 
time since cancer diagnosis is therefore established as a risk factor for VTE. Using the MEGA Study, 
Blom and coworkers found that the risk of VTE was highest the first three months after a cancer 
diagnosis (OR 53.3, 95% CI 8.6-334.3).43 In the same study, the risk decreased to 14-fold (OR 14.3, 95% 
CI 5.8-35.2) in the four to 12 months following the cancer diagnosis date, and a 2.4-fold increased risk 
was found even up to 10 years after cancer diagnosis. In a recent report from the STAC cohort, VTE risk 
was apparently highest in the 6 months after cancer diagnosis, but when mortality was taken into 
account, the risk estimates were substantially lowered and became equally high in the period 6 months 
before and 6 months after cancer diagnosis.185 This could indicate that the cancer itself, rather than 
treatment-related factors (e.g. surgery, chemotherapy, and radiotherapy), or complications of cancer 
(e.g. immobilization and infections) cause the increased VTE risk. 
 
1.4.2. Treatment-related risk factors for venous thromboembolism in cancer 
VTE is a frequent complication of surgery in both cancer and cancer-free subjects. The 30-day 
cumulative risk of VTE after cancer surgery is found to be 1.6%.191 White and colleagues found that 
cancer patients undergoing major surgery had a 2- to 4-fold higher risk of VTE compared to cancer-
free patients after major surgery.192 In a cohort study of surgical patients with cancer and benign 
neoplasms, higher rates of VTE were found in cancer patients, despite the similar treatments. Further, 
in a study by Gould and colleagues, the risk of cancer-related VTE was particularly high after surgery 
of the abdomen and pelvis.193 Contrary, another study found no association between surgery and VTE 
in cancer patients,194 and some studies have even found a protective effect of major surgery on VTE 
risk in patients with breast, colon and ovarian cancer.186,195,196 The proposed protective effect of 
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surgery might be explained by the selection of patients most eligible for surgery, such as cancer 
patients with better performance status and less advanced cancers. Further, surgical removal of 
tumors may increase survival, improve the disease burden and thus, reduce VTE risk in these patients.  
 Chemotherapy is associated with a 2- to 6-fold increased risk of VTE compared to the general 
population, and several studies have convincingly demonstrated the association between 
chemotherapy and VTE.40,194 In a case-control study of Olmsted County, the risk of VTE was 4.1 (OR 4.1, 
95% CI 1.9-8.5) for cancer patients not receiving chemotherapy, while the risk increased to 6.5-fold 
(OR 6.5, 95% CI 2.1-20.2) when chemotherapy was used.40 In a recent systematic review and meta-
analysis, the pooled incidence of VTE was 7% during neoadjuvant chemotherapy.197 The highest VTE 
rates were found for patients with bladder and esophageal cancer. The incidence of VTE in cancer 
patients receiving chemotherapy is increasing, from 3.9% per hospital admission in 1995, to 5.7% per 
hospitalization in 2003.50 Further, some chemotherapy agents are associated with higher rates of 
VTE.198 Immunomodulatory drugs (e.g. thalidomide and lenalidomide) increase VTE risk, especially 
when combined with dexamethasone or chemotherapy in treatment of multiple myeloma.199 
Conversely to chemotherapy, data on the epidemiology and clinical features of VTE during 
radiotherapy are scarce. Radiotherapy may be initiated in early stages of cancer, when the risk of VTE 
is high, or as a part of radical cancer treatments of localized tumor, in addition to or without 
chemotherapy. Further, radiotherapy and chemotherapy are also used in palliative settings for pain 
relief, to reduce tumor compression of surrounding tissue etc. In a prospective study using the CATS 
data, 47% of cancer patients were treated with radiotherapy.200 In this study, radiotherapy yielded a 
2.3-fold (95% CI 1.2-4.4) increased VTE risk. Using the RIETE database, Guy and coworkers were the 
first to use a large cohort study to investigate the association between radiotherapy and VTE.201 They 
found that 13% of cancer patients who had experienced a VTE event, received radiation therapy. 
Cancer patients with VTE receiving radiotherapy in this cohort had a higher rate of cerebral bleeding, 
PE recurrence and DVT recurrence during the course of anticoagulant treatment, compared with 
cancer patients who had suffered a VTE but did not receive radiotherapy. 
Central venous catheters (CVC) are vital components of cancer therapy in several cancer types 
and those undergoing hemodialysis, parenteral feeding, and in administration of blood products, 
hydration and different drugs. CVCs are associated with higher rates of DVT in the upper extremities, 
and the incidence of CVC-related VTE in cancer patients varies from 0.3% to 28.3% in different 
populations.202 In a study on 400 cancer patients with a newly implanted port that were followed for 
a median of 12 months not receiving thromboprophylaxis, 8.5% (95% CI, 6.0 -11.7) had symptomatic 
VTE.203 Other treatment-related factors such as blood transfusion and erythropoiesis-stimulating 
agents are also found to increase VTE risk in cancer.204,205 
28 
 
1.4.3. Patient-related risk factors for venous thromboembolism in cancer 
Acquired risk factors for venous thromboembolism in cancer 
Several of the acquired risk factors for VTE in the general population apply to cancer patients. 
However, while the effect of increasing age on VTE risk in the general population is clear, the impact 
of high age in cancer patients is inconclusive. In a Danish population-based cohort of 57791 cancer 
patients, the crude incidence rates of VTE increased with increasing age, but the adjusted relative risk 
showed the opposite tendency with the VTE risk declining by increasing age.44 In an Italian prospective 
observational study of cancer patients undergoing surgery, patients above the age of 60 had a 2.6-fold 
higher risk of VTE compared to cancer patients under the age of 60 years.206 Most studies have 
however, found no association between age and VTE risk in cancer. In a large registry-based study of 
40787000 hospitalized cancer patients, the incidence rates were essentially similar in cancer patients 
aged 40-59 years and 60-79 years.51  In a study by Chew and colleagues based on the CCR, no 
association was found between advancing age and overall cancer-related VTE. However, the effect of 
high age differed among cancer sites, displaying a modest effect on VTE for patients suffering from 
non-Hodgkin’s lymphoma, breast- and ovarian cancer.45 Finally, age is not included in the Khorana risk 
score for assessment of VTE risk in ambulatory cancer patients, as they have not found an association 
between age and cancer-related VTE.207 
 A history of previous VTE is a risk factor for recurrent VTE in the general population.68,71 The 
risk of VTE due to previous VTE is even stronger in cancer patients, and the recurrence rate is 
significantly higher compared to subjects without cancer.208 In the Tromsø study, the cumulative 
incidence of VTE recurrence in cancer patients was 2.7% (95% CI 1.0-7.0) at 30 days, 8.2% (95% CI 4.3-
15.7) at 6 months, 16.3% (95% CI 9.9-25.9) at 12 months and 22.0% (95% CI 16.2-41.0) at two years 
following an incident VTE event. In a study by Prandoni and colleagues, the 12-month cumulative 
incidence of VTE recurrence was 20.7% in cancer patients on anticoagulants, while as low as 6.8% in 
cancer-free subjects receiving anticoagulant treatment.66 Active cancer is associated with a 2- to 9-fold 
higher risk of VTE recurrence compared to cancer patients without VTE,1,66,209 and similar to cancer-
free subjects, the risk of recurrence in cancer is higher after a DVT event compared to PE events.210 
 The presence of medical comorbid conditions may increase VTE risk in cancer, especially when 
several comorbidities are present at the same time. In a study of hospitalized cancer patients, Khorana 
and coworkers found an increased VTE risk by the presence of renal disease (OR 1.5), pulmonary 
disease (OR 1.4), arterial thromboembolism (OR 1.5) and anemia (OR 1.4).50 Further, acute infection 
has been proposed as an important risk factor for cancer-related VTE (OR 1.8),50 with a particularly 
increased risk in neutropenic patients.51 Several studies have demonstrated that increasing number of 
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comorbidities enhance VTE risk in cancer.186,188,195,196,211 Using the CCR study of 108255 patients with 
breast cancer, three or more medical comorbidities present were found to be a predictor for VTE (HR 
2.9, 95% CI 2.4-3.5) when compared to patients with no comobidities.195 
 Obesity, defined as a BMI ≥35 kg/m2, is one of the variables in the Khorana risk model for 
cancer-related VTE, displaying an OR of 2.5 (95% CI 1.3-4.7).207 Overweight and obesity are major risk 
factors for a number of chronic diseases, and are considered a rising problem in both high- and low-
income countries. A meta-analysis reported a 2.3-fold increased risk of VTE in obese patients in the 
general population.212 However, the association between high BMI and VTE in cancer is less 
established. Contradictory to the findings of Khorana et al., BMI ≥35 kg/m2 was not associated with 
cancer-related VTE in European populations included in the Vienna Cancer and Thrombosis Study 
(CATS).213 Further, obesity was associated with increased VTE risk in some studies on ovarian 
cancer,214,215 while no association was seen in other studies on ovarian and prostate cancer.216,217 
 Immobilization is common in cancer patients as immobilization is related to surgery, cancer 
treatment with chemotherapy or radiation, and end-stages of cancer. Although it is a strong predictor 
for VTE in the general population, immobilization has been scarcely investigated in cancer. 
Immobilization was present in 23% of cancer patients in the Tromsø Study and were found to be the 
most frequent provoking factor for both cancer-related VTE and VTE in cancer-free subjects.218 In a 
prospective observational study by Agnelli and coworkers, immobilization after surgery, defined as 
bedrest more than three days, displayed a 4.5-fold (95% CI 2.5-7.8) increased VTE risk in cancer 
patients.206 
 
Biomarkers for venous thromboembolism in cancer 
The Food and Drug Administration (FDA) defines a biological marker, shortened biomarker, as 
“a defined characteristic that is measured as an indicator of normal biological processes, pathogenic 
processes or response to an exposure or intervention, including therapeutic interventions”.219 
Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers.219 A 
biomarker is not an assessment of how an individual feels, functions or survives.219 A number of 
subtypes of biomarkers have been identified according to their presumed applications. One single 
biomarker may meet multiple criteria for different uses, and some definitions may overlap. Categories 
of biomarkers include biomarkers of susceptibility/risk, diagnostic biomarkers, monitoring biomarkers, 
prognostic biomarkers, predictive biomarkers, response biomarkers, and safety biomarkers.219 
Further, a biomarker that indicates the potential for developing a disease or medical condition in an 
individual who does not currently have clinically apparent disease or the medical condition is classified 
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as a susceptibility/risk biomarker.219 These biomarkers are fundamental for the conduct of 
epidemiological studies about risk of disease.220 The most ideal biomarkers have high sensitivity and 
specificity for the outcome of interest, is safe to measure and does not vary across comparable groups 
(e.g. sex, ethnicity). In recent years, several biomarkers have been identified for VTE in cancer, of which 
several different biomarkers have been included in prediction models for cancer-related VTE. 
Studies have consistently demonstrated no association between white blood cell count221,222 
and platelet count139,223,224 with the risk of VTE in the general population. However, both high levels of 
white blood cells and platelets have been found to be associated with VTE risk in ambulatory cancer 
patients.207 The Awareness of Neutropenia in Chemotherapy (ANC) Study group registry includes 
roughly 4000 cancer patients which are followed from prior to chemotherapy initiation, to a maximum 
of four rounds of chemotheraphy.207 In this cohort, leukocytosis (>11 x 109/L), thrombocytosis (≥350 x 
109/L) and low hemoglobin levels (<10 g/dL) were identified as biomarkers for chemotherapy-
associated VTE, with a 2.2-fold, 1.8-fold and 2.4-fold increased risk of VTE, respectively. Similar findings 
for leukocytosis were found for cancer patients in the RIETE registry, with a 60% increased risk of 
recurrent VTE in cancer patients with leukocytosis at the VTE event.225 Further, pre-cancer diagnosis 
platelet count and leukocyte values were associated with incident cancer-related VTE in the Tromsø 
Study, whereas no association was found for cancer free subjects. In this study, leukocytosis (defined 
as leukocytes ≥8.6 x 109/L) was associated with a 2.4-fold increased VTE risk,221 and thrombocytosis 
(defined as platelet count ≥295x 109/L) with a 2-fold increased VTE risk.226 Moreover, in the Tromsø 
Study, the combination of elevated platelet counts and leukocyte counts displayed a synergistic effect 
with an age- and sex-adjusted three-fold (HR 3.0, 95% CI 1.8-5.0) increased risk of VTE in cancer, 
compared to cancer patients with low values of both platelets and leukocytes.226 These findings 
suggest that platelets and leukocytes play a role in the pathogenesis of VTE in the presence of a 
malignant environment.226 Both activated platelets and platelet-derived microparticles promote a 
procoagulant membrane surface for thrombin activation,227 which again enhances platelet-tumor 
interaction and further tumor progression.228 Thus, elevated platelet counts may result in a larger 
membrane surface facilitating an interaction between tumor cells and coagulation factors, and thereby 
promoting coagulation activation. 
Markers of hemostasis activation, especially D-dimer, have been found to be elevated in 
cancer patients.229-232 D-dimer is a product of degradation of cross-linked fibrin, and positive measures 
in blood indicate activation of both coagulation and fibrinolysis. Elevated levels of D-dimer are found 
to be associated with increased risk of VTE in the general population,233-235 and today, D-dimer is used 
in the clinical algorithm for VTE diagnostics.236 The sensitivity and negative predicting value are high, 
i.e. it is unlikely that a VTE event is present if the D-dimer levels are below cutoff.237,238 The specificity 
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however, is low, as other conditions also can result in elevated D-dimer, such as infections, trauma, 
cancer, and inflammation.  In a cohort study of 108 lung cancer patients, Ferroni and colleagues found 
that the risk of VTE was 11-fold increased for patients with lung cancer and elevated D-dimer (>1.5 
µg/ml), compared to lung cancer patients with D-dimer levels below 1.5 µg/ml.232 In the prospective 
CATS cohort of 821 cancer patients, elevated D-dimer levels (>75th percentile) were associated with a 
2.4-fold (95% CI 1.4-4.0) increased risk of VTE in cancer.239 
 P-selectin is a marker of activation of platelets and endothelial cells.240,241 It is an adhesion 
molecule stored in α-granules of platelets and Weibel-Palade bodies of endothelial cells that is 
expressed on the cell surface when these cells are activated,240,241 and mediates adhesion and 
migration of leukocytes, platelets and cancer cells in inflammation, thrombosis and cancer growth and 
metastasis.242 Again, in the CATS Study, plasma P-selection levels above the 75th percentile was found 
to be an independent risk factor for VTE with a HR of 2.6 (95% CI 1.4-4.9) after adjustment for age, sex, 
surgery, radiotherapy and chemotherapy.243  
 Finally, other biomarkers suggested for VTE in cancer patients are tissue factor-positive 
microparticles (TF+ MPs), factor VIII and C-reactive protein.244-247 Additionally, elevated levels (≥358 
pmol/L) of prothrombin fragments 1+2 (F1+2), i.e. products of prothrombin cleavage, have been found 
to be associated with a 2.0-fold (95% CI 1.2-3.6) increased risk of VTE in cancer, compared to cancer 
patients with F1+2 levels below 358 pmol/L.200 In the same study, a combined effect was observed for 
the presence of both elevated prothrombin fragments and D-dimer levels, indicating an even higher 
risk of VTE when two biomarkers of a prothrombotic state are present. 
Today, a few risk assessment scores that aim to stratify cancer patients by their VTE risk exist. 
However, none of these risk models are recommended in current guidelines. Risk reduction for VTE is 
mainly seen in high-risk patients compared to low-risk patients. Furthermore, the risk of bleeding on 
anticoagulant treatment is high and the benefit-to-harm ratio should be taken into consideration. 
Thus, the decision to provide anticoagulation for prevention of VTE in cancer should ideally be provided 
by a valid risk stratification strategy based on the presence of risk factors and biomarkers for cancer-
related VTE.248 With a concrete and individual approach, only high-risk cancer patients of VTE would 
receive thromboprophylaxis, avoiding the burden and risks of anticoagulants in low-risk cancer 
patients. The Khorana Risk Score is the most recognized risk prediction score for VTE in cancer.207 The 
Khorana risk model was derived and validated in an independent cohort of 1365 patients receiving 
chemotherapy in the observational Awareness of Neutropenia in Chemotherapy (ANC) Study Group 
Registry.207 This score includes different clinical and laboratory parameters, with points given for 
specific cancer sites (i.e. stomach, pancreatic, lung, lymphoma, gynecological, bladder and testicular 
cancer), elevated platelet and leukocyte count, low hemoglobin or use of erythropoietin-stimulating 
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agents (ESAs), and high BMI. The Khorana prediction score has been externally validated in the Vienna 
CATS cohort and several other studies.249-251 However, the reproducibility in some cancer patients and 
populations has been questioned, and several variations of the prediction model has been proposed 
to improve the Khorana risk score. Ay and coworkers found an improvement of accuracy to identify 
high-risk patients when D-dimer levels and P-selectin were added to the Khorana risk prediction model 
(the extended Vienna CATS Score).252 However, P-selectin is not measured routinely in cancer patients, 
which limits its clinical use. Verso and colleagues included type of chemotherapy to the Khorana risk 
assessment score (the PROTECHT score), resulting in an improved ability to identify patients at high 
VTE risk.250 Further, Pelzer and coworkers replaced BMI with WHO performance status in the Khorona 
score (the CONKO score) for patients with pancreatic cancer.251 Comparison of risk prediction scores 
has been made, and in a cohort study of 876 cancer patients the Vienna CATS and PROTECHT scores 
appeared to discriminate better between low- and high-risk patients of VTE than the CONKO score and 
the Khorana score.253 Even though today’s biomarkers and prediction models seem to be able to 
differentiate between cancer patients at high and low risk of VTE, the risk assessment models are not 
adequate to be used in clinical practice. There is still a need for research in this field. 
 
Genetic risk factors for venous thromboembolism in cancer 
The impact of genetic risk factors on cancer-related VTE is not well-established, as cancer 
patients often are excluded from studies investigating the association between genotypes and VTE. As 
discussed in the thrombosis potential model, inherited risk factors alone may only mildly increase VTE 
risk, but in the presence of other provoking factors such as cancer, genetic variants may push the 
patient’s thrombosis potential above threshold and thus, result in thrombus formation (Figure 5). 
Prothrombotic genotypes are potential biomarkers for risk stratification of VTE in cancer, being of 
particular interest as they are fixed, only need to be measures once, and are not influenced by 
malignant disease, interventions or complications of cancer. 
 Factor V plays an important role in the coagulation cascade, functioning as a cofactor for 
conversion of prothrombin to thrombin and promoting activation and degradation of factor VIII.254,255 
Factor V Leiden (FVL) is a gain-of-function missense mutation that results in APC resistance by 
debilitated down-regulation of activated factor V by APC, and in an abnormal degradation of factor VIII 
by APC.256-258 A total of 3-7% of the European population are carriers of FVL, and the genetic variation 
is very rare in Asian and African populations.165 Several studies have reported no association between 
FVL and VTE risk in different cancers such as gynecological,259 breast,260,261 pediatric,262 
gastrointestinal260,263 and unselected cancers.264,265 The lack of associations in these studies may be 
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explained by small population sizes (67-281 subjects) and the prevalence of the genetic variation. 
However, later population-studies with larger study populations have found an increased VTE risk by 
the presence of FVL. In a large case-control study using data from the Multiple Environmental and 
Genetic Assessment (MEGA) Study, the VTE risk was 3-fold increased in subjects with FVL, 5-fold 
increased in subjects with cancer, and notably, 12-fold (OR 12.1, 95% CI 1.6-88.1) increased in subjects 
with the presence of both FVL and cancer.43 Similar results were found in an Austrian cohort of nearly 
1000 cancer patients, with a HR of 2.0 (95% CI 1.0-4.0) for VTE risk in cancer patients with FVL 
compared to cancer patients without FVL.266 Further, in a case-cohort derived from the Tromsø Study, 
FVL was associated with a 2-fold increased VTE risk in cancer and displayed a synergistic effect on VTE 
risk when combined with cancer.267 A meta-analysis of 10 studies showed that FVL was associated with 
CVC-related VTE in cancer patients, with a pooled OR of 4.6 (95% CI 2.6-8.1).268 
 The prevalence of prothrombin G20210A mutation is found to be 0.7-4% in the general 
population and varies from 0.6 to 2.6% in cancer patients.167,264,269-272 The genotype is a gain-of-function 
mutation resulting in high plasma levels of factor II (prothrombin).273 Most studies have demonstrated 
a positive association between G20210A and VTE with risk estimates alternating between 1.5 and 
6.7,43,263,274-276 while some smaller studies have found no association.260,264,277 In the MEGA Study, the 
prothrombin genotype displayed an OR of 2.3 (95% CI 1.6-3.3) for VTE risk in carriers of the risk allele 
compared to non-carriers. In the same study, no analysis was done for cancer patients with the 
prothrombin mutation, as there were zero control participants with the genotype in this group. 
Further, the pooled OR for CVC-related VTE in cancer patients with G20210A was found to be 4.9 (95% 
CI 1.7-14.3) in a meta-analysis of seven studies.268 The F2 G20210A mutation is also associated with 
slightly increased plasma levels of F11 leading to increased thrombin generation, which results in a 
hypercoagulable state.171 
Non-O blood group is thought to be the most common genetic risk factor for VTE.162 Recent 
studies have established that A1 (about 90% of A blood) and B blood groups are associated with a 1.5 
to 2-fold increased risk of VTE, while A2 (about 10% of A blood) and O blood groups have a protective 
effect against VTE. 161,177,278,279 The increased risk of A1 and B blood groups is thought to be mediated 
by elevated levels of vWF and FVIII, however, the association between these blood groups and VTE 
remains even after adjustments for vWF and FVIII.163 Several SNPs, such as rs8176719, rs8176750, 
rs505922 and rs817646, have been used to differentiate between O and non-O blood groups. Non-O 
blood has in most studies been identified by the presence of these SNPs, and the rs8176719 has been 
most widely studied with regards to VTE.  Non-O blood group has been found to be an independent 
risk factor for cancer-related VTE in pancreatic cancer,280 in children with acute lymphoblastic 
leukemia281 and adults with malignant gliomas.282 In the Tromsø Study, non-O blood was found to be 
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associated with a 30% increased risk of cancer-related VTE (HR 1.32, 95% CI 0.95-1.83), compared to 
cancer patients with O-blood group.283 In the same study, the combined effect of non-O blood group 
and cancer on VTE risk was 12-fold (HR 12.29, 95% CI 9.63-15.68) higher than in non-cancer subjects 
with blood group O.283 In a study of 219 patients with myeloproliferative disorders (essential 
thrombocytosis, polycythemia vera and primary myelofibrosis), no association between the ABO SNP 
rs8176719 and VTE risk was found.284 
Other SNPs have also been investigated in relation to VTE risk in cancer patients, however, 
most of these studies were small and had limited statistical power.283 In a study of 78 cancer patients, 
none of the nine genetic variations investigated (i.e. FVL, FV H1299R, FII G20210A, MTHFR C677T, 
MTHFR A1298C, PAI-1 4G/5G, β-fibrinogen–455 GA, FXIII Val34Leu and GpIIIa HPA-1a) were found 
to be associated with VTE risk.285 Further, in 1079 tumor patients derived from the Vienna CATS Study, 
the polymorphisms of fibrinogen (-455G>A) and FXIIIa (Val34Leu) were not found to be associated with 
VTE risk.286 Finally, a study of 60 cancer patients found no association between three different genetic 
variations of the FVII gene (−323ins10-bp, −401GT, and −402GA) and VTE risk.287 
Genetic risk scores may have the potential to predict VTE risk in cancer. Preliminary data based 
on 251 cancer patients undergoing chemotherapy treatment, showed that a GRS of 11 SNPs performed 
better in detection of high risk patients of VTE, compared to the Khorana Risk Score (AUC 0.70 vs. 
0.55).288 Further, a Swedish population-based study of around 4000 women with breast cancer 
investigated the risk of VTE based on the presence of nine established VTE loci, with the highest risk 
found for subjects above 59 years in the top 5% of the polygenic risk score.289 As described in section 
1.3 of this thesis, de Haan and coworkers created a GRS of 5 prothrombotic SNPs, which has been 
evaluated in cancer-free populations.181 Further, in recent years the 5-SNP score has also been tested 
in combination with other conditions such as ischemic stroke, body height and family history of 
myocardial infarction.290-292 However, the predictive capacity of the 5-SNP score has not been 
evaluated in cancer. 
During the last decades, major advances have been made in our understanding of genetic risk 
factors in VTE development. However, the role of prothrombotic genotypes on VTE in cancer is scarcely 
studied in larger studies, and several established prothrombotic genetic variants such as GP6 
rs1613662 and FGG rs2066865 have never been investigated in cancer patients. Moreover, no previous 
study have investigated any of the known prothrombotic SNPs or combination of SNPs in a GRS on VTE 
risk in occult cancer. A deeper understanding of prothrombotic genotypes in cancer-related VTE might 
improve risk prediction, thromboprophylaxis guidelines and thus, improve prognosis for these 
patients. There is a need to adequately evaluate established and novel genetic risk factor for VTE in 
cancer, and further, to develop and validate genetic risk assessment models for VTE in cancer patients. 
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2. Aims of the thesis 
The aims of the thesis were: 
 
o To investigate the association between GP6 rs1613662 and VTE risk in the general population 
and stratified by cancer status to explore the combined effects of GP6 rs1613662 and active 
cancer on the risk of VTE (Paper I) 
 
o To investigate the joint effect of FGG rs2066865 and active cancer on the absolute and relative 
risks of VTE in a population-based case-cohort (Paper II) 
 
o To investigate the impact of increasing number of risk alleles in the 5-SNP score on the risk of 
VTE in patients with and without cancer using a population-based case-cohort (Paper III) 
 
o To investigate the effect of five individual prothrombotic genotypes and a genetic risk score 
(GRS) on VTE risk in occult cancer, using a large case-cohort recruited from the general 




3.1. Study populations 
3.1.1. The Tromsø Study 
The Tromsø Study is a single center prospective population-based study with repeated health 
surveys of the inhabitants of Tromsø municipality, North Norway.293 Overall, seven surveys (Tromsø 1-
7) of the Tromsø Study have been conducted, ranging from 1974 to 2016. The study was first initiated 
to investigate causes of the high cardiovascular mortality in northern Norway, and to develop methods 
to prevent myocardial infarctions (MIs) and strokes. However, the study has evolved over four decades 
and now provides information on a wide range of examinations and diseases.293 Further, the study 
offers several favorable features, such as a long-term follow-up, a longitudinal design, repeated 
measurements, high attendance rates and a single center follow-up.  
The fourth survey of the Tromsø Study (Tromsø 4), conducted in 1994-1995, was the Tromsø 
survey used for this thesis. In Tromsø 4, all inhabitants aged 25 or older were invited, and 27158 
individuals participated, yielding an attendance rate of 77%. All participants aged 55 to 74 years and a 
random 5-10% sample in the other age groups were invited to a second, more extensive examination. 
VTE registration started on January 1, 1994 and all incident and recurrent VTE events were registered 
until December 31, 2012. Tromsø 4 was included in all four papers (I-VI) of this thesis. However, in 
Paper I and III, the Tromsø 4 survey was combined with the second survey of the Nord-Trøndelag 
Health Study (HUNT 2).294 Finally, in Paper IV, Tromsø 4 was included as one of three cohort studies 
merged into one large population-based study, the Scandinavian Thrombosis and Cancer (STAC) 
cohort.295 
 
3.1.2. The Nord-Trøndelag Health Study 
The HUNT Study encompass health information and biologic material of the inhabitants of 
Nord-Trøndelag County, Norway. The study was primarily designed to determine the prevalence of 
diabetes, hypertension and undiagnosed tuberculosis, and to assess the quality of health care provided 
to patients with these conditions. Data in the HUNT Study has been collected through the four 
following population surveys: HUNT 1 (1984-1986), HUNT 2 (1995-1997), HUNT 3 (2006-2008) and 
HUNT 4 (2017-2019). Overall, approximately 150 000 individuals have participated, and more than 
100 000 subjects have provided blood samples. The main objective of the second survey of the HUNT 
Study (HUNT 2) was public health issues such as cardiovascular disease and other chronic conditions 
in accordance with national health priorities. In HUNT 2, all individuals aged 20 years and older living 
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in Nord-Trøndelag were invited and 66 140 participated, giving an attendance rate of 71%.294 
Participants of HUNT 2 were followed from the inclusion in 1995-1997, until December 31, 2008. HUNT 
2 was used for Paper I and III, and were also included in the STAC cohort, used for Paper IV. 
 
3.1.3. The Scandinavian Thrombosis and Cancer Cohort 
In Paper IV, participants were included from the STAC cohort, which is a large population-based 
cohort comprising of data from three Scandinavian cohorts: The Tromsø 4 Study, the HUNT 2 Study 
and the Danish Diet, Cancer and Health (DCH) Study. The Tromsø 4 Study and HUNT 2 Study have 
already been described in the sections above. The DCH Study was conducted in 1993-1997 and aimed 
to assess the effect of diet and lifestyle factors on the development of cancer and several other chronic 
diseases. All inhabitants aged 50 to 64 years and living in the urban areas of Copenhagen and Aarhus, 
without a previous cancer diagnosis were invited to take part in the DCH Study. In total, 57 053 
individuals participated, being 35% of those invited.296 The STAC cohort was created to investigate the 
epidemiology and risk factors for VTE in cancer. Study participants were followed from date of 
inclusion (1993-1997) until end of follow-up (2007-2012) in the individual cohorts. Registration of VTE 
events was done until December 31, 2007 in HUNT 2, April 30, 2008 in the DCH Study and December 
31, 2012 in Tromsø 4. Cancer diagnoses were registered until December 31, 2008 in HUNT 2 and 
December 31, 2012 in Tromsø 4 and the DCH Study. In total, 144 952 individuals aged 19 to 101 years, 
without previous VTE or cancer were included in the STAC cohort.295 
 A case-cohort design was used for all the four papers in this thesis. This was done to limit the 
costs and time required for genotyping in our studies. All incident VTE events during follow-up were 
included as cases in the different studies, and a sub-cohort of age-weighted subjects randomly selected 
from the original cohort(s) was sampled. The case-cohort design is further explained and discussed in 
the section of methodological considerations. 
 
3.2. Baseline measurements and prothrombotic genotypes 
Baseline data at study inclusion in Tromsø 4, HUNT 2 or the STAC cohort, was obtained by 
physical examination, non-fasting blood samples and self-administered questionnaires. Trained 
personnel recorded blood pressure using an automatic device. Three measurements were performed 
after two minutes at rest in Tromsø 4 and HUNT 2, and the average of the two last measurements were 
chosen. In the DCH Study, blood pressure was measured twice after five minutes at rest, and the lowest 
measurement was used. Body height and weight were measured in participants wearing light clothing 
38 
 
and no shoes, and was used to estimate the body mass index (BMI, kg/m2) as body weight (kg) divided 
by height squared (m2). Information on diabetes mellitus, smoking status, physical activity, education 
level and history of cardiovascular disease (MI, angina or stroke) was obtained from standardized, 
validated self-reported questionnaires. 
 For participants in Tromsø 4 and HUNT 2, DNA was isolated from whole blood and stored at 
minus 70⁰C at the national CONOR (Cohort Norway) biobank, located in Levanger, Norway. All blood 
samples drawn from participants in the DCH Study were processed and frozen within two hours at 
minus 20⁰C, and at the end of the day of collection, all samples were stored in liquid nitrogen vapor 
(max minus 150⁰C). The following SNPs were genotyped: rs1613662 in the glycoprotein 6 gene (GP6), 
rs2066865 in the fibrinogen gamma gene (FGG), rs8176719 in ABO (non-O blood type), rs6025 in F5 
(FVL), rs1799963 in F2 (prothrombin G20210A), and rs2036914 in F11. In the Tromsø Study, rs1613662 
(GP6), rs8176719 (ABO), rs6025 (F5), rs1799963 (F2) and rs2036914 (F11) were genotyped using the 
Sequenom platform, and rs2066865 (FGG) by the TaqMan platform, as previously described.291 The 
HUNT Study performed genotyping using the Illumina HumanCore Exome array. In the DCH Study, 
genotypes were determined using predesigned TaqMan SNP genotyping array, as described 
elsewhere.179 
 Participants were considered carriers of the prothrombotic risk gene when one or two risk 
alleles were present. In Paper I, homozygosity for the major allele at GP6 rs1613662 was used as 
reference group and risk according to carriership of the minor allele was investigated. In Paper II, the 
FGG SNP was genotyped and the presence of one or two risk alleles (minor alleles) was defined as 
hetero- and homozygosity, respectively. For the last two papers, Paper III and IV, ABO rs8176719 (non-
O blood type), F5 rs6025 (Factor V Leiden), F2 rs1799963 (prothrombin G20210A), FGG rs2066865 and 
F11 rs2036914 were genotyped. The major allele of the different SNPs was used as reference group, 
however, for the F11 SNP, the minor allele was used as reference as the minor allele of the F11 SNP 
has been found to decrease VTE risk.180 For the ABO SNP, zero risk alleles were classified as O blood 
type, and thus one or two risk alleles present were considered non-O blood type. In Paper III and IV, 
we did not differentiate between hetero- and homozygotes. A genetic risk score conceived by de Haan 
and colleagues was created by summarizing the number of risk alleles from the five sequenced SNPs 




3.3. Cancer assessment 
3.3.1. Identification and validation of cancer diagnoses 
Incident cancer diagnoses during follow-up were identified by linkage to the Cancer Registry 
of Norway (CRN) (Paper I to IV) and the Danish Cancer Registry (Paper IV) by the use of participants’ 
individual unique national civil registration number, which is assigned to all residing in the Nordic 
countries. The CRN and the Danish Cancer Registry are similarly organized, receiving information from 
several medical sources such as general practitioners, hospital doctors, death certificates and 
pathological laboratories. The registries are also linked to the Norwegian National Cause of death 
Registry and the Danish Register of Cause of Death in the respective countries. Cancer registration and 
reporting cancer cases has been mandatory by law since 1953 in Norway and 1987 in Denmark.297,298 
Reports have found both cancer registries complete and valid, reporting a completeness of 98.8% in 
Norway and 95-98% in Denmark.297,298 The percentage of microscopically confirmed diagnoses in the 
registries were 94% in Norway and 93% in Denmark, respectively.297,298 The two cancer registries 
provide information regarding the cancer diagnosis date, cancer location (ICD10 codes C00-96 and 
ICD7 codes 140-205), histological grade (ICO-3) and cancer stage (localized, regional, distant or 
unknown). Subjects with non-melanoma skin cancers (ICD10 C44) and no other cancer diagnosis were 
regarded as cancer-free, due to the non-metastatic potential of this disease. 
 
3.3.2. Definition of occult cancer and active cancer 
Temporal proximity to cancer is shown to be a strong predictor for VTE risk.24,35,185 Studies have 
found an increased VTE risk already one year preceding the cancer diagnosis date, with a seven-fold 
increased risk six months prior to the cancer diagnosis date.24,25,185 Further, previously undiagnosed 
cancer is frequent in patients with unprovoked VTE, with a period prevalence of undiagnosed cancer 
increasing from 6.1% at baseline to 10.0% from the time of VTE diagnosis to 12 months after.25 Hence, 
we defined occult cancer (the presence of an undiagnosed cancer) as the 12 months prior to a cancer 
diagnosis date. In Paper IV, we investigated the effect of individual and combination of prothrombotic 
genotypes in a GRS on the risk of VTE in occult cancer, compared to subjects that were cancer-free. 
Two sensitivity analyses were additionally performed to test the robustness of the occult cancer 
variable, where the occult cancer period was defined as six months and two years preceding the cancer 
diagnosis. VTE events occurring after the occult cancer period were censored from the analysis as the 
main objective was to investigate VTE’s related to occult cancer, and not overt cancer. 
40 
 
In Paper I, II and III, we investigated different prothrombotic genotypes and a GRS on the risk 
of VTE in active cancer.  Several studies have found that nearly 50% of cancer-related VTE events occur 
in a two and a half year period around the cancer diagnosis (i.e. from six months before cancer 
diagnosis to two years after),24,35,185 an observation that supports evidence suggesting that VTE risk is 
closely related to the rate of cancer growth, rather than the extent of cancer.196 We therefore chose 
this timeframe to define the active cancer period. Thus, a VTE event was classified as related to active 
cancer if it occurred within six months preceding a cancer diagnosis until two years following the cancer 
diagnosis date. Patients who were still alive and VTE-free at the end of the active cancer period were 
censored at this time, as information regarding cancer progression and remission was not available 
and extending the active cancer period could result in dilution of the results by including VTE events 
that were not related to cancer. 
 
3.4. Assessment of venous thromboembolism 
Only first lifetime, objectively confirmed symptomatic VTE events were included in the Tromsø 
Study, the HUNT Study and the STAC cohort. Trained personal reviewed and validated the medical 
records for each potential case of VTE in both in- and outpatients. A VTE event were classified as DVT 
or PE, and if both conditions occurred concurrently the VTE were recorded as a PE. The VTE events 
were further classified as provoked or unprovoked, depending on the presence of provoking factors at 
the time of VTE diagnosis. The definitions of provoking factors were slightly different between the 
three cohorts in the STAC cohort. However, in the STAC cohort, all three cohorts defined surgery, 
trauma, active cancer, CVC’s and marked immobilization as provoking factors. 
In Tromsø 4, all VTE events in the study period from January 1, 1994 until December 31, 2012 
were identified by searching the hospital discharge diagnosis registry, the radiology procedure registry 
and the autopsy registry at the University Hospital of North Norway (UNN).143 UNN is the sole provider 
for all VTE-related health care and diagnostic radiology procedures for VTE events in the area.  The 
discharge diagnosis codes of interest were the International Classification of Diseases, revision 9 (ICD-
9) codes 325, 415.1, 452, 453, 671.3, 671.4 and 671.9 for the period 1994 to 1998, and ICD-10 codes 
I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1 and O87.3 for the period 1999 to 2012.124 A diagnosis of 
VTE was verified and recorded when the presence of clinical symptoms of DVT of PE was combined 
with objective confirmation by radiologic procedures (i.e. compression ultrasonography, venography, 
pulmonary angiography, spiral CT, perfusion-ventilation scan, or autopsy), and resulted in a VTE 
diagnosis and treatment initiation (i.e. LMWH, vitamin K antagonist or similar anticoagulant 
medications, thrombolytic therapy, vascular surgery). For cases derived from the autopsy registry, a 
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VTE was recorded only if the autopsy report indicated the VTE event as the cause of death or as a 
significant contributing cause of death. 
In HUNT 2, VTE events during follow-up from January 1, 1995 until December 31, 2007 were 
identified by searching the hospital discharge registry and the radiology procedure registry at the two 
local hospitals, Levanger Hospital and Namsos Hospital, and at the tertiary-care center of the region, 
St Olav’s Hospital.2 The discharge diagnosis codes used were ICD-9 codes 415, 451, 452, 453, 325, 
362.3, 433, 557.0, 634–638 (with decimals 6 and 7), 639.6, 639.8, 639.9, 671, 673, 674, and 997.2, and 
ICD-10 codes I26, I80, I81, I82, I63.6, I67.6, K55, H34.8, O08, O22, O87, and O88.2 VTE events were 
included if they presented as symptomatic and treatment requiring, and were confirmed by objective 
diagnostic tests (i.e. ultrasonography, venography, CT scan or perfusion-ventilation scan). 
In the DCH Study, VTE events were recorded from December 1, 1993 until April 30, 2008 using 
the participants’ civil registration numbers and linkage to the Danish National Patient Registry and the 
Danish National Death Registry. The discharge diagnosis codes of relevance were ICD-8 codes 450.99, 
451.00, 451.08, 451.09, 451.99 and ICD-10: I26, I80.1–I80.9.299 Trained personnel reviewed the medical 
records for each potential VTE case including typical clinical symptoms, laboratory blood tests and 
further diagnostic procedures. A verified VTE event required clinical symptoms of VTE and a 
confirmatory diagnostic test (i.e. ultrasonography, echocardiography, venography, CT scan, perfusion-
ventilation scan or autopsy).299 The Danish National Death Registry was used to identify VTE as a cause 
of death, and only VTE events verified with an autopsy were included. 
 
3.5. Statistical analyses 
Statistical analyses for all four papers in the present thesis were performed using STATA 
version 15.0 and 16.0 (Stata Corporation, College Station, TX, USA). Cancer was entered as a time-
varying covariate, and the data was split in relation to the date of cancer diagnosis. For Papers I-III, 
subjects who developed cancer contributed with person-time as unexposed (i.e. cancer-free) from 
date of inclusion until six months prior to the cancer diagnosis, and thereafter contributed with person-
time as exposed (i.e. active cancer) until two years following the cancer diagnosis. In Paper IV, subjects 
contributed with person-years as unexposed until one year prior to the cancer diagnosis date, and then 
as exposed to occult cancer until diagnosed with cancer, and were thereafter censored from the 
analyses. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) 
with 95% confidence intervals (Cis) for incident VTE according to the presence of the different 
prothrombotic genotypes or categories of genotypes in a genetic risk score and by cancer status. All 
analyses were adjusted for age, sex and/or BMI.  
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3.6. Calculation of biological interaction 
Interaction refers to the situation where the effect of one exposure on a certain outcome is 
different across strata of another exposure.300 Meaning that if interaction between two exposures is 
present, these exposures are not independent in causing a certain outcome. Biological interaction can 
be approached in several ways, e.g. by calculating the relative excess risk due to interaction (RERI) or 
the proportion attributable to interaction (AP) or assessing the synergy index (SI) developed by KJ. 
Rothman.301 RERI was calculated in Papers II-IV as HR11-HR10-HR01+1, where HR10 was the hazard ratio 
of one exposure (i.e. cancer) without the presence of the other exposure (i.e. prothrombotic 
genotypes), H01 was the hazard ratio of the presence of prothrombotic genotypes only, and finally, 
HR11 indicated the hazard ratio with both exposures present (cancer and prothrombotic genotypes). 
RERI values below 0 indicate a negative interaction, whereas values above 0 indicate synergism. AP 
was calculated as RERI/HR11, and can be interpreted as the proportion of cases in the combined groups 
that is due to interaction between the two exposures (i.e. the amount of VTE events in subjects with 
cancer and prothrombotic genotypes that occur due to the biological interaction between cancer and 
these SNPs). AP values below 0 indicate negative interaction or less than additivity, whereas values 
above 0 indicate a positive interaction. SI indicates the excess risk from the presence of interaction, 
relative to the risk from exposure when there is no interaction.302 Values of RERI and AP equal to 0 and 
SI equal to 1.0 indicate no interaction.300 
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4. Main results 
4.1. Paper I 
Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism 
VTE is a frequent complication in patients with cancer. In recent years, several SNPs have been 
found to influence VTE risk, however, these SNPs have been scarcely studied in cancer. Glycoprotein 
VI (GP6) rs1613662, is a missense mutation affecting the glycoprotein VI (GPVI) receptor for collagen 
and consequently affecting platelet adhesion and activation. The impact of GP6 rs1613662 on the risk 
of VTE has only been investigated in case-control studies, and the combined effect of GP6 rs1613662 
and cancer on VTE risk has not been previously investigated. Thus, we aimed to investigate the 
association of GP6 rs1613662 on the risk of VTE in the general population and stratified by cancer 
status, using a large case-cohort. Cases with incident VTE (n=1493) and a subcohort (n=13072) were 
derived from the fourth survey of the Tromsø Study (Tromsø 4) and the second survey of the Nord-
Trøndelag Health Study (HUNT 2). Cox regression was used to calculate age-, sex- and body mass index-
adjusted hazard ratios for the association between GP6 variation and VTE by the presence of GP6 
alleles and cancer status. During the study period, 1536 were diagnosed with cancer, of which 233 
(15.2%) experienced a VTE. In cancer-free subjects, the risk of incident VTE decreased with the number 
of minor alleles, and subjects homozygous for the minor GP6 allele (GG) had 34% decreased risk of 
incident VTE (HR 0.66, 95% CI 0.43-1.01) compared to subjects homozygous for the major allele (A 
allele) at GP6. In contrast, cancer patients homozygous for the minor allele (GG) had an increased risk 
of VTE, particularly PE (HR 1.96, 95% CI 0.78-4.94), compared to cancer patients homozygous for the 
major allele (AA). The association between homozygosity at the G-allele and VTE risk was moderately 
attenuated after adjustment for cancer type and stage, as this genetic variant was associated with 
prothrombotic cancers and advanced stages. In conclusion, the GP6 rs1613662 G-allele displayed a 
protective effect on VTE risk in cancer-free subjects, while an increased risk of VTE was observed in 
cancer patients homozygous for the G-allele. Our findings support a role of platelet reactivity in the 






4.2. Paper II 
Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism 
Homozygous carriers of the fibrinogen gamma gene (FGG) rs2066865 have a moderately 
increased risk of VTE, but the effect of the FGG variant in cancer is unknown. We aimed to investigate 
the effect of the FGG variant and active cancer on the risk of VTE. Cases with incident VTE (n=684) and 
a randomly selected age-weighted subcohort (n=3931) were derived from a population-based cohort 
(the Tromsø 4 Study). Active cancer was defined as six months prior to and two years following the 
cancer diagnosis date, and thus, VTE events occurring in this timeframe were considered to be cancer-
related. Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for 
VTE according to categories of cancer and FGG. During a mean follow-up of 12.6 years, 854 subjects 
had active cancer, of whom 167 experienced an incident VTE. In subjects without cancer, homozygosity 
at the FGG variant was associated with a 70% (HR 1.7, 95% CI 1.2-2.3) increased risk of VTE compared 
to non-carriers. Cancer patients homozygous for the FGG variant had a two-fold (HR 2.0, 95% CI 1.1-
3.6) higher risk of VTE than cancer patients without the FGG variant. Moreover, the six-month 
cumulative incidence of VTE among cancer patients was 6.4% (95% CI 3.5-11.6) in homozygous carriers 
of FGG and 3.1% (95% CI 2.3-4.7) in those without risk alleles. A synergistic effect was observed 
between rs2066865 and active cancer on the risk of VTE (synergy index (SI) 1.81, 95% CI 1.02-3.21), 
indicating a biological interaction between the FGG genotype and cancer. Estimation of the 
attributable proportion (AP) due to interaction revealed that 43% (95% CI 0.11-0.74) of the VTE events 
in study participants with cancer and the FGG variant were due to the interaction between the two 
exposures. In conclusion, homozygosity at the FGG variant and active cancer yielded a synergistic effect 




4.3. Paper III 
Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous 
thromboembolic event 
The role of combined prothrombotic genotypes in cancer-related VTE is scarcely studied. We 
aimed to investigate the impact of a 5-SNP score on the risk of VTE in patients with and without cancer 
using a population-based case-cohort. Cases with a first VTE (n=1493) and a subcohort (n=13072) were 
derived from the fourth survey of the Tromsø Study (1994-2012) and the second survey of the Nord-
Trøndelag Health Study (1995-2008). All participants were genotyped for the five SNPs in the genetic 
risk score proposed by de Haan et al., including ABO (rs8176719), F5 (rs6025), F2 (rs1799963), FGG 
(rs2066865), and F11 (rs2036914). Active cancer was defined as six months prior to and two years 
following the cancer diagnosis date, and thus, VTE events occurring in this timeframe were considered 
to be cancer-related. Cox regression were used to calculate hazard ratios (HRs) for VTE according to 
cancer status, individual prothrombotic genotypes and the number of risk alleles in the 5-SNP score 
(0-1, 2-3, and ≥4 alleles). During a median follow-up of 12.3 years, 1496 individuals were diagnosed 
with cancer, of whom 232 experienced VTE. The VTE risk increased with the number of risk alleles in 
the 5-SNP score among subjects without and with cancer. In cancer-free subjects, the HR was 2.17 
(95% confidence interval [CI] 1.79-2.62) for ≥4 versus 0-1 risk alleles. In cancer patients, the 
corresponding HR was 1.93 (95% CI 1.28-2.91). The combination of cancer and ≥4 risk alleles yielded a 
17-fold (HR 17.1, 95% CI 12.523.4) higher risk of VTE compared with cancer-free subjects with 0-1 risk 
alleles. This combined effect was higher than expected on the basis of the individual effects of cancer 
and ≥4 risk alleles (RERI 6.72 95% CI 1.17-12.26). The attributable proportion (AP) revealed that 39% 
of the total VTE events in participants with cancer and ≥4 risk alleles were attributable to the 
interaction between the two exposures (i.e. cancer and ≥4 risk alleles). In conclusion, the risk of VTE 
increased with the number of prothrombotic risk alleles in subjects with and without cancer, and the 
combination of prothrombotic risk alleles and cancer displayed a supra-additive effect on the risk of 
VTE, indicating a biological interaction between the risk factors. Our findings suggest that the 5-SNP 






4.4. Paper IV 
Prothrombotic genotypes and risk of venous thromboembolism in occult cancer 
Unprovoked VTE can be the first manifestation of an occult cancer, and around 5% of patients 
with unprovoked VTE are diagnosed with cancer within one year of follow-up. Some SNPs are found 
to have biological interaction with overt cancer, resulting in a synergistic effect on VTE risk. Whether 
individual prothrombotic genotypes or number of risk alleles in a genetic risk score (GRS) affect VTE 
risk in occult cancer have not been addressed. Thus, we aimed to investigate the individual and joint 
effect of five prothrombotic genotypes and occult cancer on VTE risk in a general population. Occult 
cancer was defined as one year preceding the cancer diagnosis date, and thus, VTE events occurring in 
this period were defined as related to occult cancer. Cases with incident VTE (n=2141) and a subcohort 
(n=14911) were sampled from the Scandinavian Thrombosis and Cancer Cohort (1993-2012). Five SNPs 
previously reported in a GRS were genotyped: ABO (rs8176719), F5 (rs6025), F2 (rs1799963), FGG 
(rs2066865) and F11 (rs2036914). Hazard ratios (HRs) for VTE by individual SNPs and GRS were 
estimated according to non-cancer and occult cancer exposure using Cox regression.  During a median 
follow-up of 12.2 years, 1817 subjects developed occult cancer, and of these, 93 experienced a VTE. 
The VTE risk was 4-fold higher (HR 4.05, 95% CI 3.28-5.00) in subjects with occult cancer compared to 
those without cancer. Subjects with an occult cancer and VTE had a higher proportion of prothrombotic 
and advanced cancers compared to cancer patients without VTE. The VTE risk increased according to 
individual prothrombotic genotypes and the GRS in cancer-free subjects, while no such effect was 
observed in subjects with occult cancer (HR for ≥4 versus ≤1 risk alleles in the GRS: 1.14, 95% CI 0.61-
2.11). In conclusion, five common prothrombotic genotypes, individual or combined, were not 
associated with risk of VTE in occult cancer. Our findings suggest that prothrombotic mechanisms 
related to rapidly advancing cancers at high-risk sites are prominent for VTE risk in occult cancer and 






5. General discussion 
5.1. Methodological considerations 
5.1.1. Study design 
The papers (I-IV) in this thesis are based on data from three large, prospective, population-
based cohort studies. Further, we used a case-cohort study design for all the four papers. Therefore, 
both the cohort study design and case-cohort design will be discussed. 
Cohort studies and case-control studies are the most commonly used observational study 
designs in clinical medicine.303 Observational studies often aim to examine and quantify risk factors for 
health-related outcomes and to identify preventable causes of a disease or medical condition. Contrary 
to experimental studies (i.e. trials), the researchers or investigators in observational studies do not 
intervene but rather observe and assess the strength of the relationship between an exposure and an 
outcome.304 In cohort studies, information on exposure and various predefined characteristics are 
obtained for all study participants at study enrollment, with subsequent follow-up until occurrence of 
an outcome, or until migration, death or end of study period. Thereafter, the group of exposed subjects 
and the group of non-exposed subjects are compared with respect to the outcome.  
Cohort studies offer several advantages.305 The prospective study design makes it possible to 
calculate incidence rates (IR), as a measure of the absolute risk of a disease, and relative risk estimates 
of disease in exposed and unexposed individuals. Compared to other observational studies, the nature 
of the cohort study design also allows several exposures and outcomes to be investigated 
simultaneously. Furthermore, if the cohort study is based on a large sample size and a defined and 
well-characterized population (representative sample), with a low degree of bias and confounding 
(high internal validity), the results can be extrapolated beyond the source population to similar 
populations (i.e. external validity). Additionally, as the information on exposure is collected prior to 
the outcome in cohort studies, the criteria of temporality is met. The criteria regarding the temporal 
sequence between an exposure and an outcome is one of the criteria needed to provide epidemiologic 
evidence for causality.306  Other criteria for determination of causality are for instance strength of the 
association, a plausible mechanism between exposure and outcome, a biological gradient (dose-
response relationship), reversibility and consistency with other studies.306  
Results from one cohort study are not sufficient to establish causality. For this matter, a 
randomized controlled trial (RCT) would be preferable. In RCTs, comparison groups are similar in all 
characteristics except from the exposure or intervention, and thus considerably reducing confounding 
and bias. However, even though RCTs are the most suitable study design to conclude on causality, RCTs 
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require a lot of resources and are both time-consuming and expensive. Further, RCTs may rise ethical 
concerns and may be impossible to perform. For example, it would be unethical and impossible to 
inflict cancer on study participants for the purpose of investigating the association between cancer and 
VTE. Therefore, a cohort study design would be a suitable approach to investigate cancer-related VTE. 
Some limitations of the cohort study design require attention. Cohort studies and other observational 
study designs are prone to bias and confounding, which can cause over- and/or underestimates or 
even false assumptions if not taken into consideration. Moreover, the cohort design is poorly suited 
to investigate rare outcomes with low incidence rates, since the design requires large populations and 
a long-term follow-up for enough outcomes to occur and yield an adequate statistical power. However, 
the outcome of interest in this thesis (VTE) occurs frequently in the general population. 
A case-cohort design, a variation of the cohort study 
design, was used for all the papers in this thesis. A case-
cohort design includes only the selected cases of an 
outcome (e.g. VTE) and a random age-weighted sample of 
subjects, a sub-cohort, derived from the entire cohort study 
(Tromsø 4, HUNT 2 or the STAC cohort) independent of 
outcome status (Figure 8). The sub-cohort is meant to 
reflect the occurrence of the exposure in the original cohort 
population.307,308 The case-cohort design is often used when large cohorts are needed to observe a 
sufficient amount of cases, but it is not feasible to collect data on covariates for the whole cohort. 
Prothrombotic genotypes were exposure variables in all the papers (I-IV), and genotyping had to be 
done for all subjects included in the different studies. Genotyping is both time-consuming and costly. 
Therefore, we chose the case-cohort design to limit the costs and time required for genotyping, as the 
full covariate data (e.g. genotyping) in case-cohort designs is only required for cases and sub-cohort 
members. 
Similar to the cohort study design, the case-cohort study has the temporal sequence of 
exposure and outcome, reducing the risk of recall bias or reverse causation. Further, the temporality 
also limits reverse causation, a type of temporal bias where the outcome influences exposure status. 
Like cohort studies, the incidence rates, absolute risks and relative risks can be calculated in case-
cohort studies. Every person in the original cohort, including the cases, has the same probability of 
being selected to the sub-cohort regardless of how much person-time this participant has contributed 
with or whether the person has experienced an outcome or not.309 With appropriate sampling and 
analyses, the risk estimates in the case-cohort are similar to those in the original cohort.307 The case-
cohort study design also carries some limitations. The cases are often overrepresented in the case-




cohort sample, which should be taken into consideration and accounted for. 307 In our studies, the sub-
cohort samples are large, thus limiting overrepresentation of cases. 
 
5.1.2. Validity and generalizability 
Validity refers to how accurately the results of a study represent the true findings and are free 
from bias. The validity of a study can be separated into two domains, internal and external validity, 
both essential in epidemiological research.309 Internal validity is the extent to which an observed 
association is true for the population studied, where bias and confounding are minimized and any 
differences between the studied groups can be truly attributable to the exposure.309,310 External 
validity, often referred to as generalizability, is the extent to which the study results can be 
generalized to populations outside the study population.309,310 Further, external validity is reliant on 
internal validity, however, the presence of external validity does not guarantee internal validity (i.e. 
the study participants are representative for the study population, but there is a presence of 
confounding or bias affecting the association between the exposure and the outcome).311  Most 
violations of internal validity are due to confounding, selection bias and/or information bias.309 Though 
RCTs are designed for minimizing bias and confounding, ensuring high internal validity, the strict 
inclusion criteria for participants in most RCTs limits the external validity of the trials.312 In cohort 
studies derived from general populations with well-defined inclusion and exclusion criteria, high 
attendance rates and minimal loss to follow-up enhances the chance of high external validity.313 
 
5.1.3. Bias and misclassification 
In epidemiological research, errors in estimation can occur either random or systematic. The 
random errors can be minimized by the increase in the sample size, but the systematic errors will 
remain despite a large sample size. Bias is the term for systematic errors in the study design, analysis 
or conduct of the study that results in incorrect estimates of the true association between an exposure 
and an outcome.309 Bias can lead to either over- or underestimation of the risk estimates, depending 
on the type of systematic error. Further, bias may influence both internal and external validity. There 
are several types of biases and several classifications of bias with some overlap.311 However, most 
biases in epidemiology occur under the definition as either selection bias or information bias.311,314 
 Selection bias refers to any systematic error in the recruitment and/or retention of study 
participants, which occur when the exposure or outcome status of an individual influence the 
probability of participating in the study.173 Selection bias is mainly a problem in case-control studies, 
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however, rarely lead to erroneous associations in prospective cohort studies as participants in cohort 
studies are recruited prior to the outcome event.313 Cohort studies are prone to non-response bias (or 
self-selection/participation bias), a type of selection bias which is introduced when subjects who 
volunteer to participate differ from those who do not. In cohort studies, the non-responders are often 
less concerned about health, more often institutionalized elderly or patients suffering from different 
medical conditions than the responders. Overall, participation in epidemiological studies have declined 
over the past years, and attenders are more likely to have higher socioeconomic status and education, 
be female and married.315 This is also seen in the latest surveys of the Tromsø Study, where the 
attendance rate has decreased from approximately 83% in Tromsø 1-3 to 66% in Tromsø 6, and the 
non-responders being younger, more often unmarried and men.293  
In the largest survey of the Tromsø Study, Tromsø 4 (Papers I-IV), all inhabitants aged 25 or 
older were invited, and the attendance was 77%.293 The HUNT 2 survey (Papers I, III and IV) had a 
similarly high attendance rate of 71%, with participants aged above 19 years and living in Nord-
Trøndelag.294 As the participation rates were high, selection bias was likely minimized. However, the 
non-responders will always be an issue. In both Tromsø 4 and HUNT 2, some groups were less 
represented than others. Participation rates were lower among those under the age of 40 years and 
above 80 years, threatening the generalizability in the youngest and oldest populations.293,294 Further, 
men were less represented than women in both studies.293 However, the age-specific IRs of cancer in 
both men and women in Tromsø 4 and HUNT 2, were similar to those reported nationally in Norway,316 
indicating that our study populations are representative for the inhabitants of Norway. In our studies, 
the generalizability of the youngest would not be a large issue, as the incidence of VTE and cancer in 
this age group is low. However, it could be a concern for the oldest populations as VTE and cancer 
occur frequently in elderly, and an underrepresentation of this population would diminish the 
generalizability of the results for these subjects. A study on non-responders of HUNT 2 revealed that 
the main reason for not attending among the youngest was lack of time or having moved to another 
country, and for the oldest the main reason were already having many health-related visits or medical 
consultations and no need for further examinations.294 Around 10% did not attend the health survey 
due to medical immobilization.294.  
For Paper IV, we also used data from the DCH Study. In the DCH Study, people from urban 
areas of Copenhagen and Aarhus aged 50 to 64 years were invited to partake, and the attendance rate 
was 35%.295 It is to be noted that age standardized IRs for cancer in Denmark and in the DCH Study 
were comparable.296 The DCH Study had high proportions of participants with high education level and 
high socioeconomic status.296 Cancer is thought to occur more frequent in individuals with lower 
socioeconomic status, and an underrepresentation of participants with low socioeconomic status 
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could result in a lower incidence of cancer. This could indicate that participants who develop cancer in 
our study are more health-aware than cancer patients in general, being more aware of symptoms, 
resulting in earlier cancer detection, earlier treatment and thereby lowering the risk of VTE. However, 
some cancers develop with vague symptoms or with late developing symptoms, and so, symptoms are 
presented first in advanced cancer stages and late detection despite increased health-awareness. 
Nevertheless, as the age standardized incidence rates (SIR) of cancer in the DCH Study did not differ 
from the general Danish population,296 the low participation rate in subjects with lower socioeconomic 
status should not have considerable impact on the validity in this cohort study. The equal SIRs of cancer 
seen in study participants of the DCH Study and the general population of Denmark might be due to 
the small differences between social classes in Scandinavian countries, compared to the rest of the 
world. 
The incidence of VTE ranges from 1 to 2 per 1000 person-years in other studies.1,2,122 The IRs 
of VTE per 1000 person-years in Tromsø 4 (IR 1.7, 95% CI 1.6-1.9), HUNT 2 (IR 1.5, 95% CI 1.4-1.6) and 
the DCH Study (IR 1.2, 95% CI 1.1-1.3)295 are approximately of the same size, and thus, our cohorts are 
comparable to other Western populations. Additionally, the incidence of cancer in all the cohorts used 
in this thesis seems to be similar to reports from the Norwegian Cancer Registry and Danish Cancer 
Registry.295,316 All of these findings indicate that the study populations in our studies are representative 
for the general Norwegian and Danish population. However, the majority of the study participants in 
our cohorts are of Caucasian ethnicity, and consequently, generalizing our results to populations with 
other ethnicities must be done with caution. 
In this thesis, we used genotyping information for the following prothrombotic SNPs: 
rs1613662 in GP6, rs2066865 in FGG, rs8176719 (non-O blood type) in ABO, rs6025 (FVL) in F5, 
rs1799963 (prothrombin G20210A) in F2, and rs2036914 in F11. As there are large global variations in 
the human genome, the distribution of prothrombotic genotypes may vary greatly.317 Yet, the allele 
frequency of the different SNPs investigated in our studies (Papers I-IV), is essentially similar to other 
Western reference populations, indicating that our results on genetics and VTE risk could be 
generalizable to both Scandinavian and other Western populations.163 
 Differential losses to follow-up is another type of selection bias, that occurs when the 
participants lost to follow-up (i.e. censored or dropped out) differ from those who remain in the 
study.173 This type of selection bias is always a concern in cohort studies,311 especially for cancer and 
VTE, where competing risk of death has been found to overestimate the associated risk for some 
cancers.318 In survival analysis, death is handled as a censoring event the same way as for migration, 
meaning that people who move or die do not contribute with person-time after this date because it is 
unknown whether the outcome occurs in these subjects or not. An assumption of survival analysis is 
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that participants who are not censored, have the same probability or risk of the outcome as those who 
are censored (also called non-informative or independent censoring).  In all of the four papers in this 
thesis, subjects were censored for migration or death. Censoring for migration rise no concerns, as 
there is no reason to believe that those who moved from either Tromsø, Nord-Trøndelag, Copenhagen 
or Aarhus had a different risk of cancer or VTE than those who remained in the areas. However, death 
naturally prevents future outcomes to occur, and when mortality differs between groups, death is 
consequently considered a competing event. As cancer patients have higher mortality than people 
who do not develop cancer, they also have a higher probability of being censored by death. Thus, the 
censoring affects exposed (cancer patients) and non-exposed (cancer-free subjects) differently, and 
further, could result in less person-time of cancer patients at risk and an overestimation of the risk of 
cancer-related VTE. One way of dealing with competing risk of death is the statistical method 
introduced by Fine and Gray where death is considered a competing event rather than a censoring 
event.319 This method presents the ‘true’ probability of an outcome to occur, regardless of competing 
mortality, theoretically resulting in unbiased and meaningfully interpretable results.320 Ay and 
colleagues performed a study using the CATS cohort, comparing the performance of traditional 
analysis (e.g. Kaplan-Meier and Cox regression) to competing risk of death analysis on the risk of VTE 
in cancer patients.318 They found that VTE risk was overestimated when using the traditional analysis 
compared to competing risk of death regression in cancers with high early mortality (e.g. pancreatic, 
gastric and lung cancer). However, minimal differences between the analyses were found for cancers 
with lower mortality rates (e.g. lymphoma and breast cancer). This study conclude that competing risk 
of death should be taken into account for biomarker studies with high mortality, RCTs with 
interventions in groups with different mortality rates, non-randomized trials with differences in risk 
factors for death between groups, and in prognostic studies (e.g. studies on risk prediction models) 
that can have an impact on clinical decision making.318 However, when investigating causality between 
an exposure and an outcome (etiological research), the exposed and unexposed individuals alive and 
actually at risk of an outcome to occur are compared. In these situations, the censored participants 
contribute with exposed or unexposed person-time before the censoring event, and do not affect the 
hazard ratio after being censored.321 In other words, in studies investigating etiological questions, 
traditional analysis methods can be used. This is what we have done for all of the four papers included 
in the present thesis, with subjects contributing with non-exposed person-time and exposed person-
time (when diagnosed with cancer). Further, we did Cox regression analysis stratified by cancer status, 
with cancer patients carrying genetic risk factors being compared to cancer patients without risk 
alleles, and cancer-free carriers compared to cancer-free non-carriers. The presence of the 
prothrombotic SNPs is not known to be associated with mortality. Consequently, we would not expect 
the risk of death to differ in cancer patients with and without the presence of the SNPs. In Paper I, we 
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implemented the competing risk of death analysis. Not surprisingly, the hazard ratios (Cox regression) 
and sub-distribution hazard ratios (competing risk regression) were nearly identical for cancer patients 
with and without the presence of GP6 rs1613662.  
In Paper VI, we investigated the association between prothrombotic genotypes and VTE in 
occult cancer. In order to be registered with occult cancer, patients had to survive until their date of a 
cancer diagnosis. Thus, subjects with occult cancer who died from either a VTE, a underlying cancer or 
other causes before a cancer was diagnosed would be misclassified as cancer-free (immortal time bias). 
Such misclassification could cause an underestimation of the VTE risk in occult cancer. However, the 
five prothrombotic SNPs are not expected to increase the death-rate in the general population 322,323, 
and thus, we believe that such misclassification, if present, would have negligible impact on our results. 
 Information bias refers to an error in the methods used for data collection on the study 
participants that leads to in inaccurate or erroneous information about the exposures or outcome. 
Information bias may result in misclassification, which occurs when the study participants are placed 
in the wrong exposure or outcome category. There are two types of misclassification: differential/non-
random and non-differential/random misclassification.309 Differential misclassification occurs when 
the misclassification is dependent on the exposure or outcome status, resulting in one of the groups 
more often being misclassified than the comparison group, altering the degree of association between 
an exposure and an outcome.173 Differential misclassification can result in either overestimation or 
underestimation of the true association. In the three cohorts used in this thesis, the study participants 
were included prior to the exposure and outcome assessment, and thus, differential misclassification 
is unlikely. Non-differential misclassification is a misclassification of the exposure that is independent 
of the outcome, which results in equal probability of misclassification in cases and non-cases. Non-
differential misclassification tends to bias the association towards the null hypothesis, underestimating 
the true association. Several variables used in our studies are self-reported through questionnaires 
(e.g. smoking habits, physical activity, diabetes), which may introduce misclassification. However, the 
main exposures (prothrombotic genotypes and cancer) and outcome variables (VTE) in the present 
thesis are extracted from the patients’ medical records by trained personnel (VTE), derived from well-
validated national registries (cancer) or laboratory testing (genetics). Therefore, the degree of 
misclassification should be limited. Even though information in medical records rely on reporting from 
doctors, nurses and health care professionals, the main exposure and outcome variables in this thesis 
are major clinical events less likely to be unreported and thereby misclassified. Further, several Cox 
regression models in this thesis were adjusted for age, sex and BMI, which are variables not likely to 
be wrongly reported. In addition, BMI was calculated from trained professionals measuring height and 
body weight in participants wearing light clothing and no shoes.  
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In Papers I-IV, we performed genotyping of different exposure variables of prothrombotic 
SNPs. As for all laboratory testing, there is always some risk of technical errors during the process of 
measuring and testing. To minimize misclassification, DNA testing were repeated if the cell rates were 
low. Further, we excluded SNPs that were out of the Hardy-Weinberg Equilibrium for allele frequencies 
or with allele frequencies inconsistent with those previously reported. If measurement errors did occur 
in this process, it would be by chance and thus, defined as random errors and not systematic. The other 
main exposure in our studies was cancer. Incident cancer diagnoses were identified by linkage to the 
Cancer Registry of Norway (CRN) (Papers I to IV) and the Danish Cancer Registry (Paper IV). Cancer 
registration and reporting cancer cases is mandatory by law in Norway and Denmark,297,298  and reports 
have found both cancer registries complete and valid, with a completeness of 98.8% and 95-98% in 
Norway and Denmark, respectively.297,298 Further, a cancer diagnosis is regarded as more accurate if it 
is based on morphological verification, and the percentage of microscopically confirmed diagnoses in 
the registries has been found to be 94% in Norway and 93% in Denmark.297,298  
In all the four papers in the present thesis, VTE was the main outcome variable of interest. 
Misclassification of VTE cases as false-positives in our studies were largely avoided by the use of strict 
validation criteria. The four criteria included radiological evidence, signs and symptoms of VTE that 
resulted in a clinical diagnosis and treatment of DVT or PE. We therefore assume that there is a limited 
amount of misclassification concerning the most important variables in our studies. Thus, information 
bias would only have a minor influence on the risk estimates. 
Medical surveillance bias refers to when a exposure variable leads to closer surveillance and 
increased probability of detection of the outcome of interest.324 This is especially a potential problem 
when the outcome is subclinical (i.e. symptoms develop over time or there are no symptoms at all) 
and exposed people are more frequently examined. This type of bias often result in an overestimation 
of the risk. As the risk of cancer increase the risk of VTE and vice versa, one of them occurring increases 
the probability of the other to be detected. Cancer patients are frequently examined by health 
personnel, and undergo frequent imaging, and thus, the close medical surveillance increases the 
probability of VTE detection. For instance, patients with suspected PE are examined with CT, which 
may also detect lung cancer. Further, guidelines recommend cancer screening in patients with 
unprovoked VTE that could result in cancer detection, which may have overestimated the IR and HR 
according to the exposure in our studies. Another consideration is the detection of asymptomatic VTE 
cases when subjects for instance undergo imagining (e.g. CT of the thorax) due to an underlying cancer. 
However, to avoid differential bias, the asymptomatic VTEs were not included as VTE cases in our 
cohorts because this could have overestimated the VTE events in cancer patients compared to cancer-
free subjects, as cancer-free subjects would not have had the same medical surveillance and imaging. 
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Thus, the thorough validation process and strict criteria of VTE events were important to avoid 
wrongful classification of VTE events. There are however, some cases where it might be difficult to 
differentiate symptoms of an underlying cancer and symptoms of VTE, for instance when they occur 
from the same organ. An example of such a situation is when a person with lung cancer undergoes 
imaging due to dyspnea. Dyspnea could be a symptom of both the lung cancer itself and a newly 
developed PE, and thus, a PE may be detected as the patient are being examined and undergo imaging. 
In these situations it might be difficult to define the causes of dyspnea (i.e. lung cancer or the PE event), 
and the classification of the PE events as either asymptomatic or symptomatic. 
 
5.1.4. Biological interaction 
Biological interaction refers to when the combined effect of two or more variables on a given 
outcome results in deviance from an additive effect.325 Interaction on an additive scale means that the 
combined effect of two exposures is larger (or smaller) than the sum of the individual effects of the 
two exposures, whereas interaction on a multiplicative scale means that the combined effect is larger 
(or smaller) than the product of the individual effects.300 Several epidemiologists have argued that 
biological interaction should be assessed on an additive scale rather than a multiplicative scale.300 A 
departure or deviance from additivity implies that the number of cases attributable to the joint effect 
of exposure variables is more or less than the sum of the number of cases that would be caused by 
each exposure variable separately.326 In other words, the observed combined effect of the exposure 
variables on an outcome differs from what is expected based on their independent effects.173 Most 
importantly, this would imply that in absence of bias, some subgroups would obtain a greater absolute 
risk reduction from the intervention than others would.326 
We assessed the presence of synergism, a positive biological interaction, in subjects with 
different prothrombotic genotypes and cancer on VTE risk in Papers II, III and IV. Synergism was 
assessed by calculating the relative excess risk due to interaction (RERI), the proportion attributable to 
interaction (AP), and assessing the synergy index (SI). These measures of interaction (i.e. RERI, AP and 
SI), were developed by K.J. Rothman to assess biological interaction for risk factors rather than 
preventive factors, and the measures are designed for estimates pointing in the same direction.300 Risk 
factors meaning that the relative risk of the factor with the outcome is larger than one (i.e. from one 
to infinite), and preventive factors meaning that the relative risk of the factor with the outcome is 
smaller than one (i.e. ranging from zero to one).300 These scales, which are 0-1 and 1-infinite, are not 
suitable to be combined. In a study by Knol et al., they showed that calculating measures of interaction 
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on an additive scale using preventive factors can give inconsistent results, and they suggested that 
preventive factors should be recoded to risk factors before calculating RERI, AP and SI.300 
In Paper II, we investigated a genetic variant of FGG and active cancer on the risk of VTE. In this 
paper, both hetero- and homozygosity of the FGG SNP, as well as cancer, displayed an increased risk 
of VTE and thus, we were able to calculate biological interaction. The risk of VTE due to the combined 
effect of active cancer and the FGG SNP were 22.2-fold (HR 22.2, 95% CI 12.9-38.1) increased when 
compared to cancer-free subjects without the presence of the FGG SNP. The 22.2-fold increased risk  
was much more than what would be expected from summarizing the individual effects of active cancer 
(HR 11.9, 95% CI 9.3-15.2) and presence of the FGG SNP (HR 1.7, 95% CI 1.2-2.3). In Paper I, we did not 
aim to assess biological interaction. However, it would not be possible to do measures of biological 
interaction for the GP6 SNP and cancer, as the risk estimates of the GP6 SNP rs1613662 pointed in 
different directions for subjects with and without cancer. Further, the risk estimates also differed in 
heterozygous (AG) and homozygous (GG) subjects of the GP6 SNP in cancer patients, being protective 
of VTE by the presence of one G-allele, and increasing the VTE risk by the presence of two. 
It is also to be noted that, RERI, AP and SI are all measurements based on the risk estimates 
(i.e. hazard ratios) of the exposures. This indicates that if the hazard ratios calculated for the different 
exposures have wide confidence intervals and lack of statistical power, it results in wide confidence 
intervals also for the measurements of interaction. In Paper II, the hazard ratios for VTE by the 
presence of cancer and the presence of two risk alleles of the FGG SNP, were 11.9 (95%CI 9.3-15.2) 
and 1.7 (95% CI 1.2-2.3), respectively. In the same paper, calculations of RERI had low statistical power 
as the confidence intervals ranged from -2.4 to 21.6 (RERI 9.6). Even though there are some 
uncertainties, the effect size and not the statistical significance level, should be the main focus. 
However, it is to be noted the results must be interpreted with caution. 
 
5.1.5. Confounding 
Confounding represents a threat to the 
evaluation of causal relationships in cohort 
studies.173 In epidemiology, confounding refers to 
a situation where a non-causal association 
between an exposure and an outcome is observed 
as a result of the influence of a third, known or 
unknown, variable (Figure 9).173 The confounding 
variable (i.e. a confounder) has to be associated 




with both the exposure and the outcome, to be unevenly distributed between the groups of interest 
and cannot be an intermediate variable in the causal pathway from the exposure to the 
outcome.173,309,327 A variable that represents an intermediate step in the causal chain between the 
exposure and the outcome should not be handled as a confounder but treated as an intermediate 
factor (i.e. a mediator).309,327 Confounding may strengthen, weaken or even change the direction of the 
true association. In RCTs, the participants are randomly assigned to intervention groups, and all 
potential confounders are thought to be evenly distributed among the comparison groups, not 
affecting the risk estimates.327 Unlike RCTs, cohort studies and other observational studies are not able 
to randomize the exposure variables and are particularly vulnerable to residual confounding. 
Accordingly, all associations observed in cohort studies must be assessed for possible confounders in 
the statistical analysis. There are several strategies to deal with confounding in cohort studies. 
Common strategies to minimize confounding in epidemiological studies include regression 
techniques and stratification.328,329 Regression techniques, adjustments for confounders, is the most 
frequently used method to reduce confounding in cohort studies.328 In such regression models, 
confounding variables are included as covariates in multivariable analysis.173 Further, regression 
models use data to estimate how confounders are related to the outcome and are used to minimalize 
the effect of confounders on the risk estimates.173 Several types of regression exist, such as linear, 
logistic-, and Cox regression. The main advantage of this approach compared to stratification, is that 
data from all subjects are taken into account, and thus, the statistical power of the study is not 
reduced.328 In Papers I-IV in the present thesis, the hazard ratios of the outcome (VTE) were adjusted 
for age and sex in Cox regression models, and additionally, more complex multivariable models 
including age, sex, BMI and other potential confounders were also used. In Paper I, we investigated 
the effect of the genetic variation in glycoprotein VI (GP6 rs1613662) on the risk of VTE in subjects with 
and without cancer. In cancer patients, the presence of advanced stages could potentially be a 
confounder, as higher cancer stages are associated with increased VTE risk.15 In this study, the 
percentage of distant metastasis were higher in subjects heterozygous for the G-allele at GP6 
compared to those without G-alleles. Furthermore, carriers of the G-allele were found to be associated 
with more prothrombotic cancers (i.e. lung, colorectal, hematological cancer and lymphomas). 
However, including the variables ‘cancer type’ and ‘cancer stage’ (i.e. localized disease, regional spread 
and distant metastasis) in a multivariable regression model the risk estimates were only moderately 
attenuated, and accordingly, cancer type and cancer stage were not considered as confounders. Some 
variables in cancer patients, such as chemotherapy and hospitalization, may also be intermediates in 
the causal pathway. Adjusting for such mediators could result in an overestimation and also potentially 
obscure the results. 
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As mentioned, stratification is a second method to reduce confounding in cohort studies.173 In 
stratified analyses, the study population is divided into strata, or sub-groups, of the confounder, and 
the effect of the exposure is estimated in each separate sub-group. However, stratification is not 
always practical if there are small numbers of outcome cases in the sub-groups, which could reduce 
the statistical power. Another disadvantage of stratification is the possible additional confounding of 
other variables that suddenly differ between the sub-groups by stratification. It is of importance to 
specify that even though we used both regression techniques and stratification to minimize 
confounding, unknown confounding factors may still be present and result in residual confounding. 
Matching could be viewed as a type of stratification, where study participants are as equal as 
possible between groups. A case-cohort design was used in the present thesis for all the four papers. 
When creating the case-cohorts, the sub-cohorts were randomly sampled from the original cohorts 
(i.e. Tromsø 4, HUNT 2 and the DCH Study). The sub-cohort members were matched to the VTE cases 
by five-year age categories. This matching was done as the incidence of VTE differ in age groups, and 
the average age of people with a VTE event is higher than the mean age of the populations in the 
original cohorts. 
Even though various methods for dealing with confounding factors were applied in our 
analysis, residual confounding is always a concern. This type of confounding refers to a situation where 
the effect of a confounder is not fully resolved due to incomplete handling of confounding.173 Residual 
confounding in cohort studies can occur when confounders are unknown, misclassified or 
unmeasured, or when the stratification leads to imbalance of characteristics between sub-groups. Due 
to the randomization of exposure/intervention in RCTs, they are the golden standard for minimizing 
confounding and establishing a causal relationship. Unfortunately, residual confounding will always be 
a challenge in observational studies. 
 
5.1.6. Statistical power and precision 
Statistical power can be defined as the probability of rejecting a false null hypothesis (H0). A 
null hypothesis implies that no difference or association exists on the outcome variable of interest 
between the groups being compared.330 An alternative hypothesis (Ha), the opposite of the null 
hypothesis, typically implies that a difference in the population studied does exist between groups that 
are compared on the outcome of interest.330 Epidemiological studies often seek to either reject or 
confirm the null hypothesis (i.e. statistical hypothesis testing), based on the belief that the alternative 
hypothesis might be true. A type I error (also known as false positive) is the incorrect rejection of a 
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true null hypothesis, whereas type II error (also known as false negative) is the non-rejection of a false 
null hypothesis. 
Statistical tests were developed in the early 1900s and became popular, especially in the field 
of medicine, because they provided clear-cut conclusions about whether an association existed or 
not.331 Since the 1980s, an opposition against the use of statistical tests and clear cutoff p-values  has 
been growing.331 Several papers have debated on the division of results as “significant” or “non-
significant” according to the commonly used threshold of P-values of 0.05.331 The P-value is a function 
of the strength of the true association and the sample size.331 This leads to a potential problem both in 
studies based on large sample sizes and studies based on small sample sizes. In an extremely large 
sample size, even the smallest differences becomes significant. Further, in a small sample size, large 
effects might not reach significant levels and thus, misleadingly, not be considered to be a true 
association. For instance, an intervention which reduces VTE risk by 1% could provide statistically 
significant results when tested in a large sample size. Contrary, an intervention that reduces the risk of 
VTE by a total of 50% tested in a small sample size could display a non-significant p-value, and thus, 
not be considered for clinical use. Thus, interpretation of the results in light of effect size and sample 
size is essential. 
In the four papers in the present thesis, we analyzed our data using Cox regression models. 
The statistical power provided by Cox regression models depends on the number of events (i.e. VTE 
events). In all papers, we investigated different prothrombotic genotypes and the risk of VTE, also in 
relation to cancer status. For subgroups analysis, especially for rare genetic variations further 
categorized by cancer status, the number of VTE cases were low. For instance, there were only 10 VTE 
events in cancer patients homozygous for the GP6 SNP in Paper I. Thus, the analyses did not reach 
statistical significance, and the confidence intervals ranged from 0.85 to 3.07. The low statistical power 
is unfortunately seen in all papers, resulting in broad and overlapping confidence intervals. Our limited 
statistical power increases the risk of type II errors, a wrongfully rejection of the alternative hypothesis. 
Let’s say that the finding of a 22.2-fold increased VTE risk by homozygosity of the FGG SNP and cancer 
investigated in Paper II, is in fact true. A low statistical power and a rejection of this finding could result 
in the prothrombotic genotype not to be further investigated or included in future prediction models. 
For small studies, confidence intervals can remind us that results are consistent with both the null 
hypothesis and the alternative hypothesis, indicating that both hypotheses can reflect the actual truth. 
In a paper by J. Sterne and G.D. Smith, the authors describe how results of medical research 
should not be reported as “significant” or “non-significant” but should rather be interpreted in the 
context of the type of study and other available evidence.332 In the paper “No P Please” by F.R. 
Rosendaal and P.H. Reitsma, the authors encourage to show effect sizes with confidence intervals and 
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limit the use of statistical hypothesis tests.331 Several publications support their point of view, that 
presentation of statistical analysis should be done by presenting confidence intervals in addition to, or 
in place of, P-values, moving away from a mechanistic accept-reject dichotomy.332 As stated in all the 
articles in the present thesis, the results should be interpreted with caution due to the wide confidence 
intervals. However, the low statistical power is a result of a low number of cases in subgroup analysis, 
and we consider the risk estimates to be representative. We therefore chose to focus on the risk 
estimates and the effect size and not only the significance levels as one should be seen and interpreted 
in the light of the other. 
 
5.2. Discussion of main results 
5.2.1. Effect of prothrombotic genotypes on venous thromboembolism in overt cancer 
Prior to the present thesis, family and twin studies indicated that heritability explains up to 
60% of VTE events,155 and in recent years, several genetic variations have been found to influence the 
risk of VTE.36 The majority of the genetic studies have, however, excluded individuals with cancer and 
thus, several of the known prothrombotic SNPs have never been investigated in cancer patients. 
Further, studies investigating different SNPs on VTE risk in cancer, are often small, with case-control 
designs and of selected populations, limiting the validity and generalizability of the results. 
In Paper I, we reported that the risk of VTE decreased with the number of minor alleles at GP6 
rs1613662 in the total case-cohort (i.e. including both subjects with and without cancer), with a 21% 
decreased risk of incident of VTE in carriers of the minor allele (i.e. AG/GG) at GP6. In cancer-free 
subjects, we found that homozygous carriers (GG) had a 34% decreased risk of incident VTE compared 
to subjects homozygous for the major allele (AA) at GP6. These findings are similar to previous 
observational case-control studies which have consistently demonstrated that carriers of the G-allele 
at GP6 have a 20% decreased VTE risk and inversely, that A-allele carriers are at a 15% higher risk of 
VTE than non-carriers. 177,178 In 2008, Bezemer and colleagues reported an OR of 1.15 (95% CI 1.01-
1.30) for DVT risk for A-allele carriers of the GP6 SNP in the MEGA Study, including 1314 cases and 
2877 controls.172 In a report published in 2009, Tregouet et al. evaluated the effect of the GP6 SNP 
(rs1613662) on VTE risk in the three following case-control studies: The Marseille Thrombosis 
Association Study (MARTHA), the FARIVE Study, and a GWAS screening of 453 cases and 1327 controls 
recruited from four different French centers.177 The OR of VTE according to the presence of the A-allele 
at the GP6 SNP in the three case-control studies ranged from 1.08 to 1.27.177 Further, in a case-control 
study using data from the Genetic Attributes and Thrombosis Epidemiology (GATE) Study, Austin et.al 
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reported an OR of 1.04 for VTE by the presence of the A-allele at GP6 in 546 VTE cases and 663 controls 
of white Americans.178 
GP6 rs1613662 distinguishes isoforms of the GP6 gene, which encodes the platelet receptor 
GPVI. GPVI is considered to play a crucial role in platelet adhesion and activation.333 Platelets carrying 
the minor allele (G-allele/Pro219) at GP6 rs1613662 express fewer GPVI receptors,175 which leads to 
attenuated platelet adhesion and activation.176 Experimental animal studies have shown that platelets 
play a fundamental role in the formation of venous thrombi.334-336 Using the Tromsø Study, Brækkan 
et al. have demonstrated that subjects with high MPV, a phenotype associated with increased platelet 
reactivity,337-340 had 30% and 50% increased risk for total- and unprovoked VTE, respectively.224 Further, 
Tsai et al. have reported that subjects with high levels (the highest quartile) of von Willebrand factor 
in plasma, a factor instrumental for adhesion of platelets to the vascular wall, have an almost 5-fold 
higher risk of future VTE compared to subjects in the lowest quartile.222 In addition, randomized clinical 
trials have shown that treatment with the platelet inhibitor aspirin is associated with 20-30% reduced 
risk of recurrent VTE. 341,342 Our findings that carriers of the G allele(s) at GP6 have lowered risk of 
incident VTE provide further evidence that platelet function is involved in thrombus formation in VTE. 
To the best of our knowledge, we were the first to investigate the effect of GP6 rs1613662 on 
VTE risk in cancer. We found that among cancer patients, subjects heterozygous for the minor GP6 
allele (AG) exhibited decreased VTE risk of similar magnitude to that found in subjects without cancer. 
In contrast, cancer patients homozygous for the G-allele displayed an increased risk of VTE, when 
compared to cancer patients homozygous for the A-allele (AA). We also reported that the G-allele was 
associated with more prothrombotic cancers (i.e. lung, colorectal, hematological cancer and 
lymphomas) and presented with more severe stages of cancer (i.e. distant metastasis), when 
compared to subjects heterozygous or homozygous for the A-allele. The inverse effect may be 
explained by a differential impact of the G-allele at GP6 rs1613662 on the cancer type, cancer stages 
and mortality rates. However, variants at the GP6 rs1613662 may also have differential impact on 
platelet reactivity under various conditions. When we adjusted for cancer types and stages, the risk 
estimates were only moderately attenuated, indicating that the prothrombotic and metastatic cancers 
cannot be the whole explanation for the opposite effects observed in hetero- and homozygous carriers 
of the GP6 SNP. 
Our findings support a role of platelet reactivity in the pathogenesis of VTE, which may differ 
according to cancer status. Elevated platelet counts are frequently observed in cancer patients, have 
been found to be associated with decreased survival,113,115 and have been shown to predict future risk 
of cancer-related VTE events. 226,343 In contrast, no association between platelet count and the VTE risk 
has been observed in general populations. 139,223,224,226 In addition, mean platelet volume (MPV) has 
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shown differential association with VTE risk in subjects without and with cancer. Whereas high MPV is 
associated with an increased risk of VTE in the general population,224 it is associated with a lower VTE 
risk and improved survival in cancer patients.344 The mechanism(s) underlying the combined, but 
apparent opposite effect of homozygosity at the G-allele of GP6 rs1613662 and cancer on VTE risk 
remains elusive. Of note, we cannot rule out the possibility of a chance finding, as there are only 10 
VTE cases in cancer patients homozygous for the G-allele at GP6. 
 Even though the role of prothrombotic genotypes in the pathogenesis of VTE in malignant 
disease have been scarcely studied, previous studies have found that some prothrombotic genotypes 
(e.g. factor V Leiden and prothrombin G20210A) are associated with increased risk of VTE in cancer 
patients.264,266,271 Further, the combined effect of cancer and factor V variants (e.g. factor V Leiden 
rs6025 and rs4524) has been found to exceed the sum of the individual effects of the genetic variants 
and cancer, implicating a biological interaction on the risk of VTE.43,267 Due to the findings of a 
synergistic and supra-additive effect of prothrombotic genotypes and cancer, we were interested in 
investigating the joint effect of other prothrombotic SNPs and cancer of the risk of VTE. 
 In paper II, we reported that homozygosity of the risk allele (C-allele) at FGG rs2066865 was 
associated with an increased risk of VTE.  In 2005, Uitte de Willige et al. were the first to propose FGG 
rs2066865 as a novel risk factor for VTE in the Leiden Thrombophilia Study.168 In this study, they 
demonstrated that the FGG polymorphism influences VTE risk merely in Caucasian populations, and 
not in African-Americans.168 Further, the FGG SNP has not been found to influence VTE risk in Chinese 
populations.345 Since 2005, several observational studies have reported an association between 
homozygosity of the FGG SNP risk alleles and an increased risk of VTE in Caucasians.168,169,346 In a meta-
analysis of seven observational studies, the OR was 1.61 for VTE in subjects with two risk alleles at the 
FGG SNP.169 In correspondence with these results, we reported that subjects without cancer had a HR 
for VTE of 1.7, when compared to cancer-free subjects with zero risk alleles. 
 We also reported the combined effect of the FGG SNP and cancer on VTE. The combination of 
homozygosity (CC) at rs2066865 and active cancer displayed a synergistic effect on VTE risk on an 
additive scale, and the effect was particularly increased for the risk of PE. The finding might indicate 
that the FGG variant plays a more important role in the pathogenesis of PE than DVT in the presence 
of cancer. The underlying mechanism(s) for the latter observation is unknown, but may imply that 
rs2066865 is associated with fragile thrombi, which are more prone to embolization and manifest 
clinically as PE rather than DVT in cancer patients. 
 The mechanism by which the rs2066865 affects susceptibility to VTE is not fully elucidated. 
However, the current hypothesis is that it acts through a phenotype with altered fibrinogen 
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composition and formation. The FGG rs2066865 is thought to tag the FGG-H2 haplotype, meaning that 
the prothrombotic SNP is inherited along with other specific genotypes. Carriers of the FGG-H2 
haplotype are found to have lower levels of γ’ fibrinogen and γ’ fibrinogen/total fibrinogen,168 without 
altering the total fibrinogen level.347 Fibrinogen γ’ inhibits thrombin activity and thus, lower levels of γ’ 
fibrinogen results in less inhibition of thrombin-mediated activation of FVIII, FV and platelets.348-351 In 
addition, fibrinogen γ’ has been found to increase the sensitivity for activated protein C (APC),352 and 
thus, presence of FGG SNP resulting in lower levels of γ’ fibrinogen, results in a reduced APC sensitivity. 
 Similarly to the findings of Gran et al. in a case-cohort of the Tromsø Study, where the two 
SNPs of F5 (FVL and rs4524) had a strong impact on  cancer-related VTE directly surrounding the cancer 
diagnosis date,267 we found that the cumulative incidence of VTE was substantially increased the first 
six months following the cancer diagnosis in subjects homozygous for the FGG SNP. These findings are 
in accordance with the thrombosis potential model (Figure 5), where several risk factors need to be 
present for a VTE event to occur. Alone, inherited risk factors may only mildly increase VTE risk, 
however, in the presence of cancer, the thrombosis potential is further increased and may results in a 
VTE event. In the time period following a cancer diagnosis, the patients often undergo treatment, such 
as surgery, radiation and/or chemotherapy, and treatment-related complications (e.g. acute infections 
and immobilization) occur frequently. The occurrence of these additional risk factors might explain 
some of the substantial increase in VTE incidence the first months following the cancer diagnosis date. 
However, studies have shown a substantially increased risk of VTE already six months prior to the 
cancer diagnosis, which cannot be explained by treatment-related risk factors.185 The increased VTE 
risk prior to cancer diagnosis might be a result of an interplay between prothrombotic genotypes and 
the prothrombotic state of the cancer itself. 
In Paper III, we investigated the risk of VTE in patients with overt cancer by the presence of 
prothrombotic genotypes, both as individual SNPs and as categories of the 5-SNP score (0-1, 2-3, and 
≥4 risk alleles).181 Further, we investigated whether the combination of cancer and prothrombotic 
genotypes displayed a biological interaction (i.e. synergistic effect) on VTE risk. For each prothrombotic 
genotype, ABO (rs8176719), F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914), the 
VTE risk increased in subjects with and without cancer. The risk of VTE was particularly increased for 
the genotypes in F5, FGG and ABO, where we reported a more than additive effect in combination with 
cancer. These findings were in accordance with previously published studies on prothrombotic 
genotypes and risk of cancer-related VTE. Factor V Leiden,43,267 ABO rs505922 and rs8176746,280 ABO 
rs8176719,283 prothrombin G20210A,263,274-276 and FGG rs2066865353 have all been found to increase 
the risk of VTE in cancer patients. Genotypes of F5 (FVL and rs4525) and FGG have previously been 
found to exert a more than additive effect on VTE risk when combined with cancer.267,353 Accordingly, 
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we found a positive RERI for the genotypes of ABO, FVL and FGG, indicating a biological interaction 
between these SNPs and cancer on VTE risk. 
The 5-SNP score by de Haan and colleagues has been found to be associated with VTE risk in 
the general population,181 and in subjects with ischemic stroke.290 When we applied the 5-SNP score in 
Paper III, we found a dose-response relationship between the number of risk alleles and VTE risk in 
subjects with and without cancer. Further, the combined effect of cancer and the high-risk category of 
the GRS (≥4 risk alleles) yielded a more than additive effect on VTE risk, with a HR of 17 compared to 
those without cancer in the low-risk category (0-1 risk alleles). Measures of biological interaction 
revealed that 39% of the VTE events occurring among cancer patients with ≥4 risk alleles could be 
attributed to the interaction between the risk factors (i.e. cancer and SNPs). Our findings suggest that 
the GRS of the five prothrombotic SNPs could be a useful tool for identifying cancer patients at high 
risk of VTE. However, the predictive performance of the GRS in cancer patients remains to be 
determined. 
Further, the finding of a more than additive effect on VTE risk when combining cancer and the 
SNPs, could indicate that the prothrombotic genotypes act through pathophysiological pathways that 
further increases the procoagulant state of malignancy. The five prothrombotic SNPs are all related to 
functions of the coagulation system and enhance its performance. Malignant tumors release cell-free 
DNA, tissue factor and growth factors that promote the release of neutrophil extracellular traps (NETs) 
from neutrophils.112 These are main triggers of the intrinsic and extrinsic pathways of the coagulation 
system that in combination with prothrombotic genotypes will facilitate downstream coagulation 
activation with subsequent increased risk of thrombus formation. Moreover, acquired resistance to 
activated protein C is common in cancer patients, and may contribute to further increase the risk in 
patients with FVL.265 
 
5.2.2. Effect of prothrombotic genotypes on venous thromboembolism in occult cancer 
Studies have shown that the risk of VTE is increased already one year prior to a cancer 
diagnosis. 24,185 This finding might be explained by the prothrombotic state of the occult cancer alone, 
or the combination of occult cancer and other patient-related predisposing factors for VTE. It is not 
known to what extent individual prothrombotic genotypes and/or a GRS of five prothrombotic 
genotypes affect the risk of VTE in occult cancer as no study prior to ours have investigated this topic. 
In Paper IV, we reported the risk of VTE by the presence of ABO rs8176719 (non-O blood type), 
F5 rs6025 (Factor V Leiden), F2 rs1799963 (prothrombin G20210A), FGG rs2066865 and F11 
rs2036914, both as individual SNPs and number of risk alleles in a GRS in subjects with and without 
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cancer using the STAC cohort. Similar to Paper III and previous studies,181-183 we confirmed that the risk 
of VTE increased by the individual SNPs and the number of risk alleles in the GRS in subjects without 
cancer.181 In contrast, the prothrombotic SNPs were not associated with the risk of VTE in subjects with 
occult cancer, and accordingly, the combination of occult cancer and individual risk alleles or number 
of risk alleles in the GRS, did not display any biological interaction or synergism on the risk of VTE. The 
risk estimates were similar in sensitivity analyses where we altered the occult cancer period to six 
months and two years before the cancer diagnosis. 
Previous studies have shown that VTE patients with occult cancer are more often diagnosed 
with prothrombotic cancers such as pancreatic, lung, gastrointestinal and hematological 
cancers,24,29,35,79,91,354 and more advanced stages (higher degree of regional and distant metastasis) at 
the time of cancer diagnosis.24,91,355 Accordingly, we reported that subjects who developed VTE during 
the occult cancer period had a higher proportion of regional and distant metastasis, as well as a higher 
proportion of cancers at high-risk sites, when compared with those who did not develop VTE during 
the occult cancer period. The mechanisms for VTE in cancer are multifactorial and involve overlapping 
pathways related to the cancer itself and patient-related factors.249 
Our findings might indicate that the prothrombotic mechanisms related to VTE in occult cancer 
(i.e. aggressive and prothrombotic cancers) supersede the effect of the prothrombotic genotypes. 
Upregulation of tissue factor, which is found to be involved in cancer-progression, has been reported 
in advanced cancer stages,105 as well as in high-risk sites for VTE.356,357 In addition to TF expression, 
inflammatory responses with increased levels of circulating proinflammatory cytokines,106-108 inhibition 
of fibrinolytic activity through expression of plasminogen activator inhibitor-1 (PAI-1),109-111 and 
formation of NETs from neutrophils,112 may substantially contribute to a prothrombotic state in rapidly 
developing, aggressive, occult cancers. Thus, the combination of several prothrombotic pathways 
induced by an advancing occult cancer, is likely sufficient to push an individual's thrombotic potential 





o The G-allele at GP6 rs1613662 displayed a protective effect on VTE risk in cancer-free subjects, 
while an increased risk of VTE was observed in cancer patients homozygous for the G-allele. 
Our findings support a role of platelet reactivity in the pathogenesis of VTE, which may differ 
according to cancer status. 
 
o Homozygosity at FGG rs2066865 was associated with an increased risk of VTE in both subjects 
with and without cancer. The combination of homozygosity for the rs2066865 genotype and 
active cancer displayed a synergistic effect on VTE risk on an additive scale, particularly on the 
risk of PE. Our findings may suggest that FGG is an attractive gene biomarker to pursue in 
future research on prediction models for VTE risk in cancer patients. 
 
o For each of the five prothrombotic genotypes, ABO (rs8176719), F5 (rs6025), F2 (rs1799963), 
FGG (rs2066865), and F11 (rs2036914), the VTE risk increased in both cancer-free subjects and 
cancer patients. When the 5-SNP score was applied, we found a dose-response relationship 
between number of risk alleles and VTE risk in subjects with and without cancer. Further, the 
combined effect of cancer and the high-risk category of the GRS (≥4 risk alleles) yielded a 
supra-additive effect of VTE risk, indicating a biological interaction between the risk factors. 
These findings may suggest that the 5-SNP score may be useful for identifying cancer patients 
at increased risk of VTE. 
 
o Five well-established prothrombotic genotypes (ABO (rs8176719), F5 (rs6025), F2 (rs1799963), 
FGG (rs2066865), and F11 (rs2036914)), alone or in combination, were not associated with the 
risk of VTE in subjects with occult cancer. Subjects with VTE in the occult cancer period had a 
higher frequency of prothrombotic cancer types and more advanced cancers at the time of 
cancer diagnosis. These findings might indicate that the potency of prothrombotic 
mechanisms related to rapidly advancing cancers at high-risk sites in occult cancer supersede 
the effect of prothrombotic genotypes on VTE risk. 
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7. Future perspectives 
Malignancy is one of the most important risk factors for VTE.15 Cancer patients who develop 
VTE have shortened life expectancy compared to cancer patients without VTE.20,21 Further, the clinical 
consequences such as recurrent VTE, post-thrombotic syndrome and bleeding complications are 
typically more common and more severe in cancer patients suffering a VTE event compared to cancer-
free VTE patients.64-66 VTE is a potentially preventable disease by the use of anticoagulant treatment, 
however, current guidelines do not recommend routine thromboprophylaxis to all cancer patients due 
to the high risk of bleeding and uncertain benefit-to-harm ratio in these patients.37-39 The severe 
complications and potentially fatal outcome of VTE in cancer stresses the need and importance of 
identifying high-risk subjects, to determine who would benefit from targeted prevention. In our 
studies, we found that the combination of established genetic risk factors, individual or combined in a 
GRS, and cancer displayed a supra-additive effect on the risk of VTE. This implies that genetic variations 
might be genetic biomarkers to pursue in future research on prediction models for VTE in cancer 
patients. As some biomarkers, such as platelet count139,207,223,224,226 and MPV224,344 behave differently 
as risk markers of VTE in cancer and non-cancer, future studies should search for novel and specific 
genetic variants associated with cancer-related VTE. 
Several risk prediction models for VTE risk in cancer have been proposed, such as the Khorana 
score,207 the Vienna CATS score,252 the PROTECHT score,250 and the CONKO score.251 However, these 
risk scores focus mainly on clinical risk factors and modifiable biomarkers, and currently, they are not 
recommended in international guidelines due to their inadequate ability to discriminate between 
subjects of high and low VTE-risk and their unsatisfying performances in validation studies. As 
prothrombotic genotypes are fixed, not influenced by disease, interventions or complications, they are 
attractive candidates as biomarkers for VTE in cancer. New prediction models combining acquired and 
genetic risk factors for VTE may improve risk stratification.  
In 2018, the TiC-Onco risk score was proposed for cancer patients of VTE risk, being the only 
score including prothrombotic genotypes combined with clinical factors.358 The GRS of the TiC-Onco 
score is based on rs2232698, rs6025, rs5985 and rs4524, and the clinical factors included were high 
BMI (>25kg/m2), family history of VTE and primary tumor site.358 A recent study including 71 VTE 
events, showed that the TiC-Onco risk score performed significantly better at identifying high-risk 
patients of VTE than the Khorana risk score (AUC 0.73 vs 0.58, sensitivity 49 vs 22%, specificity 81 vs 
82%, PPV 37 vs 22% and NPV 88 vs 82%).358 Future studies should investigate if the genetic risk factors 
found to display a synergistic effect on VTE risk in combination with cancer, could improve the 
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Genetic variation of platelet glycoprotein VI and the
risk of venous thromboembolism
Family studies have indicated that heritability explains
50-60% of the venous thromboembolism (VTE) events,1
and in recent years, several single nucleotide polymor-
phisms (SNP) have been found to influence the VTE risk.2
Glycoprotein VI (GP6) rs1613662, also known as
T13254C, is an A/G single nucleotide variation in amino
acid 219, which results in a serine to proline substitution
affecting the glycoprotein VI (GPVI) receptor for
collagen.3 Platelets carrying the minor allele (G-
allele/Pro219) at GP6 rs1613662 express fewer GPVI
receptors,4 which leads to attenuated platelet adhesion
and activation.5 Previous observational studies in selected
populations have consistently demonstrated that carriers
of the A-allele at GP6 have a 15% higher risk of VTE than
non-carriers, and inversely, that G-allele carriers have a
20% lower VTE risk.6,7
Cancer is associated with a highly increased risk of
VTE,8 and the complex interactions between inherited
and acquired risk factors on VTE risk (e.g. genetic alter-
ations and platelet count) are more compound and often
different in malignancy.9,10 The impact of GP6 rs1613662
on the risk of VTE has only been investigated in case-
control studies, and the combined effect of GP6
rs1613662 and cancer on VTE risk has not been previ-
ously investigated. We therefore aimed (i) to investigate
the association between GP6 rs1613662 and VTE risk in
the general population and stratified by cancer status,
and (ii) to explore the combined effects of GP6 rs1613662
and active cancer on the risk of VTE, using a large case-
cohort recruited from the general population.
Cases with symptomatic, incident VTE (n=1,493) and a
subcohort (n=13,072) were recruited from the fourth sur-
vey of the Tromsø Study and the second survey of the
Nord-Trøndelag Health Study (HUNT), conducted in
1994-1995 and 1995-1997, respectively. Detailed descrip-
tions of both studies have been published previously.11,12
The Regional Committee of Medical Health Research
Ethics approved the studies, and all participants gave
their informed written consent to participate. VTE events
were identified by broad searches at the hospitals provid-
ing health care for the two regions and thoroughly vali-
dated by review of medical records, as previously
described in detail.13,14 We excluded participants not reg-
istered as inhabitants of Tromsø or Nord-Trøndelag at
study inclusion (n=3), subjects with a cancer diagnosis
prior to inclusion (n=573) or with missing values for GP6
rs1613662 (n=7). Eventually, the case-cohort consisted of
13,982 participants: 1,395 VTE cases and 12,587 subjects
in the subcohort. GP6 rs1613662 was genotyped with
the Sequenom platform as previously described else-
where.10 The HUNT study performed genotyping using
the Illumina HumanCore Exome array. Information
regarding date of cancer diagnosis, primary site of malig-
nancy (ICD-7-codes 140-205) and cancer stage during the
entire follow-up, was obtained by linkage to the Cancer
Registry of Norway.
Statistical analyses were performed using STATA ver-
sion 15.0 (Stata Corporation LP, College Station, TX,
USA). Cancer was entered as a time-varying covariate,
and the data was split in relation to the date of cancer
diagnosis.  A VTE were considered cancer-related if it
occurred within six months prior to and up to 2 years
after the date of cancer diagnosis. Subjects with cancer
who were alive and VTE-free at the end of the active can-
cer period were censored from this date onwards. Age-,
sex- and body mass index (BMI)-adjusted hazard ratios
(HR) with 95% confidence intervals (CI) for VTE were
calculated according to variants at GP6 rs1613662 sub-
jects with and without cancer. Subjects homozygous for
the major allele at GP6 (i.e. AA) were used as the refer-
ence group in the categorized analyses. The proportional
hazard assumption was confirmed by the use of
Schoeneld’s global test. The Fine–Gray model15 was
applied in a sensitivity analysis to account for mortality
as a competing event, and subdistribution hazard ratios
(SHR) were estimated. Mortality rates and HR for death
by categories of GP6 alleles were estimated for disease
free subjects, subjects with cancer only, subjects with
VTE only, and subjects with cancer-related VTE. The dis-
tribution of cancer sites and cancer stages were displayed
across GP6 variants (i.e. AA, AG and GG).
Baseline characteristics in the entire cohort and in sub-
jects with active cancer are presented in Table 1. The
allele frequency of GP6 was 0.17 in both the entire case-
cohort and in the active cancer group, which is similar to
the frequency reported in reference populations.2,3
Of the 1395 VTE events, 819 (58.7%) were deep vein
thrombosis (DVT) and 576 (41.3 %) were pulmonary
embolism (PE). The HR for VTE, DVT and PE adjusted
for age, sex and BMI by categories of GP6 alleles and can-
cer-status are presented in Table 2. The HR for incident
VTE was 21% (HR 0.79, 95% CI: 0.70-0.89) lower in
subjects with ≥1 G-alleles at GP6, when compared to
subjects homozygous for the A-allele. The VTE risk was
essentially similar for heterozygous (AG) and homozy-
gous (GG) subjects compared to those homozygous for
the major allele (AA). The number of G-alleles appeared
to have a differential effect on the risk of DVT and PE.
However, these findings should be interpreted with cau-
tion, as the number homozygous carriers in each catego-
ry was low. The mortality rates for the entire case-cohort
did not differ across the GP6 variants, and coherently, the
risk estimates from the competing risk by death model
were similar to those obtained with the traditional Cox
regression model (data not shown). 
In cancer-free subjects, the risk of incident VTE
decreased with the number of minor alleles, and subjects
homozygous for the GP6 allele (GG) had 34% decreased
risk of incident VTE (HR 0.66, 95% CI: 0.43-1.01) com-
pared to subjects homozygous for the major allele (A
allele) at GP6.
There were 1,536 patients with active cancer of which
233 (15.2%) experienced a VTE. Among cancer patients,
subjects heterozygous for the minor GP6 allele (AG)
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Table 1. Baseline characteristics of study participants.
                                            Entire Case-Cohort        Active Cancer
Subjects                                                     13,982                               1,536
Age (years)                                            51.2±16.5                        61.9±12.4
Sex (males)                                        47.4 (6,625)                     52.0 (800)
BMI (kg/m2)                                            26.3±4.2                          26.8±4.3
Daily smoking                                      29.4 (4,113)                     32.9 (505)
Self-reported CVD                              8.3 (1,161)                      12.6 (193)
GP6 rs1613662*                                           0.17                                  0.17
Heterozygous (AG)                                3,936                                  425
Homozygous (GG)                                   419                                    45
Values are numbers or percentages with numbers or means ± standard deviation
(SD) in parenthesis.  Active cancer: period from six months before a cancer diag-
nosis until 2 years after; BMI: body mass index; CVD: cardiovascular disease (stroke,
angina, myocardial infarction); *: allele frequency (G allele).
exhibited decreased VTE risk (HR 0.82, 95% CI: 0.60-
1.11), which was of similar magnitude to that found in
subjects without cancer. In contrast, cancer patients
homozygous for the G-allele had a higher risk of VTE,
DVT and PE, when compared to cancer patients
homozygous for the A-allele (AA). In cancer patients, the
risk of PE was particularly high in homozygous carriers of
the G-allele (HR 1.96, 95% CI: 0.78-4.94). 
The G-alleles were found to be associated with more
prothrombotic cancers (i.e. lung, colorectal, hematologi-
cal cancer and lymphomas) and presented with more
severe stages of cancer (i.e.distant metastasis), when
compared to subjects heterozygous or homozygous for
the A-allele (Table 3). To test whether the association
between homozygosity for the G-allele and increased
risk of cancer-related VTE could be explained by variant-
dependent differences in cancer types, cancer stages, and
mortality rates, additional adjustments of age, sex, BMI,
cancer types and stages as well as the Fine-Gray model
were applied (Table 2). When cancer types and stages
were included in the adjusted model, the risk estimates
were moderately attenuated. Moreover, the risk esti-
mates for cancer-related VTE in homozygous carriers of
the G-allele remained essentially unchanged when com-




Table 2. Hazard ratios with 95% confidence intervals for venous thromboembolism, deep vein thrombosis and pulmonary embolism by cat-
egories of GP6 rs1613662 alleles and cancer.
GP6                                                      All subjects                                       Cancer-free                                Active cancer
alleles                        Events              HR (95% CI)*               Events           HR (95% CI)*           Events         HR (95% CI)*            HR (95% CI)†
VTE                                                                                                                                                                                                                                                           
AA                                    1,039                            Ref.                               807                          Ref.                          168                        Ref.                                 Ref.
AG                                     321                    0.80 (0.70-0.89)                    242                0.77 (0.66-0.88)                55               0.82 (0.60-1.11)            0.84 (0.62-1.15)
GG                                      35                     0.83 (0.59-1.17)                     22                 0.66 (0.43-1.01)                10               1.61 (0.85-3.07)            1.39 (0.73-2.65)
AG/GG                                356                    0.79 (0.70-0.89)                    264                0.76 (0.66-0.87)                65               0.88 (0.66-1.18)            0.90 (0.67-1.20)
DVT                                                                                                                                                                                                                                                          
AA                                      593                              Ref.                               457                          Ref.                          102                        Ref.                                 Ref.
AG                                     209                    0.89 (0.76-1.05)                    158                0.88 (0.73-1.05)                37               0.91 (0.62-1.33)            0.95 (0.65-1.39)
GG                                      17                     0.70 (0.43-1.13)                     10                 0.52 (0.28-0.98)                 5                1.33 (0.54-3.28)            1.13 (0.46-2.79)
AG/GG                                226                    0.87 (0.75-1.02)                    168                0.84 (0.71-1.01)                42               0.94 (0.66-1.36)            0.97 (0.67-1.39)
PE                                                                                                                                                                                                                                                             
AA                                      446                              Ref.                               350                          Ref.                           66                         Ref.                                 Ref.
AG                                     112                    0.65 (0.53-0.80)                     84                 0.62 (0.49-0.79)                18               0.68 (0.41-1.16)            0.70 (0.41-1.18)
GG                                      18                     1.01 (0.63-1.62)                     12                 0.85 (0.48-1.50)                 5                1.96 (0.78-4.94)             1.69 (0.67-4.28
AG/GG                                130                    0.68 (0.56-0.83)                     96                 0.64 (0.51-0.80)                23               0.80 (0.50-1.29)            0.80 (0.50-1.30)
HR: hazard ratio; CI: confidence interval; *: adjusted for age, sex and body mass index (BMI); †: adjusted for age, sex, BMI, cancer site and cancer stage; Active cancer: period
from six months before a cancer diagnosis until two years after; Events: the number of venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary
embolism (PE) in each category. 
Table 3. The distribution of cancer types and stages across genotypes at GP6 rs1613662 alleles (AA, AG, GG).
Cancer site                                                AA (n=1,723)                      AG (n=702)                        GG (n=75)                     Total (n=2,500)
Colorectal                                                                283 (16.4)                                105 (15.0)                                14 (18.7)                                 402 (16.1)
Upper GI tract                                                           92 (5.3)                                    34 (4.8)                                     4 (5.3)                                    130 (5.2)
Pancreatic                                                                  53 (3.1)                                    15 (2.1)                                     2 (2.7)                                     70 (2.8)
Lung                                                                           178 (10.3)                                 85 (12.1)                                 15 (20.0)                                 278 (11.1)
Breast                                                                       176 (10.2)                                 86 (12.3)                                   2 (2.7)                                   264 (10.6)
Gynecologic                                                              102 (5.9)                                   45 (6.4)                                     1 (1.3)                                    148 (5.9)
Prostate                                                                    279 (16.2)                                119 (17.0)                                14 (18.7)                                 412 (16.5)
Urologic                                                                     155 (9.0)                                   57 (8.1)                                     6 (8.0)                                    218 (8.7)
CNS                                                                              67 (3.9)                                    33 (4.7)                                     1 (1.3)                                    101 (4.0)
Hematologic and lymph                                         154 (8.9)                                   45 (6.4)                                   9 (12.0)                                   208 (8.3)
Remaining cancers*                                              184 (19.7)                                 78 (11.1)                                   7 (9.3)                                   269 (10.8)
Cancer stage                                                                                                                                                                                                                            
Localized disease                                                   586 (34.0)                                277 (39.5)                                18 (24.0)                                 881 (35.2)
Regional spread                                                      399 (23.2)                                158 (22.5)                                17 (22.7)                                 574 (23.0)
Distant metastasis                                                 318 (15.5)                                126 (17.9)                                19 (25.3)                                 463 (18.5)
CNS: central nervous system; GI: gastrointestinal;*: ear, nose throat, melanomas, endocrine, sarcomas and unknown sites; N: indicates the number of cancers in each cate-
gory and the percentages are presented in parentheses.
Our findings support the notion that platelet function
is involved in the pathogenesis of VTE. The
mechanism(s) underlying the combined, but apparent
opposite effect of homozygosity at the G-allele of GP6
rs1613662 and cancer on VTE risk remains elusive. The
inverse effect may be explained by a differential impact
of the G-allele at GP6 rs1613662 on the cancer type, can-
cer stages and mortality rates. However, variants at the
GP6 rs1613662 may also have differential impact on
platelet reactivity under various conditions.
In contrast to cancer-free subjects where the VTE risk
decreased with the number of G-alleles, cancer patients
homozygous for the G-allele at GP6 rs1613662 displayed
an increased VTE risk.  Our findings imply that measures
of platelet function may have differential impact on the
VTE risk in cancer-free subjects and cancer patients.
Elevated platelet counts are frequently observed in cancer
patients, are associated with decreased survival,16 and
have been shown to predict future cancer-related VTE
events.9 In contrast, no association between platelet
count and the VTE risk has been observed in general pop-
ulations.9 In addition, mean platelet volume (MPV), a
marker of platelet reactivity, has shown differential asso-
ciation with VTE risk in subjects without and with can-
cer. Whereas high MPV is associated with an increased
risk of VTE in the general population,17 it is associated
with a lower VTE risk and improved survival in cancer
patients.18
The main strengths of our study are the prospective
design and the validation of VTE events and cancer diag-
noses. The high attendance rate and wide age distribu-
tion in the parent cohorts reduces the chance of selection
bias in the subcohort. Some limitations merit considera-
tion. Unfortunately, cancer treatment modality was not
available and restricted the possibility to evaluate the
relationship between treatment related factors and genet-
ics. Moreover, our study had limited statistical power,
particularly in some subgroups. This resulted in wide CI,
and our risk estimates should therefore be interpreted
with caution.
In conclusion, the GP6 rs1613662 G-allele displayed a
protective effect on VTE risk in cancer-free subjects,
while an increased risk of VTE was observed in cancer
patients homozygous for the G-allele. Our findings sup-
port a role of platelet reactivity in the pathogenesis of
VTE, which may differ according to cancer status.
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Venous thromboembolism (VTE) is a frequent complication in patientswith cancer. Homozygous carriers of the fibrinogen gamma gene(FGG) rs2066865 have a moderately increased risk of VTE, but the
effect of the FGG variant in cancer is unknown. We aimed to investigate the
effect of the FGG variant and active cancer on the risk of VTE. Cases with
incident VTE (n=640) and a randomly selected age-weighted sub-cohort
(n=3,734) were derived from a population-based cohort (the Tromsø study).
Cox-regression was used to estimate hazard ratios (HR) with 95% confi-
dence intervals (CI) for VTE according to categories of cancer and FGG. In
those without cancer, homozygosity at the FGG variant was associated
with a 70% (HR 1.7, 95% CI: 1.2-2.3) increased risk of VTE compared to
non-carriers. Cancer patients homozygous for the FGG variant had a two-
fold (HR 2.0, 95% CI: 1.1-3.6) higher risk of VTE than cancer patients with-
out the variant. Moreover, the six-months cumulative incidence of VTE
among cancer patients was 6.4% (95% CI: 3.5-11.6) in homozygous carriers
of FGG and 3.1% (95% CI: 2.3-4.7) in those without risk alleles. A synergis-
tic effect was observed between rs2066865 and active cancer on the risk of
VTE (synergy index: 1.81, 95% CI: 1.02-3.21, attributable proportion: 0.43,
95% CI: 0.11-0.74). In conclusion, homozygosity at the FGG variant and
active cancer yielded a synergistic effect on the risk of VTE.
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ABSTRACT
Introduction
Venous thromboembolism (VTE), a collective term for deep vein thrombosis
(DVT) and pulmonary embolism (PE), is a common disease associated with sub-
stantial short- and long-term morbidity and mortality.1,2 The incidence of VTE is 
1-2 in 1,000 people/ year, and it increases steeply with age.3 Malignant disease is
associated with a four- to seven-fold increased risk of VTE, and 20-25% of all first
lifetime VTE-events are cancer-related.4,5 VTE, particularly in cancer, leads to pro-
longed and more frequent hospitalizations, and has a substantial impact on quality
of life.6,7 Complications of  VTE, such as recurrence, post-thrombotic syndrome and
treatment-related bleeding, occur more frequently in cancer patients,6,8,9 and the risk
of death is higher in cancer patients with than without VTE.10,11
Family and twin studies suggest that VTE is highly heritable, and likely results
from an interplay between inherited and environmental factors.12,13 Fibrinogen, the
precursor of fibrin, is an essential component in the final stage of the coagulation
cascade. The fibrinogen molecule has three subunits called Aα, Bβ  and g, which
occur in pairs for a total number of six subunits. The g chain, transcribed from the
fibrinogen gamma gene (FGG) located on chromosome 4,
has two isoforms, gA and g’. In the Leiden
Thrombophilia Study, the FGG rs2066865 single
nucleotide polymorphism (SNP) was first proposed as a
risk factor for VTE by reducing fibrinogen g’ levels.14
Several later genotyping15,16 and genome-wide association
studies (GWAS)17,18 confirmed an association between
rs2066865 and VTE risk, whereas two cohort studies
found no significant association.19,20 In a recent meta-
analysis including seven studies, rs2066865was associated
with an increased risk of VTE (OR 1.61, 95% CI: 1.34-
1.93).21
The majority of the genetic studies have excluded indi-
viduals with cancer-related thrombosis. However, as pro-
thrombotic genotypes are fixed, and not influenced by dis-
ease, interventions and complications, they may be attrac-
tive candidates as biomarkers of VTE risk in cancer
patients. Recent studies have suggested that interactions
between cancer and other prothrombotic genotypes (fac-
tor V variants rs6025 and rs4524 and prothrombin
G20210A) have synergistic effects on the risk of VTE.22-25
To the best of our knowledge, no study has investigated
the impact of rs2066865 on the risk of VTE in cancer
patients. Therefore, we aimed to investigate the joint
effect of rs2066865 and active cancer on the absolute and
relative risks of VTE in a population-based case-cohort.
Methods 
Study population
The Tromsø Study is a single-center population-based cohort,
following residents of the municipality of Tromsø, Norway, with
repeated health surveys. The case-cohort was derived from the
fourth survey (Tromsø 4), which included 27,158 participants aged
25-97 years. A detailed cohort profile of the Tromsø study has
been published previously.26 The study was approved by the
Regional Committee for Medical and Health Research Ethics in
Northern Norway, and all participants provided informed written
consent to participation. From enrolment in Tromsø 4 (1994/95),
subjects were followed until December 31, 2012. Detailed infor-
mation regarding identification and validation of VTE-events are
described in the Online Supplementary Material and Methods.
In total, 710 participants developed VTE during follow-up. Of
these, 26 did not have blood samples available or of sufficient
quality for DNA analyses. The remaining 684 subjects were
included as the cases in our study. A subcohort (n=3,931) was
composed by randomly sampling individuals from Tromsø 4
weighted for the age distribution of the cases in 5-year age-groups.
Due to the nature of the case-cohort design, where each partici-
pant has the same probability of sampling, 72 of the cases were
also in the subcohort. Subjects with a history of cancer prior to
inclusion (n=232) and subjects with missing information on
rs2066865 (n=9) were excluded from the analysis. The final case-
cohort consisted of 4,374 subjects, with 640 cases and 3,734 in the
subcohort. A flow chart of the case-cohort is displayed in Figure 1.
Baseline measurements and genotyping
Baseline measurements and genotyping methods are described
in the Online Supplementary Materials and Methods.
Cancer exposure
Cancer assessment is described in the Online Supplementary
Materials and Methods. Previous studies have shown a strong tem-
poral relation between cancer diagnosis and incident VTE, and up
to 50 % of cancer-related VTE events presents within a 2.5-year
interval (from six months preceding the cancer diagnosis until 2
years following the cancer diagnosis).27,28 Therefore, a VTE was
defined as related to active cancer if it occurred within this time
period. 
Subjects who survived the active cancer period without a VTE
were censored at the end of the active cancer period (i.e. 2 years
after cancer was diagnosed). The censoring was performed
because information regarding remission and relapse of cancer
was unavailable, and extension of the observation period of cancer
could result in the dilution of the estimates due to inclusion of
VTE cases not necessarily caused by cancer. This approach result-
ed in censoring of 14 VTE cases that occurred after the active can-
cer period. Thus, 626 VTE cases were included in the final analy-
ses.
Statistical analysis
Statistical analyses were performed using STATA version 15.0
(Stata Corporation LP, College Station, TX, USA). Cox proportion-
al hazards regression models were used to obtain age- and sex-
adjusted HR with 95% CI for VTE across categories of cancer sta-
tus (no cancer/active cancer) and FGG risk alleles. Cancer was
assessed as a time-dependent covariate in the model. Subjects
who developed cancer contributed person-time as unexposed
from the inclusion date until six months prior a cancer diagnosis,
and thereafter contributed person-time in the active cancer group
as exposed. Absolute incidence rates (IR) were calculated based on
person-time from the original cohort (n=27,128). To calculate joint
effects conferred by active cancer and FGG risk alleles, subjects
with no cancer and no risk alleles were used as the reference group
in the Cox model. Based on the total active cancer person-time at
risk derived from the source cohort, 1-Kaplan-Meier curves were
used to estimate the cumulative incidence of VTE in subjects with
active cancer according to the presence of FGG risk alleles.
Methods for assessing synergism between FGG and active cancer
on the risk of VTE are described in detail in the Online
Supplementary Materials and Methods. 
Results
The mean follow-up of the case-cohort was 12.6 years.
In total, 854 subjects had active cancer, of which 167 expe-
rienced an incident VTE. The baseline characteristics of
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Table 1. Baseline characteristics in the entire case-cohort and in the
active cancer group.
                                               Entire case-cohort          Active cancer
Subjects (n)                                               4374                                   854
Age (years)                                              58 ± 13                             62 ± 10
Sex (males)                                         47.0 (2,048)                      53.0 (456)
BMI (kg/m2)                                             26.0 ± 4                            26.0 ± 4
Daily smoking                                       34.5 (1,464)                      43.5 (364)
WBC count (109/L)                                 7.1 ± 1.8                           7.2 ± 1.8
Platelet count (109/L)                            251 ± 60                           250 ± 58
rs2066865*                                                    0.26                                   0.26
1 risk allele                                               1,723                                   334
2 risk alleles                                              289                                     51
Values are numbers or percentages with numbers in parenthesis or means ± standard
deviation (SD).  Active cancer: period from six months before a cancer diagnosis until
two years after;  BMI: body mass index;  Daily smoking indicates smoking at the time
of enrollment; WBC: white blood cell; *: allele frequency. 
the entire case-cohort and in those with active cancer dur-
ing follow-up are presented in Table 1. Subjects who
developed active cancer were slightly older (61±10 years
vs. 58±13 years) and reported a higher frequency of daily
smoking (46% vs. 35%) compared to the entire case-
cohort. The minor allele frequency of rs2066865was 0.26,
which is comparable to reference populations.14,29 The
homozygous variant of the FGG was present in 289
(6.6%) subjects, the heterozygous variant in 1,723 (39.4%)
subjects, while 2,362 (54.0%) subjects were non-carriers
of the FGG variant. The allele frequency was essentially
similar in subjects who developed cancer.  Expected versus
observed proportions of hetero- and homozygous individ-
uals in the subcohort according to the Hardy-Weinberg
equilibrium are presented in Online Supplementary Table
S1. 
The clinical characteristics of the VTE events stratified
by the presence of active cancer are shown in Table 2.
Compared to the non-cancer-related VTE, cancer-related
VTE were more often a DVT (59.2% vs. 55.5%) than a PE
(40.7% vs. 44.4%). The prevalence of provoking factors
such as acute medical conditions, immobilization and sur-
gery were essentially similar between the two groups, as
were the total proportion of VTE with one or more con-
current provoking factors (44.3% vs. 44.7%). Non-cancer
related VTE were more likely to be associated with trau-
mas (9.6% vs. 2.4%) while other provoking factors (i.e.
venous catheters) were more frequent in cancer-related
VTE (8.4% vs. 3.7%). 
In participants without cancer, the IR of VTE increased
from 1.2 (95% CI: 1.1-1.4) per 1,000 people/year among
non-carriers of FGG rs2066865 to 2.0 (95% CI: 1.5-2.7) per
1,000 people/year among those with two risk alleles.
Accordingly, the risk of VTE was 70% (HR 1.7, 95% CI:
1.2-2.3) higher in those with two risk alleles at FGG com-
pared to non-carriers (Table 3). In subjects with active can-
cer, the risk was 12-fold higher (HR 11.9, 95% CI: 9.3-
15.2) in those with no FGG risk alleles, and 22-fold higher
(HR 22.2, 95% CI: 12.9-38.1) in those with two FGG risk
alleles, compared to cancer-free subject without risk alle-
les. Cancer patients with two risk alleles at FGG had a
two-fold higher (HR 2.0, 95% CI 1.1-3.6) risk of VTE com-
pared to cancer patients without risk alleles. In sub-analy-
ses, the effect of active cancer and homozygosity at FGG
yielded higher risk estimates for PE (HR 2.9, 95% CI: 1.3-
6.6) than for DVT (HR 1.6, 95% CI: 0.7-3.5). 
The cumulative incidence of VTE during the active can-
cer period is shown in Figure 2. The cumulative incidence
of VTE increased particularly during the first six months
following a cancer diagnosis, where we found a substan-
tially steeper incline in the incidence curve for subjects
with two risk alleles at FGG rs2066865. The cumulative
incidence of VTE among homozygous carriers was 5.0%
(95% CI: 2.4-9.6), 6.4% (95% CI: 3.5-11.6), and 8.0%
(95% CI: 4.6-13.9) at three months, six months and 24
months after cancer diagnosis, respectively. The corre-
sponding figures for cancer patients who were non-carri-
ers were 2.1% (95% CI: 1.5-3.0), 3.1% (95% CI: 2.3-4.7),
and 4.8% (95% CI: 3.8-6.2), respectively. 
A supra-additive effect on the risk of VTE was observed
for the combination of homozygosity at the FGG variant
and active cancer (Table 4). The Relative excess risk by
FGG rs2066865 and the risk of cancer-related VTE
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Table 2. Characteristics of subjects with cancer-related and non-can-
cer-related first venous thromboembolism.
                                                                   Cancer-related VTE
                                                          Yes (167)                  No (459)
Age at VTE diagnosis (years)                    69 ±11                           68±14
Sex (Males)                                                 44.9 (75)                      47.3(217)
VTE type                                                                                                       
Deep vein thrombosis                             59.2 (99)                      55.5 (255)
Proximal upper limb                                  5.1 (5)                           2.0 (5)
Distal upper limb                                       1.0 (1)                            0 (0)
Proximal lower limb                                62.6 (62)                      65.9 (168)
Distal lower limb                                     12.1 (12)                      28.2 (72)
Other localizations                                  19.1 (19)                       3.9 (10)
Pulmonary embolism                              40.7 (68)                      44.4 (204)
Unprovoked event                                            NA                           54.9 (252)
Provoking factors                                                                                       
Surgerya                                                       12.6 (21)                       15.3 (70)
Traumaa                                                         2.4 (4)                          9.6 (44)
Acute medical conditionb                        15.0 (25)                       14.2 (65)
Immobilizationc                                         20.4 (34)                       20.0 (92)
Other provoking factord                           8.4 (14)                        3.7  (17)
Total provokede                                         44.3 (74)                      44.7 (205)
Values are numbers or percentages with numbers in parenthesis or means ± standard
deviation (SD); VTE: venous thromboembolism; NA: not applicable; awithin eight
weeks before the VTE-event; bmyocardial infarction, ischemic stroke of major infec-
tious disease; cbedrest >3 days, wheelchair, long haul travel >4 hours in the past 14
days; dpresence of other provoking factors noted by the physician (e.g. intravenous
catheters); eone or more provoking factor above 
Table 3. Age and sex adjusted hazard ratios for venous thromboembolism according to categories of fibrinogen gamma (FGG) risk alleles and
cancer status. 
                                                                   VTE                                                               PE                                                         DVT
                       Risk Alleles    Events             HR                       HR             Events            HR                      HR          Events           HR                     HR
                                                              (95% CI)              (95% CI)                          (95% CI)             (95% CI)                      (95% CI)            (95% CI)
                                      0                  242                  Ref.                             -                    112                 Ref.                           -                 130                Ref.                          -
No cancer                   1                  170           1.0 (0.8-1.2)                     -                     70           0.9 (0.6-1.2)                    -                 100        1.1 (0.8-1.4)                   -
                                      2                   47            1.7 (1.2-2.3)                     -                     22           1.7 (1.1-2.7)                    -                  25         1.6 (1.1-2.5)                   -
                                      0                   89          11.9 (9.3-15.2)                 Ref.                   32          8.3 (5.6-12.5)                Ref.                57      15.3 (11.2-21.1)             Ref.
Active cancer             1                   64          12.2 (9.2-16.1)          1.1 (0.8-1.5)            29         10.6 (7.1-16.3)        1.3 (0.8-2.2)         35       13.4 (9.2-19.6)       1.0 (0.6-1.5)
                                      2                   14         22.2 (12.9-38.1)         2.0 (1.1-3.6)             7         22.8 (10.6-49.1)       2.9 (1.3-6.6)          7       21.6 (10.0-46.4)      1.6 (0.7-3.5)
Active cancer: period from six months before a cancer diagnosis until two years after; CI: confidence interval; DVT: deep vein thrombosis; HR: hazard ratio; PE: pulmonary
embolism; VTE: venous thromboembolism.
interaction (RERI) was 9.61 (95% CI: -2.38-21.61) and the
Rothmans synergy index (RSI) was 1.81 (95% CI: 1.02-
3.21). The proportion attributable to interaction (AP) was
0.43 (95% CI: 0.11-0.74). In sub-group analysis, the esti-
mates of biological interaction were stronger for PE
(RSI=2.37, 95% CI: 1.05-5.39) than for DVT (RSI=1.46,
95% CI: 0.65-3.27).  
Discussion
In the present study, we aimed to investigate the joint
effect of the rs2066865 SNP at FGG and active cancer on
the risk of VTE in a case-cohort recruited from the general
population. Homozygosity at rs2066865, occurring in
6.6% of the study population, was associated with an
increased risk of VTE. The combination of an rs2066865
homozygous risk genotype and active cancer showed a
synergistic effect on VTE risk (on an additive scale). The
effect was particularly strong for PE. The cumulative inci-
dence of VTE increased substantially during the first six
months following a cancer diagnosis, especially among
patients with two risk alleles at FGG rs2066865. Our find-
ings suggest that homozygosity at FGG rs2066865 may
aid to differentiate patients at high and low risk of cancer-
related VTE.
Several observational studies have reported an associa-
tion between homozygous genotype of rs2066865 and
increased risk of VTE in Caucasians.14-16,21 In a recent meta-
analysis including seven observational studies, the odds
ratio of VTE was 1.61 for homozygosity at rs2066865.21
Accordingly, in cancer-free subjects, we found that those
with two rs2066865 risk alleles had a 1.7-fold higher VTE
risk than those with 0 risk alleles. The risk estimates for
DVT and PE were essentially similar in cancer-free sub-
jects. 
Even though the role of prothrombotic genotypes in
cancer-related VTE have been scarcely studied, previous
studies have found that some prothrombotic genotypes
(e.g. factor V Leiden and prothrombin G20210A) are asso-
ciated with increased risk of cancer-related VTE.22,23,30,31
Further, the combined effect of cancer and factor V vari-
ants (factor V Leiden and rs4524) exceeded the sum of the
individual effects, implicating a biological interaction on
VTE risk.22,24 Accordingly, we found that the combination
of FGG and active cancer yielded a synergistic effect on
VTE risk.
In cancer patients, the cumulative incidence curve of
VTE was substantially steeper in individuals homozygous
for FGG during the first six months following the cancer
diagnosis. According to the thrombosis potential model,32
several risk factors need to be present concurrently to
exceed the thrombosis potential and facilitate develop-
ment of a VTE. In the period following a cancer diagnosis,
treatment with surgery and/or chemotherapy is typically
initiated, and treatment-related complications such as
acute infection and immobilization frequently occur.
Thus, the accumulation of several treatment-related risk
factors, which adds to the background risk in patients
with cancer and risk alleles at FGG, may partly explain the
substantial increase in VTE incidence the first half year fol-
lowing a cancer diagnosis. 
In contrast to cancer-free subjects, we found that the
effect of rs2066865 was stronger for PE than for DVT in
cancer patients. This suggests that the FGG variant may
play a more essential role in the pathogenesis of PE than
DVT in cancer patients. The underlying mechanism(s) for
the latter observation is unknown, but may imply that
rs2066865 is associated with fragile thrombi, which are
prone to embolization and manifest clinically as PE rather
than DVT in cancer patients.  
The mechanism by which the rs2066865 affects suscep-
tibility to VTE is not fully elucidated. However, the cur-
rent hypothesis is that it acts through a phenotype with
altered fibrinogen composition and formation. The
rs2066865 SNP tags the FGG-H2 haplotype. Previous
studies have shown that homozygous carriers of the FGG-
H2 haplotype had lower levels of g’ fibrinogen and g’ fib-
rinogen/total fibrinogen concentration14 without alter-
ations in the total fibrinogen level.33 The suggested mech-
anism is that the FGG variant favors formation of the
abundant g-chain isoform (gA) above the minor g-chain
(g’) through alternative splicing of the mRNA of the FGG-
gene.14,33 Fibrinogen g’ exhibits an inhibitory activity
towards thrombin, due to a high affinity binding site on
the g’ chain for thrombin exosite II,34 which inhibits
thrombin-mediated activation of factor VIII,35 factor V36
and platelets.37 Moreover, fibrinogen g’ has been shown to
increase the activated protein C (APC) sensitivity.38
However, studies on the association between low plasma
levels of fibrinogen g’ and VTE risk have shown some-
what inconsistent results.14,20
Current anticoagulant prophylaxis regimens efficiently
prevent first VTE in cancer patients, but at the expense of
a substantial risk of major and life-threatening bleedings.39
Therefore, current international guidelines do not recom-
mend prophylactic anticoagulation to all ambulatory can-
cer patients.40,41 Thus, it is vital to recognize patients that
are at high risk of cancer associated VTE, in order to iden-
tify those who would benefit most from thromboprophy-
laxis.  Prothrombotic genotypes are attractive biomarker
candidates, which could be used to distinguish between
high and low risk of VTE in cancer patients, since they are
fixed and not affected by the clinical status or treatment-
related factors. In the present study, 6.4% of cancer
B. Paulsen et al.
1966 haematologica | 2020; 105(7)






Missing FGG rs2066865 n=9
patients with two risk alleles at FGG rs2066865 developed
VTE during the first six months after cancer diagnosis
compared to 3.1% of cancer patients without risk alleles.
Our findings suggest that FGG may be an attractive gene
candidate to pursue in future research on prediction mod-
els of VTE risk in cancer patients. We and others have pre-
viously reported similar discriminative power of two vari-
ants in the F5 gene (rs6025 and rs4524),23,24 and a genetic
model including nine SNP reported promising predictive
capacity on VTE risk in breast cancer.42 Recently, a new
risk prediction model for cancer-related VTE, including
clinical characteristics and genetic variants, reported a
strong predictive capacity with an area under the curve
(AUC) of 0.73 and performed better that the Khorana
score (AUC 0.58).43
The main strengths of present study are the prospective
design, high participation rate and long-term follow-up,
making it possible to capture a large quantity of both inci-
dent cancer- and VTE-events in the study population.
Since all participants live within a single hospital catch-
ment area, the probability of missing outcomes is low.
Moreover, both incident VTE-events and cancer diagnoses
were systematically validated and objectively confirmed.
The study was limited by the lack of statistical power in
sub-group analysis (i.e. DVT/PE), illustrated by wide CI
for our risk estimates. In addition, we did not have access
to information on treatment regimens or medical compli-
cations among cancer patients. Although there is no rea-
son to believe that the type or intensity of treatment
would be influenced by the genetic makeup, such data
could have provided further insights into the possible
interplay between genes and treatment-related risk fac-
tors. 
In conclusion, we found that homozygosity at FGG
rs2066865 was associated with an increased risk of VTE,
and yielded a synergistic effect on the VTE risk in combi-
nation with active cancer, particularly on the risk of PE.
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Figure 2. Cumulative incidence of
venous thromboembolism in the pres-
ence of FGG rs2066865 risk alleles
during the active cancer period. VTE:
venous thromboembolism; m: months.
Table 4. Measures of interaction between the homozygous fibrinogen gamma (FGG) variant and active cancer on venous thromboembolism.
                                        Rothmans synergy index (RSI)          Relative excess risk by interaction (RERI)              Proportion due to interaction (AP) 
                                                        (95% CI)                                                     (95% CI)                                                            (95% CI)
FGG rs2066865                                                                                                                                                                                                                              
VTE                                                        1.81 (1.02-3.21)                                                      9.6 (-2.4-21.6)                                                               0.43 (0.11-0.74)
PE                                                           2.37 (1.05-5.39)                                                     13.4 (-4.8-31.7)                                                              0.56 (0.21-0.90)
DVT                                                        1.46 (0.65-3.27)                                                      6.3 (-9.6-22.1)                                                              0.30 (-0.24-0.83)
Rothmans synergy index (RSI) >1 indicates a positive interaction or more than additivity; Relative excess risk by interaction (RERI) >0 indicates a positive interaction or more
than additivity; Proportion due to interaction (AP) >0 indicates a positive interaction or more than additivity. VTE: venous thromboembolism; PE: pulmonary embolism; DVT:
deep vein thrombosis; CI: confidence interval. 
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Abstract
Background: The role of combined prothrombotic genotypes in cancer-related ve-
nous thromboembolism (VTE) is scarcely studied. We aimed to investigate the impact 
of a 5-single nucleotide polymorphism (SNP) score on the risk of VTE in patients with 
and without cancer using a population-based case-cohort.
Methods: Cases with a first VTE (n = 1493) and a subcohort (n = 13 072) were de-
rived from the Tromsø Study (1994-2012) and the Nord-Trøndelag Health Study 
(1995-2008). Five SNPs previously reported as a risk score were genotyped: ABO 
(rs8176719), F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914). 
Hazard ratios (HRs) for VTE were estimated according to cancer status and the num-
ber of risk alleles in the 5-SNP score (0-1, 2-3, and ≥4 alleles).
Results: During a median follow-up of 12.3 years, 1496 individuals were diagnosed 
with cancer, of whom 232 experienced VTE. The VTE risk increased with the number 
of risk alleles in the 5-SNP score among subjects without and with cancer. In cancer-
free subjects, the HR was 2.17 (95% confidence interval [CI] 1.79-2.62) for ≥4 versus 
0-1 risk alleles. In cancer patients, the corresponding HR was 1.93 (95% CI 1.28-2.91). 
The combination of cancer and ≥4 risk alleles yielded a 17-fold (HR 17.1, 95% CI 12.5-
23.4) higher risk of VTE compared with cancer-free subjects with 0-1 risk alleles.
Conclusion: The risk of VTE increases with the number of prothrombotic risk alleles 
in subjects with and without cancer, and the combination of prothrombotic risk al-
leles and cancer leads to a highly elevated risk of VTE.
K E Y W O R D S
5-SNP score, cancer, deep vein thrombosis, prothrombotic genotypes, pulmonary embolism, 
risk, venous thromboembolism
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1  | INTRODUC TION
Venous thromboembolism (VTE), a collective term for deep vein 
thrombosis (DVT) and pulmonary embolism (PE), is a severe and fre-
quent complication of malignancy, of which the incidence is increas-
ing.1,2 Cancer is associated with a four- to seven-fold increased risk of 
VTE,3-5 and approximately 15% of cancer patients will develop a VTE 
during the course of malignancy.6 Cancer patients who develop VTE 
have shortened life expectancy compared with cancer patients with-
out VTE.7,8 The clinical consequences of VTE, such as post-thrombotic 
syndrome, VTE recurrence, and treatment-related bleeding, occur 
more often in cancer patients than in cancer-free subjects.7,9 Current 
guidelines do not recommend routine thromboprophylaxis to all am-
bulatory cancer patients due to the uncertain benefit-to-harm ratio, 
which emphasizes the importance of identifying high-risk subjects.10-12
Simulation studies have shown that mapping genetic profiles 
may be useful to detect subjects at high and low risk of disease.13,14 
Genetic profiling may therefore help to identify subjects in need of 
VTE prophylaxis in high-risk situations, such as cancer, surgery, or 
prolonged immobilization. Several single nucleotide polymorphisms 
(SNPs) are associated with the risk of VTE.15-19 To identify high-risk 
individuals, de Haan et al created a genetic score based on 31 SNPs 
previously reported to increase VTE risk.20 In this score, the SNPs 
with highest odds ratios of VTE were added one-by-one to finally 
create a genetic risk score containing five SNPs: rs8176719 (non-O 
blood type) in ABO, rs6025 (factor V Leiden [FVL]) in F5, rs1799963 
(prothrombin G20210A) in F2, rs2066865 in the fibrinogen gamma 
gene (FGG), and rs2036914 in F11. This 5-SNP score performed 
similarly to the score of all 31 SNPs,20 and detected subjects at in-
creased risk of both incident and recurrent VTE.20-22
Genetic alterations such as Factor V Leiden,23,24 ABO rs505922 
and rs8176746,25 ABO rs8176719,26 and prothrombin G20210A27-30 
have all been found to be associated with VTE risk in cancer. 
Moreover, the combined effect of cancer and the factor 5 SNPs 
rs6025 and rs4524 increased VTE risk on a supra-additive scale, in-
dicating a biological interaction.24 As prothrombotic genotypes only 
need to be measured once, and are not influenced by disease pro-
gression, interventions, or complications, they are attractive candi-
date biomarkers of VTE risk in cancer patients.
The role of genetics in cancer-related VTE is not yet fully elucidated, 
and to the best of our knowledge, no previous study has investigated 
the impact of the 5-SNP score on VTE risk in cancer patients. Therefore, 
we aimed to investigate the impact of increasing number of risk alleles in 
the 5-SNP score on the risk of VTE in subjects with and without cancer 
using a case-cohort recruited from the general population.
2  | METHODS
2.1 | Study population
Study participants were derived from the fourth survey of the Tromsø 
Study, conducted in 1994-1995,31 and the second survey of the 
Nord-Trøndelag Health (HUNT) Study, conducted in 1995-1997.32 
The Tromsø Study (Tromsø 4) and the HUNT Study (HUNT2) are 
Norwegian population-based cohorts of the inhabitants of Tromsø 
municipality and Nord-Trøndelag County, respectively. A total of 
27 158 unique individuals aged ≥25 years participated in Tromsø 4, 
and 66 140 individuals aged ≥20 years participated in HUNT, yield-
ing attendance rates of 77% (Tromsø 4) and 71% (HUNT2). Detailed 
descriptions of the studies have been published elsewhere.31,32
Participants were followed from the date of inclusion until a 
verified first VTE diagnosis, migration, death, or end of follow-up 
(December 31, 2008 in HUNT2 and December 31, 2012 in Tromsø 
4). In Tromsø 4, all VTE events were identified by searching the 
hospital discharge diagnosis registry, the autopsy registry, and the 
radiology procedure registry at the University Hospital of North 
Norway (UNN), which is the sole provider of diagnostic radiology 
and treatment of VTE in the Tromsø area. Trained personnel re-
viewed the medical records for each potential VTE case, and incident 
VTE events were included when clinical signs and symptoms of PE or 
DVT were combined with radiologic confirmation and treatment was 
initiated (unless contraindications were specified). In HUNT2, VTE 
events were identified by searching the hospital discharge diagnosis 
registry and the radiology procedure registry at the two local hospi-
tals in the county (Levanger Hospital and Namsos Hospital) and by 
searching the discharge diagnosis registry of the tertiary-care center 
of the region, St. Olav's Hospital in Trondheim. Two physicians re-
viewed the medical records for each VTE event, and the validation 
criteria included symptomatic VTE events confirmed by radiologic 
procedures (ultrasound, venography, computed tomography [CT] 
scan, or perfusion-ventilation scan) which required treatment. The 
identification and adjudication process of VTEs in both studies have 
been previously described in detail.33,34 Participants with a history 
of VTE before inclusion in the parent cohorts were excluded.
We created a case-cohort by including all cases with a first life-
time VTE (n = 1493) and a randomly sampled subcohort (n = 13 072) 
derived from the parent cohorts (Figure 1). Participants not regis-
tered as inhabitants of Tromsø or Nord-Trøndelag at study inclusion 
(n = 3) and subjects with missing information on risk alleles (n = 170) 
or body mass index (n = 80) were excluded. Further, subjects with 
a cancer diagnosis prior to or less than 6 months after inclusion 
(n = 624) were excluded. Eventually, the case-cohort consisted of 
Essentials
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13 688 participants, of whom 1362 were VTE cases. Due to the na-
ture of the case-cohort design, in which every person in the cohort, 
including the cases, has the same probability of being selected to the 
subcohort, 206 of the subjects randomly selected to the subcohort 
were also cases. All participants gave their informed written con-
sent to participate and The Regional Committee of Medical Health 
Research Ethics approved the study.
2.2 | Baseline measurements and genotyping
Baseline information was obtained by physical examination, blood 
sampling, and self-administrated questionnaires in each study. Body 
height and weight were measured with participants wearing light 
clothing and no shoes. Body mass index (BMI) was calculated by di-
viding the weight in kilograms (kg) by height in meters (m) squared 
(kg/m2). Information on history of cardiovascular disease (myocardial 
infarction, angina, or stroke), diabetes mellitus, and smoking status 
were obtained from the questionnaires.
DNA was isolated from blood, and the following five SNPs 
were genotyped: ABO rs8176719 (non-O blood type), F5 rs6025 
(Factor V Leiden), F2 rs1799963 (prothrombin G20210A), FGG 
rs2066865, and F11 rs2036914. In Tromsø 4, the Sequenom 
platform was used for genotyping rs8176719 (ABO), rs6025 
(F5), rs1799963 (F2), and rs2036914 (F11), while rs2066865 
(FGG) was genotyped with the TaqMan platform, as previously 
described.35 In HUNT2, genotyping was performed using the 
Illumina HumanCore Exome array.
F I G U R E  1   Study population. Participants were recruited from the fourth survey of the Tromsø study (1994-2012) and the second survey 
of the Nord-Trøndelag Health (1995-2008) study. VTE indicates venous thromboembolism; SNPs, single nucleotide polymorphisms
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Subjects were considered as carriers of prothrombotic geno-
types if one or two risk alleles were present. Hence, we did not dif-
ferentiate between hetero- and homozygous carriers. Because the 
minor allele at F11 rs2036914 is associated with reduced VTE risk,36 
the common allele was set as risk allele in our analysis. Zero risk al-
leles at ABO rs8176719 was defined as O blood type, whereas one 
or two risk alleles were classified as non-O blood type. The 5-SNP 
score conceived by de Haan et al was created by summing the num-
ber of risk alleles from the five sequenced SNPs.20
2.3 | Cancer assessment
Information on cancer diagnosis, primary cancer site (International 
Classification of Diseases, Revision 7 [ICD-7] codes 140-205), and 
stage during follow-up, was obtained by linkage to the Cancer 
Registry of Norway. The Cancer Registry of Norway is considered a 
complete and valid registry with reported 98.8% completeness and 
with 94% of the cases being histologically verified.37 Non-melanoma 
skin cancers (ICD-7 codes 191.0-191.9) were classified as non-can-
cer due to the pathophysiology and nature of these cancers.
As temporal proximity to cancer diagnosis is shown to be a strong 
predictor for VTE risk,1,24,38 a VTE event was classified as related to 
active cancer if it occurred within 6 months prior to a cancer diag-
nosis until 2 years following the cancer diagnosis date. Patients who 
were not diagnosed with VTE and still alive at the end of the active 
cancer period were censored at this time, as information regarding 
cancer progression and remission was not available and extending 
the active cancer period could result in dilution of the results by in-
cluding VTE events that were not related to cancer. Consequently, 
79 VTE events that occurred beyond the active cancer period were 
never counted in the analyses. Thus, the total number of VTE events 
in the analyses were 1283, of which 232 occurred in the active can-
cer period.
2.4 | Statistical analysis
Statistical analyses were carried out using STATA version 15.0 (Stata 
Corporation). Cancer was entered as a time-varying covariate and 
data were split in relation to cancer diagnosis date to distinguish be-
tween non-cancer and cancer-exposed periods. Individuals who de-
veloped cancer during follow-up contributed with exposure status 
as cancer-free until 6 months prior to their cancer diagnosis date, 
and from that point onward exposure status changed to active can-
cer. Two years after the cancer was diagnosed, the cancer patients 
who were still alive and had not experienced a VTE event were cen-
sored from the analyses. Thus, individuals who developed cancer 
contributed to both non-exposed and cancer-exposed person-years 
(PY) at risk during the study period.
Cox proportional hazard regression models were used to esti-
mate the hazard ratios (HRs) with 95% confidence intervals (CIs) for 
incident VTE according to the individual SNPs or categories of risk 
alleles (the 5-SNP score categories, ie, 0-1, 2-3, and ≥4 risk alleles) 
and by cancer status (cancer free and active cancer). In analyses 
stratified on cancer status, subjects with 0-1 risk alleles were used 
as reference category. All analyses were adjusted for age, sex, and 
BMI. The proportional hazard assumption was tested by the use of 
Schoenfeld residuals and was found not to be violated.
We also investigated the combined effect of cancer and risk al-
lele categories on VTE risk using cancer-free subjects with 0-1 risk 
alleles as reference category. The presence of a biological interac-
tion between cancer and presence of SNPs was calculated using 
the relative excess risk attributable to interaction (RERI), the attrib-
utable proportion due to interaction (AP), and the synergy index 
(SI) with corresponding 95% CIs.39,40 Briefly, the RERI can be inter-
preted as part of the total effect on outcome (eg, VTE) that is due 
to interaction (eg, between cancer and prothrombotic SNPs), the AP 
as the proportion of the combined effect that is attributable to in-
teraction between the two exposures. A RERI and an AP > 0, and a 
synergy index >1.0 suggest a positive interaction, ie, the combined 
effect of two exposures is larger than the sum of the two separate 
effects.39
3  | RESULTS
There were 1496 subjects diagnosed with cancer during a median 
follow-up of 12.3 years. The baseline characteristics of cancer-free 
subjects and cancer patients with and without VTE are presented in 
Table 1. In cancer-free subjects, participants who experienced a VTE 
were older, had more cardiovascular disease, and higher BMI than 
those without VTE. In cancer patients with VTE, there was a higher 
proportion of women and smokers and they were of younger age 
than cancer patients without VTE.
The proportions of non-cancer and cancer patients across in-
creasing number of risk alleles in the 5-SNP score are shown in 
Figure 2. The total number of risk alleles ranged from zero to seven 
in cancer-free subjects and from zero to six in cancer patients, with a 
median of two in both groups.
The risk estimates for VTE according to prothrombotic SNPs in 
subjects with and without cancer are presented in Table 2. In sub-
jects without cancer, all five SNPs were associated with an increased 
risk of VTE by the presence of one or more risk allele. The high-
est VTE risks were found for FVL (rs6025, HR 2.50, 95% CI 2.13-
2.95), prothrombin (rs1799963, HR 1.55, 95% CI 1.02-2.36), and 
ABO (rs8176719, HR 1.47, 95% CI 1.29-1.86). The greatest risk of a 
cancer-related VTE was seen in subjects with FVL (rs6025, HR 1.89, 
95% CI 1.29-2.77), prothrombin (rs1799963, HR 1.39, 95% CI 0.44-
4.37), and FGG (rs2066865, HR 1.34, 95% CI 1.03-1.74). Measures 
quantifying interaction on an additive scale (ie RERI, AP, and syn-
ergy index) suggested a positive interaction between cancer and the 
presence of three of the five prothrombotic SNPs; ABO (rs8176719), 
FVL (rs6025), and FGG (rs2066865; Table 3).
The risk of VTE increased across categories of increasing risk 
alleles in the 5-SNP score (0-1, 2-3, ≥4) in subjects with and without 
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cancer. In those without cancer, the HR for ≥4 versus 0-1 risk alleles 
was 2.17 (95% CI 1.79-2.62). In cancer patients, the correspond-
ing HR was 1.93 (95% CI 1.28-2.91). Similar results were found 
when analyzing DVT and PE separately (Table S1 in supporting 
information).
In subjects with 0-1 risk alleles, the risk of VTE was nine-fold 
higher in cancer patients than in those without cancer. Accordingly, 
there was a synergistic effect between the number of risk alleles and 
cancer on the relative risk of VTE. Subjects with cancer and ≥4 risk 
alleles had a 17-fold (HR 17.1, 95% CI 12.5-23.4) higher risk of VTE 
than cancer-free subjects with ≤1 risk allele. This combined effect 
was higher than expected on the basis of the individual effects of 
cancer and ≥4 risk alleles (RERI 6.72 95% CI 1.17-12.26). The AP re-
vealed that 39% of the total VTE events in participants with cancer 
and ≥4 risk alleles were attributable to the interaction between the 
two exposures (ie, cancer and ≥4 risk alleles).
4  | DISCUSSION
In this case-cohort study, we investigated the risk of cancer-related 
VTE by the presence of prothrombotic genotypes, both as individual 
SNPs and as categories of the 5-SNP score (0-1, 2-3, and ≥4 risk al-
leles).20 Moreover, we investigated whether the combination of 
cancer and prothrombotic genotypes had a biological interaction on 
VTE risk. For each prothrombotic genotype, the VTE risk increased 
in both cancer-free subjects and in cancer patients, and particularly 
for FVL, FGG, and ABO there was a more than additive effect in 
combination with cancer. When the 5-SNP score was applied, we 
found a dose-response relationship between the number of risk al-
leles and VTE risk in subjects with and without cancer. Likewise, the 
combined effect of cancer and the high-risk category of the genetic 
score (≥4 risk alleles) yielded a more than additive effect on VTE risk, 
with an HR of 17 compared with those without cancer in the low-
risk category (0-1 risk alleles). The AP revealed that 39% of the VTE 
events occurring among cancer patients with ≥ 4 risk alleles could be 
attributed to the interaction between the risk factors.
Our findings on the role of individual prothrombotic geno-
types and risk of cancer-related VTE are in line with the previ-
ously published studies. Factor V Leiden,23,24 ABO rs505922 and 
rs8176746,25 ABO rs8176719,26 prothrombin G20210A,27-30 and 
FGG rs206686541 have all been found to increase the risk of VTE 
in cancer patients. Moreover, SNPs in the F5 gene (FVL and rs4525) 
and FGG41 have been shown to exert a more than additive effect 
on VTE risk when combined with cancer. Accordingly, we found a 
positive RERI for the SNPs in ABO, FVL, and FGG, which indicated a 
biological interaction.
Even though the 5-SNP score has been shown to predict VTE risk 
in the general population,20 and in subjects with ischemic stroke,42 
the combined effect of the 5-SNP score and cancer has not been 
No cancer Cancer
Subcohort VTE Subcohort VTE
Participants, na  12 637 1051 1264 232
Age, y 50.2 ± 16.3 60.3 ± 15.1 62.0 ± 12.2 60.6 ± 13.4
Male sex 48.3 (5977) 47.8 (502) 53.2 (673) 44.4 (103)
BMI, kg/m2 26.2 ± 4.1 27.7 ± 4.5 26.8 ± 4.3 26.9 ± 4.2
Cardiovascular disease 7.7 (972) 14.1 (148) 12.3 (156) 12.1 (28)
Smoking 29.8 (3770) 25.0 (263) 32.2 (407) 34.9 (81)
rs8176719 (ABO)b  61.4 (7767) 69.9 (735) 60.6 (766) 68.1 (158)
rs6025 (F5)b  6.9 (873) 16.3 (171) 7.5 (95) 13.4 (31)
rs1799963 (F2)b  1.3(169) 2.1 (22) 1.3 (17) 1.29 (3)
rs2066865 (FGG)b  42.3 (5346) 45.9 (482) 40.8 (516) 47.8 (111)
rs2036914 (F11)b  78.2 (9879) 82.5 (867) 78.6 (994) 81.0 (188)
Note: Values are in % (n) or mean ± standard deviation.
Abbreviations: BMI, body mass index; VTE, venous thromboembolism.
aParticipants with cancer contributed to observation periods both in the no cancer and cancer 
group. 
bPercentage of participants with ≥1 risk allele. 
TA B L E  1   Baseline characteristics of 
the study population with and without 
cancer and VTE
F I G U R E  2   Distribution (%) of individuals across number (#) of 
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studied previously. In cancer patients, those with ≥4 risk alleles had 
an almost two-fold higher VTE-risk than those with 0-1 risk alleles, 
and the combination of cancer and ≥4 risk alleles yielded a 17-fold 
increased risk. As 39% of the VTEs occurring among those with 
cancer and the high-risk category of the genetic risk score could be 
attributed to the biological interaction, our findings suggest that ge-
netics could be a useful tool for identifying cancer patients at high 
risk of VTE. However, the predictive performance of the 5-SNP 
score remains to be determined.
Risk factors for VTE in cancer can be broadly categorized into 
patient-related, cancer-related, and treatment-related factors. 
Prothrombotic genotypes are examples of patient-related factors 
that determine the intrinsic thrombosis potential of a patient and 
are not influenced by the disease or its progression. The finding 
that cancer and prothrombotic genotypes have a more than addi-
tive effect on VTE risk is especially interesting, as it could indicate 
that prothrombotic SNPs act through pathophysiological pathways 
that further increases the procoagulant state of malignancy. The 
five SNPs are all related to functions of the coagulation system and 
enhance its performance. Malignant tumors release cell-free DNA, 
procoagulant factors such as tissue factor, and growth factors that 
promote the release of neutrophil extracellular traps (NETs) from 
neutrophils.43 These are main triggers of the intrinsic and extrin-
sic pathways of the coagulation system that in combination with 
n Events HR (95% CI)a  HR (95% CI)a 
Cancer rs8176719 (ABO)b 
− − 5210 316 Ref. Ref.
− + 8502 735 1.47 (1.29-1.68) 1.48 (1.29-1.69)
+ − 562 74 Ref. 8.68 (6.73-11.20)
+ + 934 158 1.31 (0.99-1.73) 11.07 (9.12-13.44)
Cancer rs6025 (F5)b 
− − 12 644 880 Ref. Ref.
− + 1044 171 2.50 (2.13-2.95) 2.50 (2.12-2.95)
+ − 1370 201 Ref. 8.16 (6.98-9.54)
+ + 126 31 1.89 (1.29-2.77) 15.95 (11.12-22.87)
Cancer rs1799963 (F2)b 
− − 13 497 1029 Ref. Ref.
− + 191 22 1.55 (1.02-2.36) 1.55 (1.02-2.37)
+ − 1476 229 Ref. 7.93 (6.85-9.18)
+ + 20 3 1.39 (0.44-4.37) 9.05 (2.91-28.17)
Cancer rs2066865 (FGG)b 
− − 7860 569 Ref. Ref.
− + 5828 482 1.14 (1.01-1.28) 1.14 (1.01-1.28)
+ − 869 121 Ref. 7.36 (6.03-8.98)
+ + 627 111 1.34 (1.03-1.74) 9.78 (7.96-12.01)
Cancer rs2036914 (F11)b 
− − 2942 184 Ref. Ref.
− + 10 746 867 1.27 (1.08-1.49) 1.27 (1.08-1.49)
+ − 314 44 Ref. 9.21 (6.62-12.81)
+ + 1182 188 1.11 (0.79-1.54) 9.63 (7.84-11.83)
Cancer 5-SNP scorec 
− 0-1 3106 170 Ref. Ref.
− 2-3 8111 589 1.33 (1.12-1.57) 1.33 (1.12-1.57)
− ≥4 2471 292 2.17 (1.79-2.62) 2.15 (1.78-2.60)
+ 0-1 322 41 Ref. 9.16 (6.51-12.90)
+ 2-3 931 139 1.18 (0.83-1.68) 10.3 (8.21-12.9)
+ ≥4 243 52 1.93 (1.28-2.91) 17.1 (12.5-23.4)
aAdjusted for age, sex, and body mass index. 
bPositive indicating subjects with one or two risk alleles. 
cNumber of risk alleles. 
TA B L E  2   Hazard ratios (HR) with 
95% confidence intervals (CI) for venous 
thromboembolism (VTE) by categories of 
prothrombotic genotypes and cancer
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prothrombotic genotypes will facilitate downstream coagulation 
activation with subsequent increased risk of thrombus formation. 
Moreover, acquired resistance to activated protein C is common in 
cancer patients, and may contribute to further increase the risk in 
patients with FVL.44
For decisions on use of thromboprophylaxis in cancer pa-
tients, the risk of VTE needs to be evaluated and weighted 
against the risk of bleeding. Several risk prediction models for 
VTE risk have been proposed, such as the Khorana score,45 the 
Vienna CATS score,46 the PROTECHT score,47 and the CONKO 
score.48 However, these risk scores focus mainly on clinical risk 
factors, and currently, they are not recommended in international 
guidelines due to unsatisfying performances in validation studies. 
The TiC-Onco score is the only score that includes genetics,49 
and in this score, eight prothrombotic SNPs were investigated to-
gether with clinical variables. The final TiC-Onco score included 
four SNPs (FVL rs6025, F5 rs4524, F13 rs5985, and SERPINA10 
rs2232698). Of note, the TiC-Onco score performed better than 
the Khorana score in the derivation study,49 but the performance 
of these two models has not been compared in a validation study. 
Nevertheless, the TiC-Onco results supports that prothrombotic 
genotypes may be promising candidates for risk prediction of VTE 
in cancer patients.
Major strengths of our study include the large number of 
genotyped subjects followed for a long period of time, the high 
attendance rate in the two cohorts, and the thorough outcome as-
sessment. Further, confounding by ethnicity is limited as the study 
cohorts represent a general Caucasian population. Some limita-
tions of our study need to be addressed. The number of cases was 
low in some subgroups, particularly for the rare genetic variants, 
which resulted in limited statistical power. The subgroup results 
must therefore be interpreted with caution. The effect of genetic 
variants may vary in different types of cancer, but unfortunately, 
we did not have power to stratify our analyses on cancer types. 
Unfortunately, information on cancer treatment modalities was 
not available, which could have provided additional insight to the 
relationship between genes and treatment-related risk factors for 
cancer.
In conclusion, cancer and a high number of prothrombotic gen-
otypes displayed a supra-additive effect on the risk of VTE, indicat-
ing a biological interaction between the risk factors. Our findings 
suggest that the 5-SNP score may be useful for identifying cancer 
patients at increased risk of VTE.
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Background: Studies have reported that the combination of some prothrombotic genotypes and overt 
cancer yields a synergistic effect on VTE risk. Whether individual prothrombotic genotypes or number of 
risk alleles in a genetic risk score (GRS) affect VTE risk in occult cancer have not been addressed. The aim 
of this study was to investigate the joint effect of five prothrombotic genotypes and occult cancer on VTE 
risk.   
Methods: Cases with incident VTE (n=2141) and a subcohort (n=14911) were sampled from the 
Scandinavian Thrombosis and Cancer Cohort (1993-2012). Five SNPs previously reported in a GRS were 
genotyped: ABO (rs8176719), F5 (rs6025), F2 (rs1799963), FGG (rs2066865) and F11 (rs2036914). Hazard 
ratios (HRs) for VTE by individual SNPs and GRS were estimated according to non-cancer and occult cancer 
(one year preceding a cancer diagnosis) exposure.  
Results: During follow-up (median 12.2 years), 1817 subjects developed occult cancer, and of these, 93 
experienced a VTE. The VTE risk was 4-fold higher (HR 4.05, 95% CI 3.28-5.00) in subjects with occult cancer 
compared to those without cancer. Subjects with occult cancer and VTE had a higher proportion of 
prothrombotic and advanced cancers compared to those without VTE. The VTE risk increased according to 
individual prothrombotic genotypes and GRS in cancer-free subjects, while no such effect was observed in 
subjects with occult cancer (HR for ≥4 versus ≤1 risk alleles in GRS: 1.14, 95% CI 0.61-2.11). 
Conclusions: Five well-established prothrombotic genotypes, individually or combined, were not 
associated with increased risk of VTE in individuals with occult cancer.  
 






 The role of prothrombotic SNPs on venous thromboembolism (VTE) in occult cancer is unknown. 
 We studied the role of individual SNPs and a genetic risk score (GRS) on VTE in occult cancer. 
 The prothrombotic SNPs and the GRS did not affect VTE risk in occult cancer. 






Venous thromboembolism (VTE) is a frequent, severe and often fatal complication of cancer [1, 2]. The 
incidence of cancer-related VTE is increasing [2], and about 15% of cancer patients develop a symptomatic 
VTE during the course of their disease [3]. Unprovoked VTE may occur as the first sign of an undetected 
(i.e. occult) cancer [4-6], and approximately 5% of patients with unprovoked VTE are diagnosed with cancer 
within the first year following a VTE event [7-12]. VTE patients with occult cancer are more often diagnosed 
with prothrombotic cancers such as pancreatic, lung, gastrointestinal and hematological cancers [2, 5, 7, 
13-15], and more advanced stages (higher degree of regional and distant metastasis) at the time of cancer 
diagnosis [5, 14, 16]. 
VTE has a strong hereditary component, and single nucleotide polymorphisms (SNPs) in genes 
encoding for factor V Leiden (FVL) [17, 18], fibrinogen gamma (FGG) [19], factor 11 (F11) [20], prothrombin 
(F2) [21-24] and ABO blood group [25, 26] are found to increase the VTE risk in cancer patients. Moreover, 
the combination of cancer and variations in the F5 (rs6025 and rs4524) and FGG (rs2066865) genes has 
been shown to increase the VTE risk on a supra-additive scale, indicating a biological interaction between 
the individual prothrombotic SNPs and active cancer [18, 19]. Similarly, a genetic risk score (GRS) based on 
five prothrombotic SNPs was associated with VTE risk in overt cancer, and the combination of cancer and 
a high GRS (≥4 risk alleles) yielded a synergistic effect on VTE risk [27]. 
The risk of VTE is found to be increased already one year prior to a cancer diagnosis [5, 28]. This 
could be due to the occult cancer alone, or occult cancer in combination with other patient-related 
predisposing factors for VTE. It is unknown to what extent individual prothrombotic genotypes and the 5-
SNP GRS affect the VTE risk in occult cancer. Therefore, we aimed to investigate the effect of individual 
prothrombotic genotypes and number of risk alleles in the GRS on the risk of VTE in occult cancer, using a 




2.1 Study population 
We used individual data from The Scandinavian Thrombosis and Cancer (STAC) cohort, which is a large 
population-based study established to provide comprehensive data to investigate the impact of cancer on 
VTE risk in the general population [29]. The STAC cohort consists of merged data from three large 
Scandinavian cohorts with enrollment in 1993-1997: the fourth survey of the Tromsø Study (Tromsø 4, 
Norway), the second survey of the Nord-Trøndelag health study (HUNT2, Norway) and the Diet, Cancer 
and Health Study (DCH, Denmark). All three individual cohorts [30-32] and the complete STAC cohort [29] 
have been previously described in detail. The STAC cohort has a wide age-distribution (19-101 years), long-
term follow-up and thorough validation of VTE events and cancer [29]. All subjects with cancer or VTE prior 
to enrollment were excluded, yielding a study population of 144952 participants. The participants were 
followed from date of inclusion to date of migration, death, incident VTE or end of follow-up (2007-2012). 
All first lifetime, symptomatic VTE events in both in- and outpatients included in the STAC cohort were 
validated by review of medical records, and objectively confirmed by diagnostic tests. The identification 
and adjudication process of VTE events has previously been published in detail [30, 31, 33]. During follow-
up, 2444 VTE events occurred.  
We created a case-cohort by including all incident VTE cases in which blood samples were available 
for genotyping (n=2044) and an age-weighted subcohort (n=14432) randomly sampled from the STAC 
cohort (Figure 1). We excluded participants with missing values for one of the SNPs studied (n=380) or 
body mass index (n=83). A total of 372 VTE cases were censored from the analysis as they occurred after 
the cancer diagnosis date. However, these subjects contributed with person-years prior to censoring. 
Finally, our case-cohort consisted of 16013 participants of whom 1566 were VTE cases. In case-cohort 
designs, every person in the cohort, including the cases, has the same chance of being selected to the 
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subcohort, and thus, 231 of the subjects randomly selected to our sub-cohort were also cases. All 
participants provided informed written consent, and the respective regional committees for research 
ethics in Norway and Denmark approved the individual cohort studies and the collaboration study. 
 
2.2 Baseline measurements and genotyping 
Baseline information was obtained by physical examination, self-administered questionnaires and non-
fasting blood samples for each study. Body height and weight were measured with subjects wearing light 
clothing and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by body height 
in meters (m) squared (kg/m2). Information regarding history of diabetes mellitus, cardiovascular disease 
(myocardial infarction, angina or stroke), smoking status, alcohol consumption, physical activity and level 
of education was obtained by the self-administered questionnaires. Detailed information regarding 
assessment of baseline variables in each cohort is provided elsewhere [32, 34, 35]. 
We genotyped the following SNPs: ABO rs8176719 (non-O blood type), F5 rs6025 (Factor V 
Leiden), F2 rs1799963 (prothrombin G20210A), FGG rs2066865 and F11 rs2036914. These SNPs were 
chosen because they were previously included in a parsimonious GRS model presented by de Haan et al. 
[36], which performed just as good as a comprehensive model including 31 SNPs. In Tromsø 4, rs1799963 
(F2), rs6025 (F5), rs2036914 (F11) and rs8176719 (ABO) were genotyped with the Sequenom platform, 
and rs2066865 (FGG) with the TaqMan platform, as previously described in detail [37]. In HUNT2, 
genotyping was performed with the Illumina HumanCore Exome array. In the DCH study, the genotypes 
were determined using predesigned TaqMan SNP genotyping assays, as described in detail elsewhere [38]. 
Subjects were defined as carriers of the prothrombotic SNPs when one or two risk alleles were 
present, with no differentiation between heterozygous (one risk allele) and homozygous (two risk alleles) 
carriers. Normally, the minor allele is used as risk allele. However, due an inverse association with VTE risk, 
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the minor allele of the F11 SNP (rs2036914) was used as the common allele [39]. No risk allele at ABO 
rs8176719 was defined as O blood type. Hence, one or two risk alleles at ABO rs8176719 were classified 
as non-O blood type. Further, we used the GRS by de Haan et al., which was created by summarizing the 
number of risk alleles from the five sequenced SNPs [36]. 
 
2.3 Cancer assessment 
Information on cancer diagnosis, such as location (ICD10 codes C00-96), histological grade (ICO-3) and 
cancer stage (localized, regional, distant or unknown) was obtained by linkage to the cancer registries of 
Norway and Denmark where cancer registration is mandatory by law. Reports have found both cancer 
registries complete and valid, reporting a completeness of 98.8% in Norway and 95-98% in Denmark [40, 
41]. The percentage of microscopically confirmed diagnoses in the registries were 94% in Norway and 93% 
in Denmark, respectively [40, 41]. Subjects with non-melanoma skin cancers (ICD10 C44) and no other 
cancer diagnosis were regarded as cancer-free, due to the non-metastatic potential of this disease. 
Temporal proximity to cancer is shown to be a strong predictor for VTE risk [2, 5, 18]. Studies have 
found an increased VTE risk the year before a cancer diagnosis, with a seven-fold increased risk six months 
prior to the cancer diagnosis date [5, 6, 28]. Further, previously undiagnosed cancer is frequent in patients 
with unprovoked VTE, with a period prevalence of undiagnosed cancer increasing from 6.1% at baseline 
to 10.0% from the time of VTE diagnosis to 12 months after [6]. Hence, we defined the occult cancer period 
as one year prior to a cancer diagnosis. Cancer patients who were not diagnosed with VTE and still alive at 
the end of the defined occult cancer period were censored at the cancer diagnosis date. To test the 
robustness of our occult cancer variable, we additionally performed two sensitivity analyses where we 




2.4 Statistical analysis 
Statistical analyses were performed with STATA version 16.0 (Stata Corporation, College Station, TX, USA). 
Occult cancer was entered as a time-varying co-variate. In those who developed cancer during follow-up, 
the data was split on the date one year before the cancer diagnosis date to differentiate between cancer 
free and occult cancer. Thus, subjects who developed cancer during follow-up were considered to be 
cancer-free until one year prior to a cancer diagnosis date, and subsequently they were classified as occult 
cancer. When cancer was diagnosed, the cancer patients changed exposure status to overt cancer and 
were censored from the analysis. Accordingly, subjects who developed cancer contributed to both non-
exposed and occult cancer-exposed person-years (PY) at risk in our analysis. 
Cox proportional hazard regression models were used to estimate hazard ratios (HRs) with 95% 
confidence intervals (CIs) for VTE according to the different prothrombotic genotypes or categories of risk 
alleles by the GRS (i.e. 0-1, 2-3, and ≥ 4 risk alleles) in subjects with and without occult cancer. Subjects 
with 0-1 risk alleles and no cancer were used as reference group. We adjusted all analyses for age, sex and 
BMI. The proportional hazards assumption was tested by the use of Schoenfeld residuals and was found 
not to be violated. 
To investigate the combined effect of occult cancer and risk alleles on VTE risk, we used the  relative 
excess risk attributable to interaction (RERI), the attributable proportion due to interaction (AP) and the 
synergy index (SI) with corresponding 95% CIs [42, 43]. RERI can be understood as part of the total effect 
on an outcome (e.g. VTE) that is attributable to interaction (e.g. the different exposures occult cancer and 
SNPs), and the AP as the proportion of the combined effect that is attributable to interaction between the 
two exposures. A RERI > 0, an AP > 0 and a synergy index > 1.0 suggest a positive interaction greater than 





During a median follow-up of 12.2 years, 1817 subjects developed occult cancer, of whom 93 (5.1%) 
experienced a VTE event. Overall, the risk of VTE in occult cancer was 4-fold higher (HR 4.05, 95% CI 3.28-
5.00) than in cancer-free subjects in analysis adjusted for age, sex and BMI. The baseline characteristics of 
study participants with and without occult cancer and/or VTE are summarized in Table 1. In cancer-free 
subjects, those who developed VTE were older, had a higher BMI and a higher proportion were men. In 
subjects with occult cancer, those suffering a VTE were more often women. In both cancer-free subjects 
and subjects with occult cancer, the prevalence of prothrombotic genotypes were higher in VTE patients 
than in those without VTE (Table 1). The distribution of risk alleles of the GRS in cancer-free subjects and 
subjects with occult cancer was essentially similar (data not shown). 
The distribution of cancer sites and stages in subjects with and without VTE in the occult cancer 
period are presented in Table 2. Among subjects with occult cancer, those who developed VTE were more 
frequently diagnosed with prothrombotic cancers such as pancreatic-, lung- and hematological cancers 
compared with those who did not develop VTE. Further, the cancers diagnosed within one year after a VTE 
were more advanced with a higher proportion of metastasis at the time of cancer diagnosis (Table 2). 
HRs for VTE by categories of prothrombotic SNPs and cancer status (cancer-free/occult cancer) 
are presented in Table 3. In cancer-free subjects, the VTE risk increased with the presence of risk alleles 
for all prothrombotic genotypes, with the highest risk estimates for F5 (rs6025) (HR 2.68, 95% CI 2.34-
3.06), F2 (rs1799963) (HR 1.94, 95% CI 1.41-2.65), and ABO (rs8176719) (HR 1.50, 95% CI 1.34-1-67). In 
subjects with occult cancer, the VTE risk was not affected by any of the prothrombotic SNPs (Table 3).  The 
risk estimates were essentially unchanged when the definition of the occult cancer period were changed 
to six months (Supplementary Table 1) and two years (Supplementary Table 2). 
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The VTE risk in cancer-free subjects increased by the number of risk alleles, displaying a 2.4-fold 
increased VTE risk (HR 2.39, 95% CI 1.26-1.69) in subjects with more ≥4 risk alleles compared with subjects 
with 0-1 risk alleles (Table 3 and Figure 2). In subjects with occult cancer, the VTE risk did not increase by 
the number of risk alleles in the GRS (Table 3 and Figure 2). Similar results were found in sensitivity analyses 
when the occult cancer period was changed to six months or two years (Supplementary Tables 1 and 2, 
respectively). Measures of biological interaction (RERI, AP, SI) showed that the combination of occult 
cancer and presence of prothrombotic genotypes did not yield a more than additive effect on VTE risk 







In this large population-based case-cohort study, we investigated the risk of VTE by the presence of 
prothrombotic genotypes, both as individual SNPs and number of risk alleles in a GRS, in subjects with and 
without occult cancer. In agreement with previous studies, we confirmed that the VTE risk increased by 
the individual prothrombotic genotypes and the number risk alleles in the GRS in cancer-free subjects [36]. 
In contrast, the prothrombotic genotypes were not associated with VTE risk in subjects with occult cancer, 
and accordingly, the combination of occult cancer and individual risk alleles or number of risk alleles in the 
GRS, did not yield any supra-additive effect on the VTE risk. Similar findings were observed in sensitivity 
analyses where the occult cancer period was altered to six months and two years, respectively. Subjects 
with VTE in the occult cancer period had a higher frequency of prothrombotic cancer types and more 
advanced cancers at the time of cancer diagnosis. Our findings suggest that the mechanisms related to 
VTE risk in occult cancer supersede the effect of prothrombotic genotypes. 
The mechanisms for VTE in cancer are multifactorial and involve overlapping pathways related to 
the cancer itself and patient-related factors [44]. Several studies have explored the impact of 
prothrombotic genotypes on the risk of VTE in patients with overt cancer, and reported an increased risk 
for SNPs encoding for factor V Leiden, prothrombin mutation and non-O blood type [17-26]. Moreover, 
we previously showed that in combination with overt cancer, SNPs in F5 (rs6025, rs4524) and FGG 
(rs2066865), as well as a high number of risk alleles in the GRS (≥ 4 risk alleles), increased the VTE risk on 
a supra-additive level [18, 19, 27]. Therefore, we hypothesized that prothrombotic genotypes could 
influence the risk of VTE also in occult cancer. In contrast, we found no effect of the established 
prothrombotic genotypes on the VTE risk in subjects with occult cancer. This suggests that prothrombotic 
mechanisms related to the cancer itself are more important than inherent patient-related factors for risk 
of VTE in the occult cancer period.  
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Several studies have confirmed the significance of cancer stage, grade and site  on VTE risk in overt 
malignancy, and patients with metastatic cancers, with regional or distant spread, have a higher VTE risk 
than patients with localized cancers [45]. Moreover, pancreas, brain, lung, ovarian, kidney and stomach 
cancers, as well as lymphomas, are considered high-risk sites for VTE [45]. In agreement with these 
findings, we showed that subjects who developed VTE during the occult cancer period had a higher 
proportion of regional and distant metastasis, as well as a higher proportion of cancers at high-risk sites, 
when compared with those who did not develop VTE during the occult cancer period. Tissue factor (TF), 
the main initiator of the coagulation system, is shown to be involved in cancer-progression processes such 
as tumor growth, angiogenesis and metastasis [46]. Upregulation of TF has been reported in advanced 
cancer stages [46], as well as in high-risk sites for VTE, including brain, pancreatic, lung, ovarian and 
colorectal cancers [47, 48]. In addition to TF expression, inflammatory responses with increased levels of 
circulating proinflammatory cytokines [49-51], inhibition of fibrinolytic activity through expression of 
plasminogen activator inhibitor-1 (PAI-1) [52-54], and formation of neutrophil extracellular traps (NETs) 
from neutrophils [55], may substantially contribute to a prothrombotic state in rapidly developing, 
aggressive, occult cancers. Thus, a massive orchestra of prothrombotic pathways induced by an advancing 
occult cancer, is likely sufficient to push an individual's thrombotic potential above the threshold for 
thrombus development, regardless of the presence of inherent prothrombotic risk factors.  
The main strengths of our study include the prospective design with participants recruited from 
the general population, large number of genotyped subjects, long-term follow-up and thorough 
assessment of both VTE and cancer. In agreement with previous studies, we confirmed that 5% of the VTE 
events were related to occult cancer [7-12], and similar anatomical sites for cancers [2, 5, 7, 13-15], and 
degrees of metastatic diseases were found in VTE-patients with occult cancer [5, 14, 16], which supports 
a high external validity. Some study limitations must be addressed. In some rare genetic variants, the 
number of cases was low, resulting in limited statistical power. Unfortunately, we did not have sufficient 
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power to stratify our data by different cancer sites or stages of cancer, as it would be interesting to explore 
whether the impact of prothrombotic SNPs and combination of SNPs on VTE risk would differ within 
different sites and stages of occult cancer. In order to be registered with occult cancer, patients had to 
survive until their cancer diagnosis. Thus, participants with occult cancer who died from a VTE or other 
causes before a cancer was diagnosed would be misclassified as cancer-free. Such misclassification would 
likely lead to underestimation of the VTE risk in occult cancer. However, the five prothrombotic SNPs are 
not expected to increase the death-rate in the general population [56, 57], and thus, we believe that such 
misclassification, if present, would have negligible impact on our results. 
In conclusion, five common prothrombotic genotypes, alone or in combination, were not 
associated with risk of VTE in occult cancer. Our findings suggest that prothrombotic mechanisms related 
to rapidly advancing cancers at high-risk sites are prominent for VTE risk in occult cancer and supersede 
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Table 1. Baseline characteristics of the study population with and without occult cancer and VTE. 
 No cancer Occult cancer 
 Sub-cohort VTE Sub-cohort VTE 
Participants, n* 12723 1473 1724 93 
Age, years 49.6±15.4 59.5±12.9 61.1±11.5 61.1±12.1 
Male sex 47.5 (6043) 51.5 (759) 52.8 (910) 44.1 (41) 
BMI, kg/m2 26.1±4.1 27.6±4.6 26.7±4.3 27.0±4.4 
rs8176719 (ABO)† 61.0 (7760) 70.0 (1031) 62.4 (1075) 64.5 (60) 
rs6025 (F5)† 6.8 (868) 17.8 (262) 8.2 (142) 10.8 (10) 
rs1799963 (F2)† 1.4 (172) 2.7 (40) 1.5 (25) 1.1 (1) 
rs2066865 (FGG)† 42.5 (5413) 47.0 (692) 43.0 (741) 46.2 (43) 
rs2036914 (F11)† 77.7 (9891) 82.6 (1216) 78.8 (1359) 78.5 (73) 
Values are in % (n) or mean ± standard deviation. BMI, body mass index. 
* Subjects with cancer contributed to observation periods in both the no cancer and occult c ancer group. 





Table 2. Distribution of cancer sites and stages in subjects with occult cancer, defined as one year prior 
to cancer diagnosis, with and without venous thromboembolism (VTE).  
 No VTE (n=1724) VTE (n=93) 
Cancer site Number (%) Number (%) 
Colorectal 272 (15.8) 8 (8.6) 
Pancreatic 54 (3.1) 6 (6.4) 
Lung 205 (11.9) 18 (19.4) 
Breast 198 (11.5) 2 (2.2) 
Gynecological 101 (5.9) 4 (4.3) 
Prostate 224 (13.0) 10 (10.8) 
Urological 150 (8.7) 8 (8.6) 
Central nervous system 69 (4.0) 1 (1.1) 
Hematological/Lymphoma 138 (8.0) 11 (11.8) 
Upper GI 90 (5.2) 7 (7.5) 
Malignant melanoma 66 (3.8) 0 (0) 
Other* 157 (9.1) 18 (19.4) 
Cancer stage Number (%) Number (%) 
Localized 473 (27.4) 10 (10.8) 
Regional lymph nodes 431 (25.0) 14 (15.1) 
Distant metastasis 292 (16.9) 34 (36.7) 
Metastasis diagnosed, unknown where 408 (23.7) 25 (26.9) 
Not staged 120 10 







Table 3. Hazard ratios (HR) with 95% confidence intervals (CI) for venous thromboembolism (VTE)  by 
categories of single nucleotide polymorphisms (SNPs) and occult cancer defined as the occurrence of a 
cancer diagnosis within one year after VTE diagnosis. 
  Events HR (95% CI)* HR (95% CI)* 
Cancer rs8176719 (ABO)†    
- - 442 Ref. Ref. 
- + 1031 1.50 (1.34-1.67) 1.50 (1.34-1.67) 
+ - 33 Ref. 5.01 (3.51-7.14) 
+ + 60 1.10 (0.72-1.69) 5.43 (4.14-7.12) 
Cancer rs6025 (F5)†    
- - 1211 Ref. Ref. 
- + 262 2.68 (2.34-3.06) 2.68 (2.34-3.06) 
+ - 83 Ref. 4.45 (3.56-5.57) 
+ + 10 1.26 (0.64-2.45) 5.60 (3.00-10.44) 
Cancer rs1799963 (F2)†    
- - 1433 Ref. Ref. 
- + 40 1.94 (1.41-2.65) 1.94 (1.42-2.66) 
+ - 92 Ref. 4.11 (3.33-5.09) 
+ + 1 0.82 (0.11-6.03) 3.10 (0.44-22.05) 
Cancer rs2066865 (FGG)†    
- - 781 Ref. Ref. 
- + 692 1.18 (1.06-1.30) 1.17 (1.06-1.30) 
+ - 50 Ref. 4.08 (3.06-5.44) 
+ + 43 1.10 (0.73-1.67) 4.72 (3-47-6.42) 
Cancer rs2036914 (F11)†    
- - 257 Ref. Ref. 
- + 1216 1.31 (1.14-1.50) 1.31 (1.14-1.49) 
+ - 20 Ref. 5.33 (3.38-8.40) 
+ + 73 0.95 (0.58-1.57) 4.94 (3.81-6.42) 
Cancer Genetic risk score‡    
- 0-1 224 Ref. Ref. 
- 2-3 836 1.46 (1.26-1.69) 1.46 (1.26-1.69) 
- ≥4 413 2.39 (2.03-2.82) 2.39 (2.03-2.81) 
+ 0-1 21 Ref. 6.75 (4.31-10.56) 
+ 2-3 52 0.84 (0.50-1.39) 5.44 (4.02-7.37) 
+ ≥4 20 1.14 (0.61-2.11) 8.04 (5.09-12.72) 
* Adjusted for age, sex and body mass index (BMI) 
† Positive indicating subjects with one or two risk alleles 





Figure 1. Study population. Participants were recruited from The Scandinavian Thrombosis and Cancer 
Cohort (1993-1997). 
 




Figure 2. Hazard ratios (HR) with 95% confidence intervals (CI) for venous thromboembolism (VTE) by 
categories of single nucleotide polymorphisms (SNPs) and occult cancer defined as the occurrence of a 










Supplementary Table 1. Hazard ratios (HR) with 95% confidence intervals (CI) for venous 
thromboembolism (VTE) by categories of single nucleotide polymorphisms (SNPs) and occult cancer 
defined as six months prior to cancer diagnosis. 
  Events HR (95% CI)* HR (95% CI)* 
Cancer rs8176719 (ABO)†    
- - 447 Ref. Ref. 
- + 1044 1.50 (1.34-1.67) 1.50 (1.34-1.67) 
+ - 28 Ref. 8.22 (5.60-12.05) 
+ + 47 1.05 (0.65-1.68) 8.41 (6.22-11.37) 
Cancer rs6025 (F5)†    
- - 1228 Ref. Ref. 
- + 263 2.65 (2.31-3.03) 2.65 (2.31-3.03) 
+ - 66 Ref. 6.94 (5.41-8.90) 
+ + 9 1.45 (0.71-2.97) 9.74 (5.05-18.76) 
Cancer rs1799963 (F2)†    
- - 1451 Ref. Ref. 
- + 40 1.91 (1.40-2.62) 1.92 (1.40-2.62) 
+ - 74 Ref. 6.49 (5.13-8.21) 
+ + 1 1.13 (0.15-8.38) 5.85 (0.82-41.67) 
Cancer rs2066865 (FGG)†    
- - 789 Ref. Ref. 
- + 702 1.18 (1.07-1.31) 1.18 (1.07-1.31) 
+ - 42 Ref. 6.71 (4.91-9.17) 
+ + 33 1.04 (0.65-1.66) 7.15 (5.03-10.13) 
Cancer rs2036914 (F11)†    
- - 264 Ref. Ref. 
- + 1227 1.28 (1.12-1.47) 1.28 (1.12-1.46) 
+ - 13 Ref. 6.60 (3.78-11.54) 
+ + 62 1.27 (0.69-2.32) 8.13 (6.16-10.74) 
Cancer Genetic risk score‡    
- 0-1 231 Ref. Ref. 
- 2-3 841 1.42 (1.23-1.64) 1.42 (1.23-1.64) 
- ≥4 419 2.35 (2.00-2.76) 2.35 (2.00-2.76) 
+ 0-1 14 Ref. 8.59 (5.00-14.74) 
+ 2-3 47 1.15 (0.63-2.12) 9.44 (6.89-12.94) 
+ ≥4 14 1.25 (0.59-2.65) 11.01 (6.41-18.90) 
* Adjusted for age, sex and body mass index (BMI) 
† Positive indicating subjects with one or two risk alleles  
‡ Number of risk alleles  
25 
 
Supplementary Table 2. Hazard ratios (HR) with 95% confidence intervals (CI) for venous 
thromboembolism (VTE) by categories of single nucleotide polymorphisms (SNPs) and occult cancer 
defined as two years prior to cancer diagnosis. 
  Events HR (95% CI)* HR (95% CI)* 
Cancer rs8176719 (ABO)†    
- - 431 Ref. Ref. 
- + 1020 1.52 (1.36-1.70) 1.52 (1.36-1.70) 
+ - 44 Ref. 3.49 (2.56-4.77) 
+ + 71 0.97 (0.67-1.42) 3.35 (2.60-4.31) 
Cancer rs6025 (F5)†    
- - 1195 Ref. Ref. 
- + 256 2.66 (2.32-3.04) 2.66 (2.33-3.05) 
+ - 99 Ref. 2.75 (2.24-3.38) 
+ + 16 1.57 (0.92-2.69) 4.52 (2.75-7.40) 
Cancer rs1799963 (F2)†    
- - 1412 Ref. Ref. 
- + 39 1.91 (1.39-2.63) 1.92 (1.40-2.64) 
+ - 113 Ref. 2.61 (2.15-3.17) 
+ + 2 1.37 (0.34-5.64) 3.28 (0.82-13.13) 
Cancer rs2066865 (FGG)†    
- - 770 Ref. Ref. 
- + 681 1.17 (1.06-1.30) 1.17 (1.06-1.30) 
+ - 61 Ref. 2.59 (1.99-3.36) 
+ + 54 1.12 (0.78-1.63) 3.03 (2.30-4.00) 
Cancer rs2036914 (F11)†    
- - 256 Ref. Ref. 
- + 1195 1.29 (1.13-1.48) 1.29 (1.13-1.48) 
+ - 21 Ref. 2.86 (1.83-4.46) 
+ + 94 1.18 (0.73-1.90) 3.26 (2.57-4.13) 
Cancer Genetic risk score‡    
- 0-1 219 Ref. Ref. 
- 2-3 826 1.48 (1.27-1.71) 1.48 (1.27-1.72) 
- ≥4 406 2.41 (2.04-2.84) 2.40 (2.04-2.83) 
+ 0-1 26 Ref. 4.36 (2.90-6.55) 
+ 2-3 62 0.80 (0.51-1.27) 3.40 (2.56-4.52) 
+ ≥4 27 1.23 (0.72-2.12) 5.56 (3.72-8.30) 
* Adjusted for age, sex and body mass index (BMI) 
† Positive indicating subjects with one or two risk alleles  




Supplementary Table 3. Measures of interaction on an additive scale between occult cancer and the 
individual single-nucleotide polymorphisms (SNPs) or ≥4 risk alleles in the genetic risk score. 
 RERI (95% CI) AP (95% CI) Synergy index (95% CI) 
Individual SNPs (genes)    
   rs8176719 (ABO) -0.07 (-2.27-2.12) -0.01 (-0.42-0.39) 0.98 (0.60-1.61) 
   rs6025 (F5) -0.53 (-4.15-3.09) -0.10 (-0.80-0.61) 0.90 (0.41-1.95) 
   rs1799963 (F2) -1.96 (-8.12-4.21) -0.63 (-3.85-2.59) 0.52 (0.03-9.47) 
   rs2066865 (FGG) 0.47 (-1.35-2.28) 0.10 (-0.26-0.46) 1.14 (0.68-1.92) 
   rs2036914 (F11) -0.69 (-3.29-1.92) -0.14 (-0.68-0.40) 0.85 (0.48-1.52) 
Genetic risk score (≥4 vs ≤1) -0.06 (-4.67-4.54) -0.01 (-0.58-0.56) 0.99 (0.52-1.89) 
AP, proportion attributable to interaction; CI, confidence interval; RERI, relative excess risk attributable to 
interaction. 
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